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ABSTRACT 
 
ELIZABETH ANN VASIEVICH: Lipid-Based Cancer Vaccines 
(Under the direction of Leaf Huang, Ph.D.) 
 
 
Each aim of this project ranges from vaccine formulation to whole-body response; 
starting from the structure-function relationship of the cationic lipid DOTAP (1,2-
dioleoyl-3-trimethylammonium-propane) to the immunological action in vivo. The three 
aims of this work examine DOTAP; the structural specificity, development of a 
melanoma-specific formulation and development of a joint siRNA/peptide delivery 
vehicle. 
The first aim in these studies investigates the impact of DOTAP’s chiral center on 
a peptide based therapeutic vaccine in a murine cervical cancer model. The lipid, (R) or 
(S)-DOTAP was combined with an MHC Class I restricted peptide (E7), from the E7 
oncogene in human cervical cancer. In this work, (R)-DOTAP/E7 was shown to act 
equally well as the racemic mixture in causing tumor regression, while (S)-DOTAP/E7 
had a lesser effect. This data was supported by other studies evaluating the cell-mediated 
anti-tumor response, and in each, (R)-DOTAP/E7 showed greater efficacy. 
The second aim investigates the development of a peptide/lipid melanoma vaccine 
with a different antigenic peptide that poses unique formulation challenges. The 
amphipathic Trp2 peptide antigen was formulated to address poor aqueous solubility, and 
yielded stable vaccine particles when mixed with (R)-DOTAP. (R)-DOTAP/Trp2 
delivered in high Trp2 doses to tumor-bearing mice showed enhanced tumor growth 
 iv
delay compared to lower Trp2 doses, which was supported by additional immunological 
assays. 
The third aim seeks to enhance the versatility of the delivery vector with added 
siRNA therapy. Formulation of tri-modal particle, including (R)-DOTAP adjuvant, 
melanoma antigen (Trp2 peptide) and siRNA against PD-L1 (RTP particles) expanded 
the versatility of the previously developed (R)-DOTAP/Trp2 vaccine. PD-L1 siRNA was 
incorporated to dampen the inhibitory signal that DCs express when activated, that can 
inhibit T cell function. The examination of the structure and activity of these particles in 
vitro and in vivo, led to further understandings of the vaccine. In a solid melanoma 
model, delivery of RTP showed a tumor growth delay statistically significant compared 
to particles with control siRNA.  
In closing, (R)-DOTAP is the immunologically active enantiomer, showing 
efficacy in cervical cancer and melanoma models, with the potential to deliver a variety 
of peptide antigens and siRNA, showing tumor growth delay. 
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CHAPTER 1 
INTRODUCTION 
1.1 VACCINE NECESSITIES AND DELIVERY OF ADJUVANTS AND 
ANTIGENS USING CATIONIC LIPIDS 
Three things are required in building an efficacious vaccine, and elicit an immune 
response in vivo. Figure 1.1 describes the basic immunological process of vaccination to 
T cell activation for cell-mediated immunity (protection against infected cells, or even 
cancer cells). First, vaccines are essentially delivery vehicles, meant to (safely) mimic 
infection and establish immunological memory. This can occur via a depot effect that 
allows antigen to drain into lymph vessels and eventually lymph nodes, or cause local 
inflammation to recruit antigen-presenting cells (APCs) to the site of injection.  
Second, vaccines require activation of APCs. Activation can occur through 
recognition of pathogen-associated molecular patterns (PAMPs) by Toll like receptors 
(TLRs) which can upregulate activation molecules and induce production of 
inflammatory cytokines and chemokines.  TLRs specifically identify many of different 
conserved patterns both extracellularly and in endosomes. On the surface of the cell, 
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TLRs detect surface markers from bacteria, viruses or fungi, such as lipopolysaccharide 
(TLR4), viral hemagglutinin (TLR2), bacterial flagellin (TLR5). Inside endosomes, TLRs 
respond to single or double stranded DNA or RNA utiling TLR3, 7, 8 and 9. While 
“adjuvant” could be defined as any implement that enhances a vaccine’s action, here 
we’ll follow a more narrow definition of activation of APCs.  
Finally, the body needs a signal of the infection or infected cells to recognize, 
called antigen, usually either a continuous or discontinuous peptide sequence.. How this 
antigen is presented to the immune system is important. The immune system responds 
differently to an infectious virus circulating through the blood, as compared to a virally 
infected cell. APCs present antigen differently to combat these two invaders, utilizing 
different Major Histocompatibility Complexes, either MHC I or MHC II. Circulating 
viruses or soluble antigen endocytosed by APCs will be processed into antigen fragments 
in the endosomal vesicle (never entering the cytoplasm), and presented on MHC II.  
Antigen presented on MHC II interacts with the T cell receptor (TCR) of CD4+ T cells, 
leading to humoral immunity. In contrast, antigen in the cytoplasm (in the case of 
infected cells) is presented on MHC I, and interacts with the TCR on CD8+ T cells 
(known as cytotoxic T lymphocytes, CTLs). CTLs lyse infected cells by releasing 
vesicles of Granzyme B and Perforin. Cross-presentation occurs when APCs endocytose 
antigen that subsequently escapes into the cytoplasm, therefore MHC I presentation can 
occur inducing a CTL response. Endosomal release and subsequent cross-presentation is 
crucial to creating CTL responses from antigen delivered by lipid carriers. 
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Figure 1.1 Requirements of an efficacious vaccine. 
The cationic charge on some lipids allows for endosomal escape of antigen (with varying efficiencies), 
crucial for inducing cell-mediate immunity. A successful adjuvant seeking to elicit cell-mediated immunity 
should activate antigen presenting cells (APCs) and facilitate antigen presentation to T cells. In the figure, 
the schematic representation shows how the adjuvant works as vaccine. We’ve used the example of an 
antigenic peptide encapsulated in cationic lipid adjuvant. After the s.c injection of the vaccine, complexes 
can activate APCs through different mechanisms. After endocytosis, cationic lipids facilitate the 
intracellular release, allowing APCs to present the peptide via MHC class I to CD8+ T cells. An activated T 
cell undergoes clonal expansion, generating many more T cells with the same T cell receptor specific for 
the antigen. T cells then circulates in the blood to surveillance the body for cells presenting the antigen 
they’ve been activated against. When the activated T cells find these infected (or cancer cells), they can kill 
them by releasing cytokines. Alternatively, when endosomal escape does not occur, antigen still may be 
presented, however now on MHC class II, and will elicit humoral, or antibody-based, immunity, most 
effective against soluble antigen or circulating pathogens. 
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Liposomes have been investigated as carriers of adjuvants and antigens for many 
years.1; 2; 3 The delivery capacity of liposomes is well established, with a large available 
hydrophilic payload and a lipid bilayer capable of incorporating both lipid adjuvants and 
hydrophobic adjuvants or antigen. While lipids make poor antigens themselves for 
recognition by the immune system, they have been investigated as adjuvants. 
Monophosphoryl lipid A (MPL), shown in Figure 1.2, is the most well known lipid 
adjuvant, and appears in two U.S. marketed vaccines, Fendrix® and Cervarix®,4; 5 for 
hepatitis B or HPV16/18, respectively. MPL is the immunologically active portion of 
lipopolysaccaride (LPS) from Salmonella Minnesota. Both MPL and LPS function as 
adjuvants to activate APCs through TLR4 on the surface of the cell.6; 7; 8; 9 This action is 
well characterized and understood,10 unlike the mechanism of other lipid adjuvants. 
Cationic lipid use in gene therapy has exposed interesting delivery properties allowing for 
intracellular delivery of antigen as well as some unique adjuvant properties. As delivery 
is a well established mechanism for liposomes, Chapter 1.2 will discuss cationic lipids’ 
action as immunological adjuvants, particularly focusing on the advantages of using 
cationic lipids to initiate cell-mediated immunity. 
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Figure 1.2 Different cationic lipids used in vaccine formulations (and MPL). 
The joining of the acyl chains of DOTAP with the quaternary amine form a chiral center indicated with an 
asterisk (*). The enantiomers (R)-DOTAP and (S)-DOTAP are commercially available as chirally pure 
sterospecifically synthesized compounds (Merck KGaA) or as a racemic mixture (Avanti Polar Lipids). 
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 1.1.2 Cationic Lipids as Delivery Vehicles 
Complexes of cationic lipids used to condense (negatively charged) pDNA were found to 
be strongly immunostimulatory (mainly due to the unmethylated CpG motifs on the 
pDNA). However, the use of cationic lipids as delivery vehicles also releases their 
payload into the cytoplasm. The mechanism has been explained by ion-pairing between 
the negatively charged lipids in the internal layer of the endosome and the cationic lipids 
of the particle, therefore facilitating endosomal release.11 The advantage of delivering an 
vaccine with such antigen release properties, is the ability to deposit the cargo into the 
cytoplasm. Thus, the antigen is directed to present via MHC class I, and stimulating cell-
mediated immunity becomes a possibility. Other ways that cationic lipids can assist in 
delivery is to enhance antigen loading, by increasing the adsorption of anionic proteins. 
Therefore, as a delivery vehicle, cationic lipids confer beneficial properties (as no 
other endosomal release strategy needs to be considered). Some cationic lipids are 
investigated for their vaccination delivery properties alone, formulating them with 
additional adjuvants to enhance any activity the cationic lipid may possess. A few 
examples of lipids that have been thus investigated include: DDA (as vesicles), DOTIM, 
DOTMA and DC-Chol (all shown in Figure 1.2). 
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1.1.2.1 DDA or DDAB or DODAB (dimethyldioctadecylammonium bromide) 
DDA has two unsaturated 18 carbon chains and a simple headgroup consisting of a 
quaternary amine. In vaccine formulations, this lipid has shown contradicting results. 
Some have reported its immunostimulatory potential, while others attribute its vaccine 
efficacy to a depot effect, and thus formulate with an additional adjuvant to boost 
activity. We’ve presented first how DDA acts as a carrier, and later, how others have 
explained its adjuvant activity. Then we’ll explain some possibilities for the differences. 
A formulation termed cationic adjuvant formulation 01 (CAF01) is made from 
DDA and TDB (trehalose 6,6’-dibehenate) and has been widely tested in many different 
delivery mechanisms, including as a mucosal adjuvant.12 CAF01 was attributed to 
function through TLR 2, 3, 4, and 7 independent pathways, in a MyD88-dependant 
manner.13 However, the independent function of DDA was not isolated in these studies. 
DDA doesn’t activate bone marrow-derived dendritic cells (BMDC) to upregulate MHC 
class II, CD40, CD80, CD86. Lipid cationic charge and antigen adsorption contribute to 
antigen deposition at the site of injection as seen with CAF01.14  
However, some have generalized DDA to have “adjuvant” action by targeting 
particles to antigen presenting cells.15 Increased particle size has shown faster localization 
to draining lymph nodes.16 One comparative study, formulated three different cationic 
lipids, DDA and evaluated the appearance in draining lymph nodes. In comparative 
experiments, DDA/TDB/Ag and DC-Chol/TDB/Ag complexes showed an enhanced 
retention at the site of injection and increased recruitment of monocytes to the site of 
injection. This was correlated with the smaller sized formulations for DDA and DC-Chol 
at ~500nm and ~300nm, compared to ~700nm for the DOTAP formulation. The larger 
sized DOTAP formulations showed the fastest accumulation of lipid and antigen in the 
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popliteal lymph node (draining from a quadriceps i.m. injection), indicating faster 
drainage from the site of injection and faster exposure to APCs. 
 
1.1.2.2 DOTIM (octadecenoyloxy(ethyl-2-heptadecenyl-3-hydroxyethyl) 
imidazolinium) 
DOTIM has been investigated in vaccine formulations ranging from influenza to cancer. 
Formulated with cholesterol and pDNA it is termed, “CLDC” cationic lipid-DNA 
complexes, or JVRS-100 (for commercial purposes), this complex has shown efficacy in 
tumor growth delay in an orthotopic glioblastoma model without an associated antigen.17 
However, the lipid alone (or the pDNA alone) did not have any effect on tumor volume 
(after i.v. administration). This is surprising as pDNA is known to activate TLR9 in 
APCs through its unmethylated CpG motifs. The JVRS-100 formulation was also 
successful in a transgenic model expressing the hepatitis B virus (HBV), breaking 
tolerance with humoral (IgG titer) and cell-mediated (IFN-γ with restimulation) 
responses.18 Again, in model, JVRS-100 was not able to induce antibodies against HBV. 
Finally, in a separate application, JVRS-100 was combined with Fluzone®, a 
commercially available seasonal influenza vaccine.19 JVRS-100 was added to Fluzone® 
by mixing and tested in mice and non-human primates. While JVRS-100 had no activity 
(the non-specific activation shown previously was not apparent in any figures), the 
mixture of JVRS-100 + Fluzone® caused increased humoral and cell-mediated responses 
compared to Fluzone® alone, even allowing for protection from antigenic drift. 
In these studies, DOTIM/Chol/pDNA structures have shown the ability to bolster 
the immune activity, either acting as non-specific immunostimulators (glioblastoma), 
carriers for hepatitis B surface antigen, or Fluzone®. However, as mirrored in the 
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glioblastoma study, the DOTIM lipid is not a strong enough antigen to have any anti-
tumor effect on its own. The non-specific cell-mediated effect cannot be replicated in the 
viral protection studies of HBV and influenza. Thus, we suspect, DOTIM was included in 
this formulation solely as a carrier for pDNA, with cholesterol included to stabilize the 
bilayer by reducing fluidity. 
 
1.1.2.3 DOTMA (N-(1-(2,3-dioleyloxy)propyl)-n,n,n-trimethylammonium) 
DOTMA/Chol, like DDA, has been used as a carrier of nucleotides, including CpG 
oliogos and pDNA. Complexing with modified oligos, particle sizes are small, around 
120nm, ideal for i.v. or i.p. injection.20 DOTMA/modified CpG oligo complexes were 
able to prevent peritoneal metastases as well as induce large amounts of TNF-α in ex vivo 
treated macrophages. This indicates that tumor progression (to metastases) was prevented 
by a strong inflammatory response by the lipid/modified CpG oligo combination. 
(Control groups indicated it was the modification of the oligo from a phosphodiester 
(PO)-CpG, to a phosphorothioate (PS)-CpG, that caused the increase in inflammation). In 
studies of intratracheal administration of DOTMA/Chol/pDNA, it was found how 
DOTMA and the pDNA each enhance the immune response.21 It was found that pDNA 
contributed to the IFN-γ and IL-12 secretion, and DOTMA alone did not induce IL-12. 
DOTMA was responsible for TNF-α secretion as well as acute cellular influx. The carrier 
aspect of DOTMA is also associated with the non-specific inflammation of TNF-α 
production. However, TNF-α can have toxic effects that act very quickly and safer 
vaccine components are needed to ensure cytokine storms are kept at bay while an 
efficacious vaccine can install immunological memory. 
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1.1.2.4 DC-Chol (3β-(N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol 
hydrochloride) 
Gao and Huang developed DC-Chol, as a cationic lipid for gene delivery, however it has 
been tested in vaccine formulations as well.22; 23 Cholesterol doesn’t form liposomes 
alone; it is usually formulated 1:1 with a neutral lipid to form bilayer vesicles. When DC-
Chol was combined with split inactivated influenza vaccines, antigen binding and 
immune stimulated was increased, compared to neutral cholesterol.24 Cryo-TEM pictures 
showed that DC-Chol combined with the split virus were liposomes, indicating the 
formation of virus-like particles. DC-Chol stabilized the split virus and increased the 
antigen adsorption to grater than 75 %. These particles also showed increased humoral 
and cell-mediated immunity, compared to neutral carriers of the vaccine, or antigen 
alone. However this could be due to increased particle uptake due to the cationic charge 
as well as increased antigen loading. Increased antigen loaded in an i.v. DC-Chol vaccine 
formulations (with the adjuvant Quil A, and antigen OVA protein) was shown to elicit 
equal humoral responses to alum.25 In these same studies, where DC-Chol was used to 
create a implantable vaccine, the immune response was no different than formulations 
using cholesterol (neutral charge). This could indicate the importance of delivery in this 
adjuvant’s immune stimulating properties. In one test in humans, DC-Chol was an 
ineffective adjuvant via mucosal delivery in humans (nasal or vaginal) as a protective 
HIV vaccine (using the protein gp160 as an antigen).26 Contradictory to all previous 
studies, Brunel et al showed that one large (500uL) s.c. injection of DC-Chol with HepB 
surface antigen, strong cell-mediated and humoral immunity were elicited and able to 
break tolerance in a resistant mouse model.27 Separate investigators found that even after 
multiple s.c. immunizations, DC-Chol formulated with HepB surface antigen were unable 
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to stimulate a greater immunity than antigen alone.28 DC-Chol has not shown versatility 
as an adjuvant via multiple delivery routes. However, in regards to antigen loading, DC-
Chol (like many other cationic lipids) can greatly increase the antigen loading in the 
vehicle by interacting with negatively charged antigens by charge-charge interactions or 
interacting with other carrier lipids by decreasing the bilayer flexibility and permeability.  
 
1.1.3 Cationic Lipids Multi-tasking as Adjuvants and Delivery Vehicles 
Some cationic lipids are immunostimulatory by themselves, and as such, multi-task as 
both the delivery vehicle and the adjuvant. While the mechanism of action is not known 
for all cationic lipids, the adjuvant activity of many have been studied, including: 
DOTAP, DDA (as bilayer fragments), and diC14-amidine (all shown in Figure 1.2). 
 
1.1.3.1 DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) 
DOTAP was first investigated as a non-viral gene therapy delivery agent, as an analog of 
DOTMA. As hypotheses regarding cytosolic release of nucleic acids from a 
DOTAP/gene complex involve the lipid ion-pairing to negatively charged membrane 
lipids, it is reasonable to assume that peptides and proteins might reach the cytosol as 
well from DOTAP-aided delivery. MHC class I-specific immunity against virally 
infected cells can be elicited from delivery of a protein with DOTAP.29 DOTAP/antigen 
vaccinations have shown higher T cell activity (in vitro cytotoxicity to targets) as well as 
in vivo tumor regression than treatment with Complete Freund’s Adjuvant (CFA).29; 30 
Bone marrow-derived dendritic cells (BMDCs) are a common model for 
mechanistic studies on APCs, as are RAW264.7 and DC2.1 macrophage and dendritic 
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immortalized cell lines, respectively. DOTAP liposomes have been extensively studied in 
BMDCs. They have been shown to generate ROS in a dose-dependant manner, as well as 
requiring this ROS for ERK and p38 activation as well as cytokine induction.31 CCL2, 
CCL3, and CCL4 are induced after DOTAP treatment to BMDCs.32 Upregulation of 
activation markers, CD80/CD86 has been reported after DOTAP treatment, in both in 
vitro and in vivo applications.30; 31 However, in vitro toxicity is apparent at high 
concentrations of DOTAP.31; 33 
Very often, investigation of cationic lipids in gene delivery applications has lead 
to investigation of DNA vaccines, or protein antigen delivery. LPD, or lipid-polycation-
DNA has been developed by our group to deliver DNA, siRNA, protein and peptides, 
utilizing DOTAP as the lipid component.34; 35; 36; 37; 38; 39 However, the CpG motifs of the 
DNA had been linked to pro-inflammatory cytokines. However, it was found that LPD 
was able to stimulate natural killer (NK) cell activity in a CpG independent manner.40 
Indeed, it has been shown that DOTAP does not induce TNF-α, and thus although able to 
elicit a strong immune response, is not associated with undue inflammation.41 Further 
work by Chen et al. exposed that complexes of DOTAP and an exogenous peptide alone 
was able to upregulate activation markers on DCs in draining lymph nodes and cause 
complete tumor regression in a murine cervical cancer model.30 DOTAP has also 
successfully elicited cell-mediated immunity with a protein adjuvant.42 
Interestingly, commercially available DOTAP is a racemic mixture. 
Stereospecific synthesis, by Merck KGaA, has conducted stereospecific synthesis of (R)-
DOTAP and (S)-DOTAP for evaluation as adjuvants. Our recent work has shown that 
(R)-DOTAP is the active enantiomer in adjuvant activity, able to elicit similar tumor 
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regression as the racemic mixture when utilized as an adjuvant in an exogenous antigen.33 
(R)-DOTAP was able to show preferential in vivo CTL killing, and specific activity of 
nearly 30 % of CD8+ TIL against the immunized tumor-specific peptide antigen. MPL 
analogs have been synthesized to investigate the stereospecificity as well. Similarly, 
stronger agonistic activity of the R,R,R,R-MPL analog, was shown compared to R,S,S,R-
configuration, activity, but still acting on the TLR4 receptor.43 This indicates the 
possibility that, although the exact mechanism of action that separates the DOTAP 
enantiomers is unknown, it is likely they act through the same receptor or mechanism, 
except (S)-DOTAP with a lesser affinity compared to (R)-DOTAP. This was shown in 
tumor growth delay (not regression), in (S)-DOTAP/antigen tumor-bearing mice, 
statistically significant from both the complete regression caused by (R)-DOTAP 
formulations or untreated mice with large tumors. (R)-DOTAP should be further 
investigated as an adjuvant promoting cell-mediated immunity as it contains the immune 
stimulation and cargo delivery properties necessary. 
 
1.1.3.2 DDA or DDAB or DODAB (dimethyldioctadecylammonium bromide) 
Unique formulation strategies with DDA have led to some interesting vaccines. With 
probe sonication in low ionic strength buffer, DDA vesicles are broken into bilayer 
fragments (BF), which have been investigated alone or as coating agents for solid 
particles (like silica or polystyrene sulfate).44 An advantage of utilizing the solid core 
technique for formulation allows for a possible decrease in the amount of lipid needed. 
Interestingly, no difference was detected in Th1 or Th2 cytokines from mice treated with 
DDA vaccine formulations with or without a solid core (ie. silica or polystyrene sulfate) 
using a 18kDa-hsp antigen. DDA also elicited cytokine production from cells when 
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complexed with a different antigen, indicating that it is neither the “APCs like 
aggregates” theory, nor the specific molecular surfaces the DDA/Ag complexes that 
controls activation. Thus, it must be possible that there is direct recognition of DDA by 
APCs. When compared to alum, known for its ability to induce humoral immunity, alum 
performed about the same as DDA+Ag (with or without a silica core). However, when 
examining cell-mediated immunity, DDA+Ag (with or without a silica core), performed 
better than alum, indicating a multi-modal immunity that could be elicited.45 Another 
consideration is efficacy in the two branches of immunity could indicate incomplete 
endosomal escape, and activation of APCs through a surface receptor (rather than in the 
cytoplasm). 
The formation of the bilayer fragments are through sonication using a titanium 
probe. Methods indicate that titanium fragments are allowed to settle in the sonicated 
solution for 1 hour, at which time the supernatant containing DDA BF is removed. It is 
possible that while DDA has not shown activity alone (and thus the development of 
CAF01 formulations), that by chance utilizing this titanium probe to create bilayer 
fragments, what is actually being created is a colloid system of titanium particles and 
excess DDA. This would explain why DDA BF works as adjuvants, while DDA alone 
must be formulated with an additional adjuvant to produce efficacious immune responses. 
 
1.1.3.3 diC14-amidine (3-tetradecylamino-tert-butyl-N-tetradecylpropionamindine) 
diC14-amidine is a potent immunostimulator as well as delivery agent that stimulates 
dendritic cells through TLR4, in both MyD88-dependent and Toll/IL-1R-containing 
adaptor inducing interferon IFN-β (TRIF)-dependent pathways.46 MPL, a simpler 
component of LPS that still signals through TLR4, and diC14-amidine both share similar 
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hydrophobic structures with C12-C14 chains and 2 C14 chains respectively. Treatment 
with diC14-amidine causes large amounts of inflammatory cytokines, including TNF-α 
and IL-12p40, in contrast to DOTAP and DDA. As expected, NF-κB as well as ERK1/2, 
JNK and p38 MAP kinases are associated with DC activation by diC14-amidine. Earlier 
work has shown that mannan coating of diC14-amidine/DNA vaccine formulations 
greatly increases efficacy, particularly when measuring a cell-mediated response.47 The 
well-characterized nature of this adjuvant allows for careful use in clinic, perhaps even 
pairing with a cargo or application that necessitates or could counteract the strong 
inflammation elicited. 
 
1.1.4 Conclusion 
 Many types of liposomes (charged and uncharged) have been utilized in stimulating the 
immune system.48; 49; 50 Cationic lipids allow for flexibility in delivery of polyanionic 
cargos such as pDNA and CpG oligonucleotides, encoding therapeutic cytokine genes, or 
antigen itself, or utilization of the TLR9 activity of CpG oligos. More importantly, some 
cationic lipids can both stimulate and deliver, with a variety of antigenic cargoes, and 
elicit cell-mediated response that has not yet been shown by any FDA approved 
adjuvants. 
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1.2 THE SUPPRESSIVE TUMOR MICROENVIRONMENT: A CHALLENGE 
IN CANCER IMMUNOTHERAPY 
In the past few years, the public’s perception of vaccines has radically changed. The 
retraction of Andrew Wakefield’s landmark 1998 publication in the Lancet that had 
correlated the development of autism with vaccinations and primarily the preservative 
thimerosal, had less impact than a scientist could hope. 51; 52; 53; 54 Rather, the emergence 
of preventative vaccines such as GardasilTM and CervarixTM that vaccinate against strains 
of the Human Papillomavirus (HPV) attributed to cause 70 % of cervical cancers, and 
Dendrion, a therapeutic vaccine that utilizes personalized medicine to treat prostate 
cancer have created renewed energy and interest in vaccines and immunotherapy, 
particularly for cancer treatment. 
GardasilTM is a quadravalent vaccine, immunizing against four different strains of 
HPV (6, 11, 16, 18), and is approved for women and men ages 9-26. Gardasil uses 
amorphous aluminum hydroxyphosphate sulfate as the adjuvant and uses a yeast 
expression system to manufacture the protein antigens. These protein antigens (from the 
four different HPV strains) are a major viral capsid protein, called L1, thus when 
introducing the proteins to the immune system, with the help of an adjuvant, the immune 
system can recognize the virus in circulation and kill the infected cells before it is able to 
mutate cervical epithelial cells (or any others) into cancer. 
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CervarixTM is a similar formulation, delivering the viral capsid proteins with an 
adjuvant for prevention of HPV infection, however has several distinct differences. 
Cervarix is a bivalent vaccine (against HPV16 and 18) and therefore is only approved for 
women (ages 10-25), uses a baculovirus (insect cell) expression system to manufacture 
antigens, and a different adjuvant (AS04 (3-O-desacyl-4’-monophosphoryl lipid A (MPL) 
adsorbed on to aluminum (as hydroxide salt)). 
As mentioned previously, GardasilTM is an example of a cancer vaccine that uses 
aluminum hydroxide as an adjuvant. Until recently, alum was the only approved FDA 
adjuvant, utilized in nearly every marketed vaccine. AS04 is the second adjuvant to be 
approved in the US, and only appears in one vaccine (Cervarix). It builds upon the 
success of aluminum hydroxide, quite literally, with monophosphorylated lipid A 
conjugated to aluminum hydroxide. 
However even with the recent successes, a good cancer vaccine has a great deal to 
overcome. It is not adequate to simply contain a strong adjuvant, specific antigen and 
particle form to make it attractive to the immune system. In some cases, an effective Th1 
response can be measured (via IFN-γ levels), however, the tumor remains.55 Stromal cells 
have a strong impact on the tumor microenvironment and how the immune system 
interacts with the tumor.56 Several different types of hematopoetic non-vascular stromal 
cells can be present and protect the tumor from discovery and elimination. Removal or 
suppression of these inhibitory cells can enhance the tumor recognition and regression by 
the immune system as shown in Figure 1.3. Chapter 1.3 will present different types of 
hematopoetic non-vascular stromal cells and their affect on the tumor microenvironment, 
as well as strategies to overcome these effects. 
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Figure 1.3 The suppression of the suppressive tumor microenvironment. 
By disarming the suppressive immune cell sentries in the tumor, the tumor becomes vulnerable to attack 
and destruction.  This chapter will focus myeloid-derived suppressor cells (MDSC), tumor-associated 
macrophages (TAM), and T regulatory cells (Tregs). 
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1.2.1 Tumor Associated Macrophages (TAM) 
1.2.1.1 Overview 
Chemokine (C-C motif) ligand 2 (CCL2), also known as monocyte chemotactic protein-1 
(MCP-1), has a strong influence in the recruitment of macrophages and lymphocytes into 
tumor interstitum. This chemokine is released by macrophages and some tumors, 
recruiting macrophages and lymphocytes into the tumor microenvironment. While it may 
seem that macrophages in the tumor may be beneficial, tumor associated macrophages or 
TAMs, release growth factors and angiogenic factors encouraging the survival of the 
tumor. However, some studies have shown increased recruitment of cytotoxic T 
lymphocytes in environments with tumor expression of CCL2. Also, care should be taken 
in interpreting the results of some of the studies with human cancers in nude mice, as the 
authors infer a particular immune effect, when the subject (or mouse) has a compromised 
immune system. 
In biopsies of cervical cancer patients, a correlation has been found between the 
amount of CCL2 mRNA expression by cervical tumor cells and the number of TAMs. 
Lack of CCL2 expression in 16 % of samples correlated with “increased cumulative 
relapse-free survival, increased cumulative overall survival, less post-operative surgery, 
reduced vascular invasion and smaller tumor size (<40mm).” Loss of heterozygosity 
(LOH) at 17q11.2 in six samples corresponded with the absence of CCL2 mRNA. The 
authors conclude that TAMs support tumor progression, “presumably by promoting 
angiogenesis and production of growth factors.”57 
Levels of cellular stress such as smoking or cancer have shown to sensitize some 
cells to produce more CCL2 when stimulated with LPS. Although CCL2 levels were seen 
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to be similar in a group containing patients with non-small cell lung cancer, healthy 
smokers and healthy non-smokers, these levels were seen to increase (in the supernatants) 
when peripheral blood mononuclear cells (PBMCs) were stimulated with LPS. Compared 
to baseline, CCL2 levels increased 28.5 fold in non-small cell lung cancer patients, 15 
fold in healthy smokers and 13-fold in the group of non-smokers.58 This sensitivity could 
explain the difference in the role of macrophages in a tumor microenvironment compared 
to a less severe inflammatory environment. 
CCL2 was transfected into a human gastric carcinoma model (both ectopic and 
orthotopic) that did not previously express CCL2. CCL2 transfectants induced tumor 
growth, tumorigenicity, lymph node metastasis, ascites, TAMs in and around tumors, and 
significantly higher microvessel density.59 In a xenograft prostate cancer model, CCL2 
was shown to contribute to the regulation of TAM infiltration and enhanced angiogenesis 
within the tumor.60 CCL2 concentration has been shown to increase with tumor stage 
(severity of tumor) and correlate with TAM accumulation in human colorectal cancer.61 
Recombinant adenoviruses (rAds) expressing an herpes simplex virus thymidine 
kinase (HSV-tk) gene delivered in concert with a rAd expressing CCL2 showed 
suppression of mouse colon cancer tumor growth and has been attributed, by the authors, 
“exclusively associated with the recruitment of monocytes/macrophages, T helper 1 
(Th1) cytokine gene expression and cytotoxic activity of the splenocytes.” The tumor 
itself did not intrinsically express CCL2 before treatment. The propagation of TAMs into 
tumors did increase following delivery of the CCL2 gene in contrast to delivery of the 
CD80 gene.62 The study concluded that suppression of the tumor was directly correlated 
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with macrophage presence in the tumor. However this is not congruent with the many 
other reports of CCL2 inducing negative effects of TAMs.62 
The concept of positive feedback is an important one to consider with chemokine 
induction in the tumor microenvironment. In biopsies of human head and neck squamous 
cell carcinoma, TAMs secreted CCL2 as well as IL-6.63 Both cytokines have shown to 
upregulate anti-apoptotic proteins and inhibit the caspase cascade.64 If both the tumor and 
the TAMs are secreting CCL2, there is an amplification loop to recruit more and more 
macrophages to the tumor and surrounding area, increasing the negative effects from the 
secreted cytokines and chemokines by the macrophages.65 In fact, IL-6 and CCL2 
themselves have been shown to promote mutual induction, protection from apoptosis and 
polarization towards the M2 type macrophage.64 The M2 phenotype act in an 
immunosuppressive manner, secreting IL-10 and transforming growth factor-β (TGF-β). 
In contrast,, M1 type macrophage are immunostimulatory, producing inducible nitric 
oxide synthase, IL-12 and TNF.66; 67  Transition of TAMs from the M1 to M2 phenotype 
can be induced via  HIF-1α knockout.68 
 
1.2.1.2 Solving the Tumor Associated Macrophage (TAM) Problem 
Inhibition of CCL2 has been of great interest lately as many negative effects have been 
elucidated regarding TAMs and CCL2. Gene therapy delivered to a human malignant 
melanoma (B16-F1) has shown that delivering a dominant negative CCL2 mutant gene 
(7ND) over expressing 7ND protein reduced TAMs, tumor angiogenesis, and tumor 
growth. Also, levels of TNFα, interleukin-1α (IL-1α) and vascular endothelial growth 
factor (VEGF) decreased in the tumor, attributed to less TAMs infiltrating the tumor.69 In 
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another study, inhibition of CCL2 in human melanoma xenografts reduced tumor growth 
and macrophage recruitment resulting in necrotic tumor masses.70 
Ability to switch the phenotype from M2 to M1 would solve the TAM problem 
and allow the infiltrated macrophages to become powerhouses of destruction. An 
adenovirus containing CCL16 (AdCCL16) and CpG was delivered intratumorally; the 
anti-IL10R antibody was given i.p., and complete regression in the majority of large 
tumors was observed.71 A few hours after treatment, tumor macrophages switched from 
M2 to M1 type secreting TNF, IL-12, and nitric oxide and even dendritic cells in the 
tumor had upregulated costimulatory molecules and secreted IL-12 and TNF. The 
presence of inhibitory M2 type macrophages was reemphasized as the delivery of 
AdCCL16 alone was not able to cause tumor regression. However, one weakness of this 
study is the delivery aspect, with three separate injections needed (by two different 
delivery routes) to create the desired effect, therefore more work should be done to 
further refine the delivery of this treatment. 
Specific delivery to M2 macrophages could be achieved by targeting the mannose 
receptor. Part of the change to the M2 phenotype caused by CCL2 or IL-6 is a significant 
increase in the mannose receptor (CD206).64 Mannose can be conjugated or incorporated 
to treatments to target therapies to M2 polarized macrophages. Alternatively, targeted 
immunotherapy against TAM surface markers could cause selective clearance of this 
population, A DNA vaccine for legumain, an asparaginyl endopeptidase overexpressed 
by TAMs, increased the number of mice surviving a lethal tumor challenge and decreased 
the number of remaining metastases.72 
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1.2.3 Myeloid Derived Suppressor Cells (MDSC)  
1.2.3.1 Overview 
Myeloid derived suppressor cells (MDSC) are often CD11b+Gr-1+, but are broadly 
defined and have many functions.73 Not only are these two markers found on neutrophils, 
but also immature dendritic cells, monocytes and early myeloid progenitors. MDSC are 
immunosuppressive, and also promote neovascularization. In humans, MDSC are 
CD34+CD33+CD13+.74 When directly exposed to a murine ovarian cancer cell line, 
MDSC express high levels of CD80 (but not CD86).75 As with all immune cells, new 
subpopulations are constantly being defined and re-defined; MDSC are no different, with 
mononuclear or MO-MDSC, and low-density polymorphonuclear cells or PMN-MDSC. 
MO-MDSC was shown to function through STAT1, IFN-γ or nitric oxide (NO), whereas 
PMN-MDSC required IFN-γ, but not STAT1 or NO.76 
The appearance of MDSC has been documented in many different cancers 
including mouse mammary carcinoma77, 4T178; 77, and murine colorectal 
(MC38/CEA2)79. It has been shown in breast cancer that CD11b+Gr-1+ are recruited into 
tumors with type II TGF-β receptor gene (Tgfbr2) deletion.78 Recruitment of MDSC to 
tumors has also been shown by several different chemokines including CXCL12, SDF-
1α, CCL2, CXCL5 and KIT ligand.80 Secretion of TGF-β1 by MDSC in the tumor 
microenvironment has been shown to promote metastasis in breast cancer.78 In human 
breast cancer, numbers of MDSC was proportional to the clinical stage and lymph node 
metastasis (with stage III having more than stage I/II, and >3 metastases having more 
MDSC than <3.81 
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Immature myeloid cells inhibit CD8+ T cells in direct cell-cell contact, show 
increased amounts of reactive oxygen species (ROS) caused by accumulation of H2O2. 
Also, MDSC have increased ROS production in the presence of stimulated Ag-specific T 
cells (stimulated with their specific Ag and producing IFN-γ.82 MDSC are inversely 
correlated with NK function in the liver and the spleen and have been shown to inhibit 
NK cell production of IFN-γ by MDSC membrane-bound TGF-β1.83 
In a tumor that produced IL-1β, accumulation of CD11b+Gr-1+ cells correlated 
with poor prognosis.84 Not only does IL-1β attract MDSC to tumors, but GM-CSF and 
VEGF as well. CD34+ cells showed accumulation in Lewis lung carcinoma tissues 
selectively (rather than the surrounding tissues), entirely attributed to the secretion of 
VEGF.85 High expression of GM-CSF in the tumor causes increased numbers of MDSC 
and immunosuppression.86; 87 
Not surprisingly, MDSC do not act alone. MDSC and macrophages communicate 
in the tumor via cell-cell contact, with macrophage production of IL-12 decreasing 
dependent on MDSC production of IL-10.88 The over expression of CD80 on MDSC 
allowed for the suppression of antigen specific immune responses in concert with T 
regulatory cells (see section 1.2.4).75 
 
1.2.3.2 Solving the Myeloid Derived Suppressor Cell (MDSC) Problem 
The simplest fix is to remove the draw that recruits the MDSC into the tumor interstitum 
in the first place. Resection of large tumors producing IL-1β restored immune activity, 
while treatment with IL-1R agonist reduced tumor growth.84 
Another less elegant solution is to remove the suppressive cells from the body, 
and convert them in vitro to a tumor fighting immune cell type. Isolated CD11b+Gr-
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1+CD31+ suppressor cells can be converted in vitro to myeloid dendritic cells with 
exposure to IL-4 and GM-CSF.86 This could facilitate removal of the suppressive MDSC, 
ex vivo priming of the newly formed dendritic cells with tumor antigen, and re-dosing of 
the activated DCs to the patient. However, an effective method to extract the MDSC from 
the tumor interstitum does not yet exist, and thus the need for new and innovative 
treatments to combat MDSCs. 
Formalin-inactivated herpes simplex virus (HSV) delivered to a murine system of 
colorectal cancer inactivated MDSC through B cells. It was shown that expansion of 
MDSC required B cell production of angiogenesis factors such as VEGF-A, and 
neuropilin-1 (NRP-1).89 Delivery of all-trans-retinoic acid (ATRA) to patients with 
metastatic renal cell carcinoma reduced the number of immature myeloid suppressor 
cells, if the patients retained a high plasma concentration of ATRA >150 ng/mL.90 
Combination therapy is a popular approach to combat MDSC cells’ effect on 
tumor growth. Delivery of IL-7 and IL-15 after radiofrequency thermal ablation reduced 
tumor growth, metastasis and numbers of MDSC in murine breast tumors.77 Another 
example is the delivery of 5-fluorouracil and leucovorin together with a DC vaccine 
reduced the numbers of both MDSC and T regulatory cells (another suppressive immune 
cell to be discussed in detail later) in a murine colorectal cancer model.79 Decrease of 
MDSC in the microenvironment and tumor control of colorectal tumors (inoculated with 
intrahepatic injection) was achieved by delivery of an adenovirus coding IL-12 in 
conjunction with oxaliplatin. The IL-12 expression cassette was developed to be 
mifepristone inducible, thereby allowing control of IL-12 dosing. With this treatment, an 
increase in the CD8+/Treg ratio was also observable.91 
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While this review has focused on the effect of regulating these suppressive cells 
in the tumor microenvironment, it is useful to note that eradication of the suppressive 
cells from anywhere in the body can elicit a therapeutic response. Gemcitabine was able 
to decrease splenic MDSC in large tumor bearing mice, while increasing the anti-tumor 
activity of CD8+ T cells and NK cells.92; 88 This was further augmented by an 
intratumoral injection of adenovirus containing IFN-β.92 
 
1.2.4 CD4+CD25+FoxP3+ Regulatory T cells  
1.2.4.1 Overview 
T regulatory cells (Tregs) are positive for surface markers CD4, CD25 (IL-2 receptor) 
and an intracellular marker, FoxP3. Additionally, these cells have high surface expression 
of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and glucocorticoid-induced 
TNFR-related protein (GITR).93 These cells have been found to accumulate in metastatic 
melanoma tumors and prevent tumor regression, even when CTL are present.94 Although 
their function has not been completely elucidated, the presence of Treg cells have been 
linked to poor tumor regression and can be induced by immunostimulatory treatments.30; 
95 
Presence of Tregs in tumor tissue is cancer specific. Early-stage non-small cell 
lung cancer and late-stage ovarian cancer patients were first observed to have Treg 
infiltration.96 Tregs are rarely seen in enucleated chorodial melanoma,97 however they are 
found in human prostate cancer and more common in the peripheral and transition zones 
than in the core of the tumor.98 In gliomas, infiltration of Tregs was correlated with Heme 
oxygenase-1 (HO-1) mRNA and progression of the disease.99 Increased populations of 
 27
Tregs have been found in hepatocellular carcinoma, and even in non-tumorous liver that 
contains primary hepatic tumors.100 
Tregs have been shown to migrate towards IL-6 and IL-8-producing tumors by 
induction of CXCR1 by IL-6.101 TAMs also secrete IL-6 promoting Treg recruitment to 
the tumor interstitium. Similarly, TAMs and tumor cells producing CCL22 recruited 
CCR4+ Tregs in ovarian cancer and glioblastomas.102; 103 NK depletion in mice bearing 
Lewis Lung Carcinoma (LLC), has shown increase in expression of CCL22 and 
correlated with increased levels of Tregs.104 In both human and mouse models of 
pancreatic cancer, tumors produce CCL5 that recruits CD4+FoxP3+ Tregs to the tumor.105 
Tregs contain high levels of cytotoxic T lymphocyte (CTL)-associated antigen 4 
(CTLA-4) which binds with CD80/86 on APCs. This interaction induces production of  
indoleamine 2,3-dioxygenase (IDO) in APCs,106 which interferes with the activation of T 
cells. Some types of Treg cells have been defined as secreting IL-10 and TGF-β but not 
IL-4 or IL-2.107 IL-10 production can inhibit proliferation of CD4+ cells.108 The exact 
mechanism of suppression is unknown, and the myriad of phenotypes makes 
specification difficult, however, it is well established that presence of Tregs in tumor 
interstitum correlates with poor prognosis. 
 
1.2.4.1 Solving the Regulatory T cell (Treg) Problem 
Coexpression of surface CD25 and intracellular FoxP3 (on CD4+ cells) has been used to 
characterize the Treg population. However, CD25, also known as the IL-2 receptor (IL-
2R), is upregulated on activated T cells, thus designing drugs against CD25 may have 
off-target. Preclinically, delivery of anti-CD25 antibodies have shown success in 
increasing the life span of tumor bearing animals in a variety of tumor types, including 
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glioma and pancreatic cancer. 99; 109; 110 In one study on glioblastomas, survival was found 
to be tumor burden dependent, indicating there is some limit to the strength of an 
unstimulated immune response.109 Daclizumab is a humanized monocolonal antibody 
against CD25. In a small clinical trial, it has been used in metastatic breast cancer 
patients to clear CD25+Fox3+ cells from circulation, to allow for a more preferable 
environment to dose a peptide vaccine and elicit a CTL response.111 
A simpler way to target CD25, the IL-2 receptor, is with IL-2. Denileukin diftitox, 
is a fusion protein combining IL-2 and diphtheria toxin. In a pilot study, after multiple 
doses of denileukin diftitox, T-cell response to carcinoembryonic antigen (CEA) was 
observed.112 In treating melanoma, after dosing with denileukin diftitox numbers of 
Tregs, CD4+ and CD8+ T cells decreased, but T cell repopulation included CD8+ T cells 
specific for melanoma antigens. After at least one cycle of denileukin diftitox, five out of 
sixteen patients experienced melanoma regression, some with metastatic lesions 
(NCT002996889).113 When denileukin diftitox was compared against cyclophosphamide 
and anti-CD25, cyclophosphamide provided the greatest degrease in Tregs, but also 
reduced the population of CD8+ T cells. Denileukin diftitox reduced more than half of the 
Tregs, with anti-CD25 having a lesser but longer lasting effect.114 
Other experimental treatments have varied approaches and outcomes. With the 
positive effect CD25 agonists and antibodies have performed, it is not surprising anti-
CTLA4 antibodies were also tested. Treatment consisting of chronic administration of 
anti-CTLA4 antibodies was unable to deplete Tregs or impair function in a B16 
melanoma model, and actually allowed the population of Tregs to expand in percentages 
and absolute numbers.115 A simple vaccine of DOTAP and peptide antigen has been 
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shown to decrease the number of Treg cells and cause regression of existing tumors.30 In 
one case, the addition of low dose CpG to an immune stimulatory complex (ISCOM) 
vaccine decreased the population of Tregs. Delivery of a CCR5 inhibitor (TAK-779) in 
pancreatic adenocarcinoma limits Treg migration to the tumor, as well as produces 
tumors smaller than control subjects.105 
 
1.2.5 Conclusion 
With the growing promise of gene delivery, and the plasticity of immune cells and 
lineage, it is important to consider the target genes that could be modified to reverse the 
suppressive immune environment. Table 1.1 notes several genes discussed in this review 
that play important roles in the immune regulation of the tumor microenvironment. As 
can be seen, most of the proposed strategies involve using siRNA to down-regulate the 
target gene. The only up-regulation desirable is the expression of a dominant negative 
mutant of CCL2. Thus, delivery of specific siRNA or plasmid DNA to the immune cells 
in the tumor interstitium is highly desirable. It presents a new challenge to the gene 
therapy community. 
While a great deal of work has been done in creating treatments to overcome the 
tumor microenvironment, a great deal still remains. While all cell types reviewed in this 
article deal with hematopoetic stromal cells, a recent publication in Science by Kraman 
and colleagues explore mesenchymal stromal cells and the inhibitory nature with the 
expression of fibroblast activated protein–α (FAP-α). The study showed that the removal 
of FAP-α expressing cells permits the efficacy of a therapeutic vaccine in a solid tumor 
model.116 While the model of expression is transgenic and artificial, the importance of 
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FAP-α lends insight to yet another method utilized by tumors to prevent immune 
recognition. Whatever the method of immune suppression the tumor employs, it seems 
that any therapeutic cancer vaccine that hopes to be efficacious must simultaneously be 
able to switch the immune system on, and switch the tumor microenvironment off. 
 31
 
Table 1.1 Target genes in the suppressive tumor microenvironment.  
Gene/Protein Target Cell(s) Strategy 
CCL2 TAMs siRNA to ↓ expression 
IL-6 TAMs siRNA to ↓ expression 
dominant negative CCL2 mutant 
gene (7ND) 
TAMs Gene transfer to ↑ expression 
CCL16 TAMs Gene transfer to ↑ expression 
IL-10 TAMs, Tregs siRNA to ↓ expression 
Heme oxygenase-1 (HO-1) Tregs siRNA to ↓ expression 
Transforming growth factor-β 
(TGF-β) 
TAMs, MDSC, Tregs siRNA to ↓ expression 
STAT1 MDSC siRNA to ↓ expression 
Indoleamine 2,3-dioxygenase 
(IDO) 
APCs siRNA to ↓ expression 
IL-6, IL-8, CCL22 Tumor (to prevent 
TAM recruitment) 
siRNA to ↓ expression 
CXCL12, SDF-1α, CCL2, 
CXCL5, KIT ligand, IL-1β, GM-
CSF, VEGF 
Tumor (to prevent 
MDSC recruitment) 
siRNA to ↓ expression 
CCL5 Tumor (to prevent 
Treg recruitment) 
siRNA to ↓ expression 
 
 32
1.3 CHEMICAL VECTORS FOR DELIVERY OF NUCLEIC ACID BASED 
DRUGS 
1.3.1 Introduction 
The blossoming field of gene therapy is a clever way to regulate the proteins in a tissue 
by making the host cells produce (or silence) the protein of interest by its own 
mechanism. One could consider it protein “dosing,” and it can be used to treat many 
genetic and acquired disorders including cancer. Many different types of nucleic acid 
based drugs can be delivered, such as plasmid DNA, oligonucleotides, and various forms 
of RNA interference (RNAi): siRNA, shRNA or miRNA (short interfering RNA, short 
hairpin RNA or micro RNA). Delivery vectors range a wide gamut of biomaterials, the 
two largest classifications being viral and non-viral. While viral vectors are able to 
produce the highest gene transfection efficiency,117 complications with immune response 
push our interests towards the newer field of non-viral vectors, also called chemical 
vectors, including cationic polymers, liposomes and peptides, among others. While many 
different vectors can be used to control size of payload, transfection efficiency and 
immune response, the delivery route is also an important consideration because the 
treatment needs to be efficient, simple to administer and suitable to the application. This 
chapter will briefly review systemic barriers to gene delivery via chemical vectors, then 
discuss different vehicles used in nucleic acid delivery. Targeting moieties and triggered 
release will also be reviewed as ways to enhance systemic or local delivery. Finally, 
delivery of nucleic acids with chemical vectors in recent clinical trials will be covered. 
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1.3.2 Barriers to Delivery of Nucleic Acids 
1.3.2.1 Anatomical 
In systemic circulation, the first barrier encountered is the blood stream. The blood 
contains serum proteins, nucleases and macrophages that can aggregate, degrade or 
phagocytose the delivery vector, respectively, even before it reaches the tissue of interest. 
Naked plasmids have been shown to have a half-life of 1.2 minutes for supercoiled 
pDNA, 21 minutes for open circular pDNA and 11 minutes for linear pDNA in rat 
plasma.118 However, in the same study, complexing pDNA with cationic liposomes 
(DOTAP:DOPE, 1:1 w/w), prevented degradation and allowed the supercoiled plasmid to 
be detected after 5.5 hours.  
Clearance by the reticuloendothelial system (RES) is of great concern, and 
particle size often determines by what organ (liver, kidney or spleen) and how quickly the 
particle will be cleared from the blood. Extended plasma circulation is desired to allow a 
majority of the injected dose to reach the target tissue. Poly(ethylene glycol) (PEG), a 
hydrophilic inert polymer has been conjugated to many chemical vectors to extend 
circulation time, such as liposomes, patented by Lasic’s group, later termed Stealth® 
liposomes.119; 120; 121; 122 Once in the vasculature of the target tissue, the delivery vector 
must leave the blood stream and transverse into the interstitial space of the tissue. 
Tumor vasculature is inherently disorganized, immature, and tortuous due to the 
presence of discontinuous endothelium and an incomplete basement membrane. The 
blood vessels in the tumor attempt to supply tumor cells with nutrients, and cannot grow 
fast enough to fully develop. The Enhanced Permeability and Retention (EPR) effect is 
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often utilized in cancer therapy to deliver drugs to the interstitum of tumors, skipping the 
usual barrier of transversing the endothelium.123; 124; 125; 126 However, this permeability is 
not universal in tumor vasculature. Heterogeneous permeability of tumor endothelium 
and interstitum was shown in window chamber experiments using by Rhodamine-labeled 
stealth liposomes.127 Doxil® (a commercial formulation of doxorubicin encapsulated in 
stealth liposomes), showed increased accumulation in tumor tissue compared to normal 
tissue in humans.128 
While the EPR effect is useful in many tumor microenvironments, other methods 
have been developed to further enhance the delivery. For efficient delivery, the vector 
may be targeted to the specific tissue of interest by ligand attachment on the vector, to 
target a receptor on the cells in the tissue of interest or by triggering release at the desired 
site. These two topics will be discussed in depth later. Being able to discriminate between 
target and non-target cells is crucial to ensure specific expression of the nucleic acids 
delivered. 
 
1.3.2.2 Cellular 
Once at the plasma membrane, the chemical vector must be endocytosed to enter the cell. 
Endocytosis can occur by many routes including macropinocytosis, clathrin-mediated and 
non-clathrin mediated endocytosis and entry via caveolae.129 Polyplexes of 
polyethyleneimine (PEI) complexed with pDNA were shown to attach to cell surfaces, 
migrating into clumps, and then endocytosed.130 It has been postulated that cationic lipid 
carriers can enter cells through fusion with the cell membrane however, much more 
evidence exists for endocytotic pathways.131 However, Douglas et al, have recently 
published results arguing that endocytosis is cell-line dependent. The authors report that 
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after clathrin-mediated endocytosis, complexes follow the endo-lysosomal pathway, 
which initiates the proton-sponge effect for release (to be discussed later, in the section 
entitled ‘Triggered Release’). Further, the author’s report that caveolin-mediated 
endocytosis leave the complexes trapped in vesicles that become “transfection-
incompetent.”132 In the endosome, the nanoparticle or naked plasmid must escape before 
being degraded upon fusion of a lysosome with the current endosome.133 
Once the particle or naked plasmid is in the cytoplasm, it faces additional 
intracellular barriers. Diffusional mobility of plasmid DNA is limited due to the 
cytoskeleton, particularly actin and molecular crowding in the cytoplasm.134 Intracellular 
mobility of DNA was shown to be size dependent. Double stranded DNA >250 bp had 
significantly decreased diffusion compared to DNA of 100 bp or less.135 Active cytosolic 
nucleases can degrade the plasmid. However, if the nucleic acids being delivered function 
via an RNAi mechanism, they need travel no further than the cytoplasm where crucial 
enzymes such as RISC and Dicer reside. Entry into the nucleus by the plasmid is rate 
limiting, and can only be achieved when the cell divides or through nuclear membrane 
pores, which have size limitations on what can enter or exit. Nucleus localization 
sequences (NLS) can be conjugated to pDNA to facilitate entry through the nuclear 
pores,136 which can increase in size from 9 to 39 nm from docking of appropriate NLS.137 
However, most delivery systems rely on non-specific entry to the nucleus.135 
 
 
 
 
 36
1.3.3 Major Classes of Delivery Vectors 
1.3.3.1 Introduction  
Cationic moieties are able to condense DNA, RNAs, and other oligonucleotides, through 
the ionic interaction of the nucleic acid’s negatively charged phosphate backbone, with 
cationic charges, which can come from lipids, polymers, or peptides. These different 
classes of delivery vectors have been developed with individual limitations on size, 
charge ratio, nucleic acid capacity, and toxicity. 
 
1.3.3.2 Cationic Lipids 
Cationic liposomes were first used for DNA transfection by Felgner et al. in 1987 with 
the introduction of the cationic lipid, N-[1-(2,3-dioleyloxy)propylJ-N,N,N-
trimethylammonium chloride (DOTMA).138 Soon after, DOTMA’s ester analogue 
DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) also saw popularity as a cationic 
lipid used in drug delivery.29; 139 
Lipoplexes are a popular chemical vector delivery technique, due to the relatively 
low immune response accompanying their delivery. These vectors combine cationic 
lipids with DNA to produce a complex, a product of the interaction of the negatively 
charged phosphate backbone and the positively charged lipid head groups. Transfection 
has been shown to be a function of charge ratio (lipid:DNA). Using a 4:1 charge ratio, the 
in vivo transfection of IL-12 plasmids was improved by conjugating albumin to the 
exterior of the lipoplex in combination with intratumoral (i.t.) delivery.140 The lipids used 
were 1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (EPOPC) and cholesterol 
(chol) in a 1:1 ratio. Albumin was added to the outside of the membrane, to enhance the 
escape of DNA from the endocytotic pathway, since it has been described to undergo a 
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low-pH induced conformational change, acquiring fusogenic properties.141 Similar to IL-
18, IL-12 enhances the proliferation and cytotoxic activity of both T and NK cells and 
induces the production of IFN-γ. Also delivered (in a separate experiment) by this 
albumin conjugated lipoplex was the “suicide” gene, HSV-tk, which when delivered with 
the prodrug ganciclovir (GCV), converts into a toxic active metabolite that causes cell 
death. The attachment of albumin greatly increased the transfection efficiency of the 
lipoplex at all charge ratios (4:1, 2:1 and 1:1). This study showed that 4 i.t. injections of 
these plasmids over several days at 40 μg each (with HSV-tk accompanied by 
intraperitoneal (i.p.) injections of GCV) showed significant tumor growth delay in a 
subcutaneous TSA model (a mouse mammary adenocarcinoma, which is highly 
aggressive, immunogenic and has a high proliferation capacity) compared to the control 
injection of buffer. Complete tumor regression was seen in one member of the 
immunogene therapy group (one of six). Even after 4 i.t. injections of the control 
plasmid, some growth delay was seen, the authors attributing this to cytosine-phosphate-
guanine (CpG) motifs in the plasmid that elicited a slight immune response. Higher T-
lymphocyte infiltration was seen from control plasmids verses untreated mice, showing 
the immune response from even an empty plasmid. However, albumin coated lipoplexes 
containing the IL-12 plasmid (40 μg) showed significant tumor regression, high T-
lymphocyte infiltration and extensive necrotic and hemorrhagic areas. Also, with both 
formulations (with and without albumin) this study demonstrates a frequent problem of 
high transfection in the lung, rather than the target tissue. 
LPD, which stands for “liposome-polycation-DNA,” was developed by Huang’s 
group, and uses cationic liposomes differently than other groups. While most cationic 
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liposomes condense nucleic acids in layers, with the cationic bilayers associating with 
negatively charged nucleic acids, making a multilamellar liposome, LPD is different. 
LPD first condenses nucleic acids with a polycation such as polylysine or protamine, 
making a solid particle, and then mixes that solution with charged liposomes, which 
effectively coat the surface of the solid DNA-polycation core. LPDII complexed DNA 
and polylysine at a ratio of 1:0.75, then trapped in folate-targeted anionic pH-sensitive 
liposomes. LPDII is coated with PEG conjugated to folate, to help the particle evade RES 
detection and target folate over-expressing cells such as KB cells.142 The particle’s charge 
depends on the lipid/DNA ratio, and at high lipid/DNA ratios, the anionic particles are 
formed, while at low lipid/DNA ratios, cationic particles are formed. The cationic 
particles were found to have high transfection but to not be tissue specific, whereas the 
anionic particles showed a receptor dependent transfection activity. 
In another, more recent formulation of LPD, three different siRNA sequences 
were co-formulated in each LPD to cause simulatenous silencing of three important 
proteins in cancer survival: MDM2, c-myc and vascular endothelial growth factor 
(VEGF).143 The LPD were made with DOTAP as the cationic lipid, protamine as the 
polycation, protected against RES uptake by a PEG and targeted using anisamide to the 
sigma receptor on murine lung metastasis. A 70-80 % reduction in cancerous nodules in 
the lung was seen in the targeted treatment group compared to control. 
 
1.3.3.3 Cationic Polymers 
Polyethylenimine (PEI) is a cationic polymer commonly used in gene delivery to create 
“polyplexes,” indicating the complexation of DNA and a polymer. Linkers made of PEG, 
an inert hydrophilic polymer, can also be added to prevent uptake by the RES.144 Because 
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of the enhanced release from the endosome due to the proton sponge effect, cationic 
polymers have been popular in gene delivery. However, the toxicity of the vector is often 
an issue at high molecular weights. Polyplexes have also been conjugated to targeting 
ligands, either directly to the PEI, or to a PEG linker on the PEI such in the case of RGD 
peptide.144 
Focal adhesion kinase (FAK) is a protein kinase in cell cycle progression and cell 
migration. Modified PEI (M-PEI) was used to transfect tumor cells and tissues with a 
FAK siRNA plasmid (psiFAK) to down-regulate tendency of metastases forming in the 
mouse model from left hind footpad model using B16F10 (mouse melanoma). After i.t. 
delivery of psiFAK, the tumor showed no metastases in the lungs and lymph nodes in any 
mouse (n=6), compared to PBS or either control plasmid (pLuc or pKH3). Primary 
tumors also experienced a statistically significant growth delay, and survival time when 
treated with psiFAK as compared to the controls.145. 
In addition to modified PEI, linear and branched PEI have also been used in i.t. 
gene delivery. Coll et al. has compared three routes of delivery (i.v., intracystic and i.t.) 
to human non-small cell lung carcinoma (NSCLC) using a Luciferase plasmid to discover 
the best method of polyplex administration with linear PEI.146 A charge ratio of 10 
polymer:DNA provided the best in vivo transfection, causing increasing expression from 
24 to 96 hours. When delivering intravenously to solid tumors, minimal expression was 
seen in the highly vascularized tumors, independent of size. However, a nearly 3-fold 
increase in expression was seen in the normal lung tissue, making these nanoparticles 
useless for solid tumor delivery if injected i.v., not even benefiting noticeably from the 
EPR effect. A common lung metastasis model was used here that consists of i.v. injection 
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of tumor cells which are caught in the lung and create many nodules therein. After an i.v. 
injection of these PEI particles, only tumor-free mice expressed Luciferase and no 
expression was seen in tumor loaded lungs. However, using other delivery routes, these 
particles were effective. In several cancers, including some ovarian and gliomas, the 
tumor wall expands to create a liquid filled cavity. In a cyst-forming tumor mouse model 
H358NL, after draining the internal liquid (up to 5mL), a small volume of polyplexes 
were delivered into the cyst cavity.146 This method of delivery showed high transfection 
and long-lasting expression and could also be used post-surgery, after the bulk of the 
tumor had been removed and some residual tumor cells remained. The authors found that 
the volume injected i.t. with a normal syringe traveled to the periphery of the tumor. A 
micro-pump technique was developed to deliver i.t. at a rate of 20μL/min. This method 
showed high and long-lasting expression of the transgene, where normal syringe injection 
was not effective. However, free plasmid injection was inefficient with the micro-pump, 
and more effective with the normal syringe injection, indicating that the hydrostatic 
pressure induced from normal i.t. injection possibly aided in delivery. 
Rozema et al. introduced a multifuntional polymer for delivery of siRNA to 
hepatocytes.147 Named “Dynamic PolyConjugates”, these particles utilize an 
endosomolytic polymer, an amphipathic poly(vinyl ether) termed PBAVE, composed of 
butyl and amino vinyl ethers. This polymer has the ability to connect to targeting ligands 
to reach the cell of interest, poly(ethylene glycol) to evade the RES, as well as the nucleic 
acid payload. Once inside the endosome and the pH drops, a pH-labile bond connecting 
the targeting ligand and PEG is cleaved, exposing many positive charges and inducing 
the proton sponge effect, drawing water into the endosome until it bursts, allowing the 
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siRNA to escape into the cytoplasm. This vector has a mechanism for many of the 
challenges of delivery, and lives up to its dynamic name, able to change as each event 
presents itself. 
The Davis group introduced a cationic cyclodextran-containing polymer for 
condensing pDNA in 1999 showing comparable transfection to PEI and Lipofectamine 
formulations in vitro.148 Aims were to decrease toxicity during transfection, and the 
cyclodextran formulation showed no signs of toxicity at a 70:1 (+/-) charge ratio in the 
presence of 10 % serum. Later development of this system included conjugation of an 
adamantane-terminated modifier to PEG to stabilize the particle and maximize plasma 
circulation time, as well as conjugating the modifier to targeting ligands such as 
transferring.149; 150; 151 Characterization of the particle’s formulation showed that size can 
be “dialed in” between 60 and 150 nm, similarly with a zeta potential ranging between 10 
and 30 mV depending on how the formulation is made and modified.151 
Water soluble lipopolymers (WSLP) are another class of polymers used for 
nucleic acid delivery.152 Branched PEI was conjugated to a hydrophobic lipid anchor. 
Single or repeated i.t. injections of WSLP containing IL-12 plasmid were compared to 
see the tolerance of the method and the efficacy on tumor regression and survival in a 
CT26 colorectal model. The studies also showed that the complexes could be retained in 
the tumor for up to 24 hours. The WSLP/pIL-12 plasmid complexes performed better 
against the controls of no treatment, free plasmid and 25K PEI/pIL-12 in both 4 and 8 
day repeat i.t. injections. After 45 days, 60 % of the treatment group that received 
WSLP/pIL-12 every 4 days were alive, compared to 40 % of the group that was treated 
with WSLP/pIL-12 every 8 days, while all members of the single injection and control 
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groups had reached study endpoints by day 33 and 26, respectively. However, the repeat 
injection method did cause some side effects. After six weeks of injections (either every 4 
or 8 days), the majority of mice in these groups could no longer receive injections 
because of increased tumor necrosis. 
 
1.3.3.4 Cationic Dendrimers 
Cationic dendrimers are built of positively charged molecules, usually amino groups, 
branching out from a central core. Each increased addition of branches is termed a new 
“generation.” Several consistencies are seen across dendrimer transfection research. 
Increased generation yields increased transfection, but also increased toxicity. Even 
dendrimers delivered alone (not complexed with DNA) can induce host cell DNA 
damage.153 Also, because cationic dendrimers can contain many positive charges, as they 
are formed from cationic monomers polymerized outwards from a central core, the 
proton sponge effect can be observed with dendrimers as well.154 Endocytosis of 
dendrimers complexed with nucleic acids (dendriplexes) varies across cell lines.155; 156 
Dendriplexes have been shown to internalize through a cholesterol-dependent 
mechanism, 155 but in other cells, cholesterol depletion does not seem to have an effect in 
cells which express few caveolae (HeLa and HepG2).156 These cells, as well as 
endothelial cells endocytosed dendrimers complexed with DNA (dendriplexes) even with 
inhibition of clathrin-independent, phagocytic and macropinocytic pathways. It was 
discovered by the same group (Manunta et. al), that an increased rate of uptake occurred 
with over-expression of caveolin 1. 
Issues with cationic dendrimers such as transfection efficiency and cytotoxicity 
increasing in tandem, have been solved somewhat by Zhang et al. The research group 
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conjugated polyamidoamine (PAMAM) dendrimers to the surface of poly(D,L-lactide-
co-glycolide) (PLGA) microspheres. Plasmid DNA was trapped by these particles by 
incubating PAMAM-coated PLGA microspheres (positively charged) with negatively 
charged pDNA. Unmodified PLGA microsphere were made by double emulsion and 
solvent evaporation of a mixture of PLGA to pDNA.157 
The core of the dendrimer can be modified, giving a different branching pattern 
and thus amino group density, dictated by the number of reaction centers available on the 
core.158 The core that builds a less dense dendrimer, has been shown to require a higher 
generation to effectively condense DNA. A trimesyl core that gives three places for 
dendrimer building to begin, while pentaerythritol gives four, and inositol gives six. 
Trimesyl core dendrimers required generation six dendrimers to effectively condense 
DNA, while pentaerythritol and inositol only required generation five dendrimers. 
However, interestingly, the trimesyl core generation 6 dendrimers were smaller (100-300 
nm) than the pentaerythritol or inositol generation 5 dendrimers (>600 nm), as well as 
showing greater transfection. In trimesyl core dendrimers, as commonly reported with all 
dendrimers, cytotoxicity did increase with generation, however, the toxicity was much 
less than that of PEI.158 
 
1.3.3.5 Cell Penetrating Peptides (CPP) and DNA mimics 
Cell penetrating peptide-based drug delivery systems have been developed to administer 
genes to tumors. Morris et. al. have developed an amphipathic peptide, Pep-3, suitable for 
either i.t. or i.v. delivery, with slight modifications to overcome systemic barriers when 
delivered intravenously.159 Plasmids that target antisense cyclin B1 (HypNA-pPNA) were 
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delivered to a xenograft animal tumor model (PC3, human prostate carcinoma) as a DNA 
mimic. 
The studies also showed that peptide binding of DNA mimics and uptake of the 
complex into cells are dependent on the hydrophobicity and charge of the peptide, 
respectively, with a minimum of four cationic charges require within the hydrophobic 
domain. The greatest growth delay over all the groups was seen with i.t. delivery of 5μg 
of the Pep-3 DNA mimic, outperforming even 1 μg of the same complex delivered, 
showing a dose dependency. To evade the immune system in systemic circulation, Pep-3 
was coated with poly(ethylene glycol) (PEG). The newly coated Pep-3/DNA mimic/PEG 
nanoparticle was delivered intravenously at 10 μg and saw similar tumor growth delay as 
5 μg Pep-3/DNA mimic delivered i.t. As not exemplified in previously studies, this 
chemical vector had similar growth delay effects from i.t. and i.v. delivery after some 
minor vector modifications. 
The rabies virus glycoprotein (RVG) has been conjugated to siRNA to transverse 
the blood-brain barrier.160 RVG targets the nicotinic acetylcholine receptor (AchR) on 
neuronal cells, enabling the entry of virus particles. The virus protein (RVG) was 
conjugated to a chain of nine D-arginine residues as a spacer, then to siRNA, which 
allowed transfection specifically in neuronal cells (Neuro-2a) in vitro. In vivo, after i.v. 
delivery, particles were found in the brain but not the liver or spleen and showed a high 
level of FITC fluorescence. Finally, after infecting NOD/SCID mice with flaviviral 
encephalitis and injecting an antiviral siRNA sequence conjugated to RVG, survival was 
significantly extended. 
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1.3.3.6 Naked DNA 
Degradation of free plasmids by rat plasma has been shown to have a half-life of 1.2 
minutes for supercoiled pDNA, 21 minutes for open circular pDNA and 11 minutes for 
linear pDNA.118 However, in the same study, complexing pDNA with cationic liposomes 
(DOTAP:DOPE, 1:1 w/w), allowed the supercoiled plasmid to be detected after 5.5 
hours. 
Other than hydrodynamic injection, (a large volume quickly injected, efficient in 
delivery to the murine liver), naked DNA plasmid delivery has seen little success in i.v. 
delivery.161 Eliminating many barriers encountered in systemic circulation, it makes sense 
to assume that i.t. injection would show greater transfection efficiency and anti-tumor 
effects for naked plasmids. Intratumoral delivery of a naked interleukin (IL-18) plasmid 
was delivered to CT26 tumors established in the liver.162 CT26 is an undifferentiated 
murine adenocarcinoma that models colorectal cancer, the most common site of 
metastasis being the liver. Tumors were established by injection of CT26 into the lower 
left lobe of the liver. IL-18 protein was found in all subjects injected with either the 
control vector or IL-18 plasmid, but significantly higher levels in the 50 μg plasmid-
injected group. Mice treated with the control vector did not generate a CT26-specific T 
cell response, while those treated with the IL-18 producing plasmid contained a 
significant number of IFN-γ (interferon gamma) producing CD4+ T cells and had 
significantly lower tumor growth. While most studies use solid tumor models in the hind 
flank of mice, this study shows the versatility of i.t. injection as it can also be 
administered to a solid tumor within a major organ within the body cavity. 
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1.3.4 Targeted Delivery 
1.3.4.1 Introduction 
Attaching a ligand specific to the tissue of interest increases localization of the 
nanoparticle to that tissue. Many different receptors are over-expressed in tumor tissues 
making the corresponding ligands desired as targeting agents. Also, hepatocytes express 
the asialoglycoprotein receptor in high amounts, making galactose and asialofetuin, 
desired ligands for targeting in that application. 
 
1.3.4.1.1 Galactose 
Galactose can be used as a targeting agent to the asialoglycoprotein receptor (ASGP-R) 
on mammalian hepatocytes.163 Asialofetuin, the receptor’s natural ligand can also be 
used. N-acetylgalactose (NAG) has been conjugated to the end of endosomolytic 
polymers to target the vehicle to hepatocytes for pDNA delivery.147 Galactose has also 
been conjugated to liposomes for delivery of oligodeoxynucleotides (ODN).164 
 
1.3.4.2 Targeting solid tumors and/or metastasis 
1.3.4.2.1 Transferrin 
Transferrin is an iron-binding glycoprotein often used as a targeting ligand. Expression of 
transferrin receptors on the cell surface is upregulated in quickly dividing cells due to 
their need for iron. Transferrin receptor density can be increased by treating cells with the 
cell-permeable iron chelator desferrioxamine.165 Transferrin targeting was used to deliver 
a reporter plasmid using polylysine or protamine to human leukemic cells, K-562, termed 
“transferrinfection”.165 Other systems targeting immune cells have used transferrin as a 
ligand, such a liposome targeting to rabbit bone marrow precursor cells.166 In addition to 
K-562 cells, transferrin targeting has been efficient with neuroblastoma Neuro-2A cells, 
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melanoma H225 and 16F10 cells, with increased expression in all cell lines, some as high 
as 1000 to 10,000 fold.117 Joshee et al. showed that adding pDNA to a mixture of 
transferrin and DOTAP/DOPE (1:1) cationic liposomes yielded significantly higher 
transfection in Panc-1 cells than the formulation where pDNA and cationic liposomes 
were mixed first, then mixed with transferrin, although zeta potentials of the formulations 
were similar (around -33mV). When conjugating gold nanoparticles to transferrin and 
adding pDNA to the gold-transferrin and cationic liposome mixture, both the labeled 
transferrin and pDNA colocalized at the perinuclear space and in the nucleus, suggesting 
cotransport intracelluarly and into the nucleus.167 Transferrin has been conjugated to 
many different chemical vectors including: cationic cyclodextran polymers,149; 150 
polylysine and protamine,165 PEI,117 and liposomes166; 168. Anti-transferrin receptor 
single-chain antibody fragments have similarly been used to target the upregulation of 
these receptors.162 The cationic liposome decorated with these anti-transferrin receptor 
single-chain antibody fragments was able to target solid tumors and metastasis. 
 
1.3.4.2.2 Folate 
Folate receptors are over-expressed in many tumors including ovary, kidney, uterus, 
testis, brain, colon, lung, myelocytic blood cells, as well as KB cells, a nasopharyngeal 
epidermal carcinoma cell line.169; 170; 171; 172; 173; 174; 175; 176; 142 Lee’s LPDII used polylysine 
to complex DNA, then coated with a pH-sensitive anionic lipid, as well as the folate 
ligand as a targeting mechanism to KB cells.142 It was shown that transfection was 
controlled by charge for the cationic particles (low lipid/DNA ratio), and by folate ligand 
for the anionic particles (high lipid/DNA ratio). KB cells also showed high uptake of 
neutral liposomes encapsulating doxorubicin targeted using folate conjugated to a PEG 
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linker, secured to the lipid bilayer with a cholesterol anchor.177 Wang and Low indicated 
that folate should be conjugated to the carrier at the γ-carboxyl group terminus, as not to 
interfere with the receptor-ligand binding pocket.178 Folate has also been conjugated to 
PEI179 and polylysine180 for gene delivery. 
 
1.3.4.2.3 Sigma Receptor 
Sigma receptors are expressed on many normal tissues within the body, including the 
heart, liver, endocrine glands, kidneys, lungs, gonads, central nervous system and 
ovaries.181; 182; 183 Novakova et al. showed that in a rat heart, gene expression of sigma 
receptors can be upregulated by intense stress stimuli, with hypoxia and immobilization 
showing the greatest upregulation, and exposure to cold showing no effect on gene 
expression at all.183 Hypoxia is an environment found in many tumors, thus the 
upregulation of sigma receptors under these conditions correlate with an upregulation of 
sigma receptors found in several cancers. Across both human and rodent cancer lines, 
tumors show an upregulation of the sigma receptors making substrates for the receptor 
efficient targeting moieties. Vilner et al. tested 13 different rodent and human cell lines, 
and found that all tumors except one (human MCF-7 breast adenocarcinoma) expressed 
some level of sigma receptor 1 and 2. MCF-7 did not express the sigma receptor 1 at all. 
Other cell lines tested include: T47D breast ductal carcinoma, NCI-H727 lung carcinoid, 
A375 melanoma (amelanotic), ThP-1 leukemia, U-138MG glioblastoma, SK-N-SH 
neuroblastoma, LNCaP.FGC prostate, C6 glioma (rat), NB41A3 neuroblastoma (mouse), 
N1E-115 neuroblastoma (mouse), NG108-15 mouse neuroblastoma X rat glioma 
(hybrid), S-20Y neuroblastoma (mouse).184 Other studies have discovered other cancer 
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cell lines lacking the sigma receptors include HeLa, KB, HepG2 and Chinese hamster 
ovary cells.133 
Ligands for the sigma receptor are diverse and include haloperidol, reduced 
haloperidol, fluphenazine, perphenazine, trifluoperazine, BD737, LR172, BD1008, 
SH344, trifluperidol, thioridazine, and (-)-butaclamol.185 Often these ligands can be 
conjugated to delivery vectors to target cells with over-expressing sigma receptors. 
Haloperidol has been conjugated to the distal end of PEG linked to a phospholipid and 
used to deliver a reporter gene to MCF-7 cells, showing a 10-fold increase in expression, 
compared to the untargeted lipoplex. Administration of spironolacetone (a sigma receptor 
down regulator) with the lipoplex showed a 10-fold lower gene expression than those 
cells not treated with spironolacetone.133 Benzamides have been shown to be sigma 
receptor ligands.186 Huang’s group first used anisamide, a benzamide ligand that has 
shown great affinity for sigma receptors, in targeting stealth liposomes loaded with 
doxorubicin to DU-145, a human prostate adenocarcinoma cell line, by conjugating 
anisamide to the distal end of PEG.187 The group has also used anisamide to target LPD 
to the human NCI-H460 lung cancer line188; 189 and has shown targeting effects in 
B16F10 (murine melanoma cells) as a metastatic cancer model.190 
 
1.3.4.2.4 RGD 
The sequence of RGD (arginine-glycine-aspartic acid) attaches to many proteins in the 
extracellular matrix and on the cell surface specifically being a ligand for integrin 
receptor αvβ3.191 Attachment of RGD influences cell growth, migration and 
differentiation.192 When targeted with RGD-PEG-PEI or RGD-PEI complexes, saturable 
binding was shown in Mewo human melanoma cells, and low binding was shown in 
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A549 human lung carcinoma cells.191 When the PEG spacer was not used, transfection of 
the Mewo cells was increased 1-2 fold, however, attachment of RGD to polyplexes using 
a PEG spacer delivering pDNA against vascular endothelial growth factor (VEGF), 
showed increased delivery to tumors, growth delay and increased survival rate.144 
 
1.3.4.2.5 Intratumoral Delivery 
Local injection is a promising treatment option especially in the case of solid tumors and 
has been taken advantage of for gene delivery with chemical vectors, owing to the 
inherent lower transfection ability seen with chemical vectors compared to viruses. 
Intratumoral (i.t.) delivery evades many of the barriers that i.v. delivery faces, as the 
delivery vector starts in the tumor interstitum. However, in i.t. delivery there is rapid 
plasmid DNA clearance from the tumor interstitium that can be attributed to the leaky 
vasculature, and local drug diffusion may cause non-specific toxicity.152 Also, i.t. 
delivery is only practical where direct injection is possible, such as solid tumors and, to 
an excised tumor cavity or in the case of cystic fluid filled tumors that have been drained, 
to treat the residual tumor cells as suggested by Coll et. al..146 Many of the genes 
delivered i.t. center around immunogene therapy, producing large amounts of cytokines 
to recruit T and NK (natural killer) cells to the tumor (and only the tumor, hence the 
direct injection method), to produce a localized immune response.  
Intratumoral injection may not be the most realistic treatment for all tumor types, 
but for solid tumors it is able to deliver nearly the entire volume of injection to the tumor 
interstitum without depending on the EPR effect. Although i.t. gene therapy is not a 
viable method for treating metastasis, unless the metastasis can be localized, as in the 
liver as most i.t. delivered drugs have no cancer cell targeting mechanism, or mechanism 
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to evade RES detection so they are quickly cleared from the bloodstream.162 As shown in 
previous sections, many of the same vectors employed in i.t. delivery of nucleic acid 
based drugs have been used in i.v. delivery, with slight modifications increasing the 
targeting properties and extending systemic circulation time. Intratumorally administered 
gene therapy can become a combined therapy when incorporated with a mechanical 
delivery enhancement method, such as electroporation, ultrasound or use of a micropump 
injector, showing superior transfection of tumor cells in vivo. Although not the standard 
of administering drugs, i.t. administration of these gene therapies might become a way to 
compensate for the relative low transfection efficiency of chemical vectors compared to 
viruses, especially with the enhancement from being combined with a mechanical 
delivery method. 
 
1.3.5 Triggered Release 
1.3.5.1 Introduction 
Triggered release is an important aspect of gene delivery. Triggered release can include 
anything from facilitated escape from endosomes, temperature or pH sensitive carriers or 
a mechanical method such as electroporation or ultrasound. Mechanical methods can 
trigger release by permeating cell membranes or breaking open delivery vectors and are 
often used in concert with intratumoral delivery due to the local application of the 
mechanical method.193; 194; 195; 196; 197; 198 Using mechanical methods to facilitate gene 
delivery is a broad subject and out of the scope of this chapter, however, many quality 
reviews have been written on the subject.199; 200; 201 
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1.3.5.2 Proton Sponge Effect 
Boussif et al. first coined the term for the “proton sponge effect” when describing PEI in 
endosomes, but it has been shown to be true for many different chemical delivery 
vectors.202 This phenomenon occurs when cationic delivery vectors (reported for 
polymers, lipids and dendrimers), enter an endosome. The large buffering capacity of 
non-protonated amino groups or other proton acceptors causes a large influx of hydrogen 
ions. As protons enter the endosome, so do chloride anions to maintain the electro-
neutrality. Water also diffuses in via osmosis to keep the osmotic pressure the same 
inside and outside the endosome. This influx of water causes the endosome to burst, 
releasing the delivery vector into the cytosolic space. This mechanism has been verified 
in cultured cells.203 
Cationic lipids can have interactions with negatively charged endosomal lipids 
(such as phosphatidylserine), and create non-lamellar structures, possibly disrupting 
endosomes and allowing for escape into the cytoplasm.204 Also, greater generation 
dendrimers conjugated to PLGA particles showed greater buffering capacity, which the 
authors pointed towards increased proton-sponge effect, or triggered release from 
endolysosomal compartments by lysis of endolysosomes as water diffuses through the 
membrane to compensate the large number of positive charges and the lower pH.157 
Sakae et al. used PEI/pDNA complexes coated with PEG-Suc (PEG-Succinic 
acid), using negatively charged carboxylate groups as proton acceptors, and showed an 
increase in the buffering capacity compared to polyplexes coated with another anionic 
modified PEG, called PEG-C. While PEG-C accepted 41 μmol of protons between pH 
7.4 and 5.5, PEG-Suc accepted 66 μmol. The pKa1 and pKa2 values of PEG-Suc were 
4.00 and 5.24, respectively. The addition of PEG-Suc reduced the zeta potential from 
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+37.8 mV for the PEI/pDNA complexes to -24 to -34 mV. A greater amount of PEG-C 
was needed to achieve the same negative zeta potential as with PEG-Suc 205. While much 
focus has been given to cationic chemical vectors for gene delivery, this paper shows, in 
a new light, the potential of negatively charged chemical vectors to deliver in vivo, based 
on the proton sponge effect. 
 
1.3.5.3 MagnetofectionTM (Magnetic Delivery) 
Buerli et al. presented a protocol for magnetofection reporting procedures used in the 
laboratories of Fritschy (University of Zürich, Switzerland), Medina (INMED/INSERM, 
Marseille, France) and Fuhrer (Univeristy of Zürich, Switzerland and Mount Sinai 
Medical Center, New York, US). The magnetofection reagent used by all three groups is 
CombiMag with a magnetic plate for delivery of cDNA and short hairpin RNA (shRNA) 
into rat hippocampal neurons (embryonic day 18/19). CombiMag is obtained from OZ 
Biosciences. The protocol shows effective double-magnetofection of pyramidal and 
GABAergic interneurons, with expression of two genes in one neuron.206 
Scherer et al. showed that by using superparamagnetic iron oxide nanoparticles 
coated with poly(ethyleneimine) (TransMAGPEI, obtained from Chemicell, Berlin, 
Germany) associated with chemical vectors (as well as viral vectors and naked plasmids), 
showing an increased expression of the luciferase reporter gene delivered. Particle sizes 
ranged from 400-1000 nm. All the chemical vectors used (PEI, AVET-PEI, GenePorter, 
and Lipofectamine) showed increased luciferase activity after 10 minutes of 
magnetofection with magnetic field compared to standard transfection (4 hours 
incubation) in both NIH3T3 and CHO-K1 cell lines. Magnetofection (use of 
transMAGPEI particles associated with the carrier), without magnetic field never produced 
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significantly greater gene expression over the standard transfection. Of the chemical 
vectors used, Lipofectamine™ showed the greatest enhancement in expression, with 971 
fold greater expression with magnetofection and applied magnetic field compared to 
standard transfection.207 
Xenariou et al. used TransMAGPEI to deliver Lipofectamine™ 2000 or a cationic 
lipid (GL67) complexed with pDNA in vitro, showing a 300 fold and 30 fold increases in 
Luciferase gene expression respectively, compared to the vectors/pDNA without 
TransMAGPEI after exposure to a magnetic field. However, delivering to nasal epithelium 
of mice in vivo, the control particles, GL67/pDNA had significantly higher luciferase 
gene expression (50 fold) than TransMAGPEI-GL67/pDNA complexes; also, the 
formulation precipitated in vivo. When the precipitate was removed, and treatment with 
the supernatant was also completed, no significant difference existed between the groups 
of treatment with the supernatant and the precipitates, or between use of the magnet and 
without. In vivo magnetofection was also low in TransMAGPEI-pDNA complexes with 
and without the magnet compared to naked pDNA.208 
Lee et al. used PolyMAG, a superparamagnetic iron oxide nanoparticle, for 
transfecting mouse embryonic stem cells. PolyMAG consists of a superparamagnetic 
nanoparticles (tsMAG-PEI) coated with PEI, complexed to pDNA with free PEI. 
Significant increases in transfection efficiency of GFP were seen with magnetofection 
(PolyMAG) compared to the control vector, FuGENE6. A magnetic field was applied by 
placing the plates on MagnetoFactor plate device for 15 minutes at 37ºC, then returned to 
incubate at 37ºC. After 50 subpassages in culture, the mouse embryonic stem cells that 
underwent magnetofection still expressed GFP.209 
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1.3.5.4 Hyperthermic Delivery 
Hyperthermia is often used in drug delivery to increase vasodilation in the tumor, 
increasing the EPR effect. Clinically, temperatures in the range of 40-44ºC are used for 
local, regional, part body, or full body hyperthermia.210 Chemical vectors have been made 
with thermosensitive materials such as lipids and polymers to facilitate release of nucleic 
acids (and other drugs) before, during or after heat is applied. 
Chen et al. showed a reduced transition temperature of K8-ELP(1-60) block 
copolymer particles after complexing with pDNA from 71.5 to 44.9ºC, bringing the 
particle into a clinically relevant hyperthermic temperature range. ELP is an elastin-like 
polypeptide with 60 repetitive pentapeptide units, which aggregates above it’s transition 
temperature facilitating release, while K8 signifies a cationic oligolysine used to complex 
and condense the pDNA. However, while the development of a temperature sensitive 
block copolymer gene delivery vehicle was produced, and showed delivery of GFP 
plasmids in MCF cells in vitro, hyperthermic triggered release was not established. 
Release profiles were determined by concentrations of heparin sodium, an anionic protein 
found in the body. Still, the future of this block copolymer is bright, having a clinically 
relevant transition temperature and functional activity.211 
Zintchenko et. al. produced a block copolymer with PEI and poly(N-
isopropylaryamide) (PNIPAM), which when complexing pDNA made uncharged 
particles of about 150-200 nm that aggregated to sizes of a few microns after 15 minutes 
of incubation, releasing pDNA at temperatures between 37 and 42ºC. Neuro2A cells were 
transfected and showed almost 2 orders of magnitude higher gene expression after several 
cycles through the polymer’s transition temperature. The studies showed that 
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hyperthermia was able to facilitate the rate at which the particles aggregated, but not the 
rate of uptake into cells. The enhanced gene expression was attributed to larger size of the 
aggregated thermosensitive particles in comparison to the control PEI-PEG copolymers, 
which lead to a greater osmotic pressure inside the endosomes, greater amount of PEI to 
facilitate the protein sponge effect and thus more DNA released into the cytoplasm.212 
 
1.3.5.5 Reductive Agents 
Sulfhydryl cross-linked chemical gene delivery systems have been developed to facilitate 
protection of DNA and triggered release. By creating peptides with one to four cystine 
residues, McKenzie et al. reported a greater ability to create sulfhydryl bonds and by 
including many lysine residues, the peptides could achieve an appropriate cationic 
charger to complex with DNA.213 Five peptides presented in the paper (such as Cys-Trp-
Lys18) were able to spontaneously oxidize after binding to pDNA, causing interpeptide 
disulfide bonds, decreasing the particle size, and preventing dissociation of DNA in the 
presence of concentrated sodium chloride. These five peptides fully condensed DNA at a 
peptide to DNA ratio of 0.3-0.4 nmol of peptide/μg of DNA, with a charge ratio of 2:1 
(+/-). Release of DNA was triggered by the reducing environment of the endosome and 
cytosol, reducing the sulfide bond, showing a 5-60 fold increase in DNA expression 
compared to uncross-linked peptides. Kwok et al. showed in vivo delivery of sulfhydryl 
linked PEG-peptide/glycopeptide DNA nanoparticles with large biodistribution to the 
liver. In this study, peptides with the most positive zeta potentials (18.1 to 21.5 mV) 
showed greatest distribution to the hepatocytes, and those with the most negative zeta 
potential (-16.1 to -13.0 mV) had the greatest accumulation in Kupffer cells 
(macrophages of the liver).214 
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Lee and colleagues used degradable nanogels made of hyaluronic acid (HA) to 
deliver siRNA triggering release as a function of glutathione (GSH) concentrations 215. 
Glutathione is a major reducing agent found in the cytoplasm, and triggered the release of 
siRNA from the hyaluronic acid nanogels that were crosslinked with disulfide linkages. 
When 10 mM of GSH was used, 100 % of siRNA was released in 60 minutes, compared 
to only 5.8 % siRNA released when 0 mM GSH was used. The HA/siRNA nanogels were 
also shown to be non-toxic, have GFP expression in HCT-116 silenced comparable to the 
silencing of PEI/siRNA complexes in vitro and finally, significantly better silencing of 
GFP as compared to PEI/siRNA complexes in the presence of serum in vitro. The 
hyaluronic acid nanogels also had specific endocytosis mediated by the CD44 receptor.215 
 
1.3.5.6 Biotin-Avidin 
The strong affinity of biotin for avidin has been well established. Xiong and colleagues 
developed a nanoparticle that takes advantage of this to trigger release of DNA. The 
carrier consisted of avidin conjugated to PEG, and biotin conjugated to PEI. PEI 
complexed the plasmid DNA, the biotin bound the avidin, and the PEG was included to 
protect the carrier from clearance by the RES. The group found that conjugating PEI to 
biotin decreased the binding affinity to avidin, making it possible for dissociation of 
biotin from avidin in vivo in a biotin-rich environment. Localization in vivo to tumor 
interstitium was attributed to the enhanced permeability and retention (EPR) effect. After 
polyplexes had accumulated in tumor interstitium, additional biotin could be delivered 
either orally or intravenously to bind with the avidin-PEG molecules, triggering release 
of the PEG shell from the PEI-pDNA complex. This also allows the polyplex to associate 
with the cell membrane, encouraging endocytosis.216 
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1.3.5.7 Electrochemical 
DNA conjugated to gold nanoparticles have elicit interest in electrochemically triggered 
release. Wang et al. in a proof-of-concept experiment showed that it was possible to 
immobilize non-thiolated layers of dsDNA or ssDNA on gold nanoparticles, and release 
the DNA by controlling the electric potential.217 
 
1.3.6 Recent Clinical Trials Using Nucleic Acids  
1.3.6.1 Introduction 
When searching for “gene therapy” clinical trials on www.clinicaltrials.gov, a website 
maintained by the NIH as a “registry of federally and privately supported clinical trials 
conducted in the United States and around the world1,” nearly 1500 trials were returned. 
However, the majority of these trials had been flagged because genotyping, gene 
expression analysis, or gene expression profiling was included in the studies’ aims. Other 
trials included delivery vehicles such as adenoviruses, adeno-associated viruses, 
lentiviruses, retroviruses, or cell based therapy, where immune cells were transformed 
with a virus to express a certain protein and re-injected into the body. Although these 
fields are older and more developed that those of non-viral, chemical vectors, some 
chemical vectors appeared on this list in less than two percent of the clinical trials, 
ranging from phase 1 to phase 4. In the following section, clinical trials have an 
associated number (i.e. (NCT00000000). These clinical trials can be found online by 
going to www.clinicaltrials.gov/show/NCT00000000, where NCT00000000 is the NCT 
identification number associated with the trial. 
                                                 
1 www.clinicaltrials.gov  
 59
 
1.3.6.2 Naked Nucleic Acids in Clinical Trials 
1.3.6.2.1 Naked DNA  
In phase 1 studies at the Seoul National University Hospital, Korea, IL-2 plasmids are 
being used as an immune adjuvant to vaccinate patients with HIV antigens. A human 
mutant plasmid called GX-12 contains both human IL-2 and HIV-1 antigen genes. An 
i.m. injection of GX-12 is delivered in combination with highly active antiretroviral 
therapy (HAART). (NCT00517569). 
Plasmid encoding vascular endothelial growth factor (VEGF) has been delivered 
to the heart to promote angiogenesis and vasculogenesis to treat myocardial ischemia and 
angina pectoris. In phase 1 and 2 trials, at the Cardiac Catheterization Laboratory, The 
Heart Centre, University Hospital, Rigshospitalet, Copenhagen, Denmark, VEGF-A165 
plasmid was used to treat chronic myocardial ischemia. This treatment was also 
combined with granulocyte colony stimulating factor (G-CSF) therapy, recruiting bone-
marrow derived stem cells to regenerate the cardiac tissue at the sight of damage, 
promoting angiogenesis and vasculogenesis. (NCT00135850). Similarly, at Northwestern 
University, in phase 1 trials, phVEGF165 is being delivered by intramyocardial injection 
into the heart, and G-CSF is also administered treating patients with ischemic heart 
failure. (NCT00279539). In an effort to enhance vasculogenesis, VEGF has been 
delivered with another growth factor, basic fibroblast growth factor (bFGF). In phase 2 
trials at the Institute of Cardiology Warsaw, Poland, plasmid coding human VEGF-
A165/bFGF was injected into ischemic myocardium of refractory coronary artery disease 
patients. These two important angiogenic growth factors, bFGF and VEGF-A were 
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combined into one plasmid (bicistronic). This therapy aims at stimulating 
neoangiogenesis to increase myocardial perfusion. (NCT00620217). 
In phase 2 trials at 35 locations across the U.S., recombinant plasmid DNA coding 
for VEGF2, (pVGI.1) is administered using an experimental cardiac direct injection 
catheter (Stiletto™) system for patients with angina pectoris. (NCT00090714). 
DNA encoding VEGF has also been used to treat critical limb ischemia, leg 
ulcers, peripheral artery disease and diabetic neuropathy. At over 30 study locations, in a 
phase 3 trial, plasmid XRP0038/NV1FGF (delivering phVEGF165) is being used for 
critical limb ischemia (CLI) patients with skin lesions. (NCT00566657). At three 
locations across the U.S., in a phase 1 study, a VEGF plasmid (pVGI.1) is i.m. injected 
into leg muscles to treat moderate to high-risk critical limb ischemia, and leg ulcers. 
VEGF treatment is being tested to see if it improves rest, pain and/or heals ulcers in the 
legs of patients with peripheral artery disease. (NCT00304837). 
At centers in Boston and New York, VEGF DNA is being delivered in the form of 
pVGI.1 to express VEGF2 to treat diabetic neuropathy in the legs. The study is in phase 1 
and 2 trials. (NCT00056290). In phase 1 trials by Diabetes and Glandular Disease 
Research Associates, San Antonio, Texas, plasmid hVEGF-A is used to treat diabetic 
neuropathy. The plasmid, named SB-509, by Sangamo BioSciences, is administered as an 
i.m. injection. (NCT00110500). 
A phase 1 and 2 trial at Memorial Sloan-Kettering Cancer Center in New York, 
New York, is using sargramostim, also known as granulocyte-macrophage colony 
stimulating factor (GM-CSF). DNA is used as an adjuvant for a multi-epitope vaccine to 
treat melanoma. DNA is injected subcutaneously (s.c.) on day 0 and the vaccine delivered 
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on day 5, also s.c. This study is treating stage IIB, stage IIC, stage III, or stage IV 
melanoma. (NCT00085137). 
In Connecticut, a phase 1 trial is underway to treat leaky bladder problems. The 
plasmid, hMaxi-K will be given as a single administration into the bladder through a 
catheter. Changes in incontinence episodes, maximum bladder capacity, urgency episodes 
and participant quality of life will be analyzed, among other variables. (NCT00495053). 
Turner syndrome and SHOX (short stature homeobox) deficiency is being treated 
at a phase 3 trial conducted at Eli Lilly, in Philadelphia, PA. A recombinant DNA 
plasmid for somatropin, also known as HGH, human growth hormone is being 
administered and “height velocity” of those on this treatment and those on placebo, will 
be measured. In this study, treatment will be continued until patients reach normal adult 
height. (NCT00190658). 
At two locations, Dubowitz Neuromuscular Centre, Hammersmith Hospital and 
Clinical Trails Unit, St Mary's Hospital, London, United Kingdom, Duchenne Muscular 
Dystrophy (DMD) is being treated by intramuscular administration of antisense therapy 
with the use of antisense oligonucleotides (AON) which has the potential to restore the 
production of dystrophin, the defective protein, in >70 % of DMD. The intramuscular 
administered morpholino oligomer is directed against exon 51 (AVI-4658 PMO). 
(NCT00159250). 
At locations in 6 European countries, phase 2 trials are underway to treat patients 
with severe peripheral arterial occlusive disease, Fontaine’s stage IV. The pCOR plasmid, 
named XRP0038 (NV1FGF) was constructed by inserting the gene coding for the 
fibroblast growth factor (FGF). FGF plays a role in angiogenesis. (NCT00368797). 
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1.3.6.2.2 Naked DNA with Electroporation 
In the first clinical trial to combine electroporation with free plasmid delivery, free IL-12 
plasmid is injected into melanoma tumors near the surface of the skin then 
electroporation is applied. This phase 1 study is being carried out at the H. Lee Moffitt 
Cancer Center & Research Institute, in Tampa, Florida. (NCT00323206). 
 
1.3.6.2.3 Hybrid Oligonucleotides 
In phase 1 trial at Albert Einstein Comprehensive Cancer Center, in Bronx, New York, an 
18-mer hybrid oligonucleotide is being used to study the effectiveness of combining 
docetaxel and GEM 231 in treating patients who have recurrent or refractory solid 
tumors. GEM-231 (a mixed backbone oligonucleotide) is a strand of synthetic DNA, 
which has been modified with 2'-O-methyl ribose at both ends in order to resemble RNA 
targeted against the RIalpha subunit of protein kinase A (PKA).218; 219 
 
1.3.6.3 Lipid-Based Nucleic Acid Carriers in Clinical Trials 
Cationic liposomes composed of DMRIE/DOPE, have been used to delivering pGT-1 
(cystic fibrosis gene) to cells lining the nose of cystic fibrosis patients. DMIRE is a 
cationic lipid, an abbreviation for 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl 
ammonium bromide, while DOPE is a neutral lipid, an abbreviation for that stands for L-
alpha-dioleoyl phosphatidylethanolamine. Delivery was facilitated by syringe instillation 
over thirty minutes to the right inferior nasal turbinate. Studies are in phase 1 trials at the 
University of Alabama at Birmingham. (NCT00004471). 
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At the M.D. Anderson Cancer Center, Houston, Texas, DOTAP:chol liposomes 
were complexed with the fus1 gene to deliver i.v. in the treatment of lung cancer. 
(NCT00059605). 
To treat patients with recurrent or refractory stage III or stage IV head and neck 
cancer, cationic liposomes (DOTMA/chol) were used to, delivering the interleukin-2 
gene. N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride is abbreviated 
by DOTMA. The theory behind the treatment, reasons that by inserting IL-2 DNA into 
tumor cells, an immune response will be recruited to destroy the tumor. The treatment is 
being compared to methotrexate in phase 2 studies at the H. Lee Moffitt Cancer Center 
and Research Institute. (NCT00006033). 
At University of Pittsburgh’s Cancer Institute, in a phase 1 study, DC-chol 
liposomes were delivered with EGFR antisense DNA i.t. to advanced squamous cell 
carcinoma of the head and neck. This study was sponsored by the National Cancer 
Institute. (NCT00009841). 
An IL-2 plasmid DNA/lipid complex is being used to treat stage II or stage III 
organ confined prostate cancer. Lipid portion of the vehicle is made of a mixture of 
DMIRE and DOPE.220 The lipoplex is injected intraprostatically under ultrasound 
guidance. The phase 2 studies are underway at Jonsson Comprehensive Cancer Center, 
UCLA, in Los Angeles, California and the Cleveland Clinic Taussig Cancer Center, in 
Cleveland, Ohio. (NCT00004050). Leuvectin has also been used to treat locally recurrent 
prostate cancer following radiation therapy. These are phase 1 and 2 trials at the same 
locations as the previous study. (NCT00005072). 
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In an effort to make cancer cells more sensitive to radiation therapy, the 
experimental agent LErafAON is being tested by delivering cationic liposomes carrying 
antisense oligonucleotide against the Raf-1 protein. LErafAON is delivered by i.v. 
infusions for the treatment of solid advanced tumors. These phase 1 studies are being 
conducted at three locations in the U.S. (NCT00024661, NCT00024648). 
Allovectin-7® is a plasmid/cationic lipid complex containing the DNA sequences 
encoding HLA-B7 and ß2 microglobulin, which together form a class I Major 
Histocompatibility Complex, or MHC-I antigen for treating stage III or stage IV 
metastatic melanoma.221 The therapy is administered through an intratumoral/lesional 
injection. Study locations of this phase 2 trial include Mayo Clinic Cancer Center, in 
Rochester, Minnesota; Roswell Park Cancer Institute, in Buffalo, New York, and 
Physician Reliance Network, Inc., in Dallas, Texas. (NCT00003646). 
 
1.3.6.4 Polymer-Based Nucleic Acid Carriers in Clinical Trials 
To treat patients with superficial bladder cancer who have failed other therapies, DTA-
H19 plasmid is complexed with PEI and delivered intravesically into the bladder. This 
phase 1 and 2 trial is being carried out at Meir Medical Center, Kfar Saba, Israel E. 
Wolfson Medical Center, in Holon, Israel. (NCT00393809).  
In a phase 1 trial going on in four locations across the United States, EGEN-001 
(phIL-12-005/PPC) is being administered via intra-peritoneal 61 infusion to patients with 
recurrent, platinum-sensitive, ovarian cancer. EGEN-001 is an IL-12 plasmid complexed 
by a delivery polymer to stimulate an immune response to the tumor. This polyplex 
delivery is being combined with Carboplatin and Docetaxel. (NCT00473954). 
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1.3.7 Conclusion 
Chemical vectors offer many benefits to gene delivery. These vectors have less toxicity 
compared to viral vectors and are fairly simple to manipulate. Chemical vectors vary in 
shape, particle size, nucleic acid complexation ability and release rate, allowing one to 
choose the proper delivery system for a certain application. The variety of targeting 
moieties allows the delivery system to have higher affinity for the microenvironment of 
interest, increasing the association of the particles on the cell’s surface, or the rate of 
endocytosis. Additionally, triggering mechanisms can be engineered into the design of 
the delivery system to control or facilitate the release of the DNA or RNA. Finally, the 
use of chemical gene delivery vectors in humans is quickly approaching reality with the 
progress of the field. In conclusion, the flexibility of chemical vectors to be engineered to 
a very specific application, with the reduced toxicity compared to viral vectors, point 
these delivery systems to the front of the gene delivery field. 
CHAPTER 2 
ENANTIOSPECIFIC ADJUVANT ACTIVITY OF CATIONIC LIPID DOTAP IN 
CANCER VACCINE 
Commercially available DOTAP is a racemic mixture of two enantiomers. The 
adjuvanticity of each isomer was examined using a peptide/lipid complex as a therapeutic 
vaccine in an established murine cervical cancer model. This simple vaccine consists of a 
cationic lipid (DOTAP) and a Major Histocompatibility Complex (MHC) class I 
restricted epitope of the Human Papillomavirus (HPV) 16 protein E7. Dose-dependent 
tumor regression experiments have been completed for racemic DOTAP/E7, (R)-
DOTAP/E7 and (S)-DOTAP/E7. Tumor-bearing mice treated with (R)-DOTAP/E7 
complexes have shown tumor regression in a dose-dependent manner comparable to 
those mice treated with a racemic DOTAP with E7 peptide. This data is supported by 
IFN-γ production by CD8+ splenocytes, in vivo cytotoxic T-lymphocytes (CTL) 
response, CD8+ tumor infiltrating lymphocytes (TIL) and IFN-γ production by CD8+ TIL 
in (R)-DOTAP/E7 vaccinated mice. When (S)-DOTAP/E7 is delivered, tumor 
progression is delayed. While IFN-γ production is absent from CD8+ splenocytes in mice 
vaccinated with (S)-DOTAP/E7, IFN-γ production by CD8+ TIL is present, supporting 
our hypothesis that (S)-DOTAP has limited activity. Activation of bone marrow derived 
dendritic cells by the enantiomeric formulations has also been evaluated, as well as 
cytokine production and toxicity with no considerable differences between the groups. 
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The results show the DOTAP enantiomers act differently as adjuvants in vivo, with (R)-
DOTAP being more effective at stimulating a CD8+ anti-tumor response.  
2.1 INTRODUCTION 
Therapeutic cancer vaccines are safe treatments that can create a potent immune response 
against transformed host cells. Vaccines and immunotherapy avoid the toxicity of harsh 
chemotherapy that includes side effects such as weight loss, hair loss, nausea and 
leukopenia. Instead of targeting all rapidly dividing cells, as is the case of many small 
molecule chemotherapeutic drugs, vaccines can train the immune system how to 
specifically target cancer cells only. Creating an efficacious cell-mediated response is 
crucial for anti-tumor effects.222 Many different types of antigens have been used in 
cancer vaccines, ranging from whole tumor cell lysate to MHC class I restricted peptides 
specifically recognizable by CTLs.223; 224; 225 Only the use of peptide antigens allows for 
ease of manufacturing, as well as precise control over the purity and specificity of the 
vaccine. However, peptide antigens need supplementary treatments to increase 
immunogenicity. 
There is very little variety in the adjuvants that are clinically available. The U.S. 
Food and Drug Administration (FDA) has only approved two adjuvants for use in 
humans, both aluminum hydroxide based.226 The first, Alum (aluminum hydroxide), has 
been approved since the 1920s. The second, AS04 (3-O-desacyl-4’-monophosphoryl lipid 
A adsorbed on to aluminum as hydroxide salt), was approved in the U.S. in 2009, is only 
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used in one vaccine that is currently on the market (Cervarix).227 The scarcity of available 
adjuvants, particularly in the United States, demonstrates a need for new safe adjuvants 
allowing more options in formulation and titrating of the desired immune response via 
immunotherapy. 
Development and subsequent approval of new adjuvants face several barriers. 
Encouraged by the FDA, scientists arecreating treatments that are chirally pure is a trend 
growing in popularity across pharmaceutics, with the increased ease of separation of 
enantiomers after synthesis.228; 229 However, chiral drugs can have different efficacies in 
vivo. It is known that stereoisomers of small molecule drugs can have widely varied 
effects, with one being efficacious and the other showing no therapy, or worse, 
toxicity.230 Biology provides an asymmetric environment, containing chiral components 
at its most basic molecular level, L-amino acids and D-carbohydrates. It is no surprise 
that highly purified antigens show stereospecificity in all types of immune reactions.231; 
232 However, it has never been shown that the stereospecificity of an adjuvant plays a 
vital role in its efficacy in producing an immune response. 
Our basis for investigating this line of work starts with a therapeutic vaccine we 
have previously developed for a murine cervical cancer model. This nanoparticle 
complex consists of three molecules, racemic DOTAP lipid and E7 peptide, an H-2Db 
restricted 9-mer from the HPV 16 E7 oncogene, able to cause regression in pre-existing 
tumors.30 The MHC class I restriction of the peptide promotes a cell-mediated response 
rather than a humoral response against the growing tumor. We have shown that the 
racemic DOTAP lipid is able to activate bone marrow-derived dendritic cells (BMDC) in 
vitro to elicit a cytokine response via the ERK pathway.32 
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In this study, we investigate the impact of chirality on the efficacy of DOTAP 
lipid as an adjuvant. We have evaluated (R)-DOTAP and (S)-DOTAP for its interaction 
with E7 peptide in formulation properties, measuring peptide encapsulation, particle size 
and charge. Lipid alone was used to test the interaction and ability to stimulate BMDC, 
inducing activation through CD86 up-regulation and CCL2 production. Lipid toxicity 
was also compared when treating BMDC. In vivo, (R) and (S)-DOTAP formulations were 
compared in many ways, testing for effect on tumor regression, and further elucidating 
the affected cellular mechanisms that cause regression. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Racemic DOTAP (99.9 % purity), (R)-DOTAP (100 % purity) and (S)-DOTAP (99.9 % 
purity) were obtained from Merck KGaA (Darmstadt, Germany). (R)-DOTAP stock used 
had a specific optical rotation [α]D25 of -1.77°, while (S)-DOTAP stock used had a 
specific optical rotation [α]25 of +1.99°. H-2Db restricted peptides E7 (H-RAHYNIVTF-
OH, amino acids 49-57 from the E7 protein of HPV16) and NP (H-ASNENMETM-OH, 
amino acids 366-374 from the influenza virus strain A/PR/8/34 nucleoprotein) were 
obtained from the University of Pittsburgh Peptide Synthesis Facility (Pittsburgh, PA).  
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2.2.2 Tumor cell culture 
TC-1 is a murine model of human cervical cancer. To create TC-1, lung endothelial cells 
from a C57BL/6 mouse were transfected oncogenes E6 and E7 from the Human 
Papillomavirus 16 (HPV16), as well as activated human H-ras.233 TC-1 cells were 
obtained from American Type Culture Collection (Manassas, VA) and maintained in 
RPMI 1640 media supplemented with 10 % fetal bovine serum (Invitrogen, Carlsbad, 
CA), 100 U/mL penicillin (Invitrogen) and 100 µg/mL streptomycin (Invitrogen). 
 
2.2.3 Preparation and Evaluation of Vaccine Formulations 
DOTAP/E7, (R)-DOTAP/E7 and (S)-DOTAP/E7 complexes were made as described 
previously with few modifications.30 Briefly, lipids dissolved in chloroform were dried in 
glass vials under a stream of nitrogen and stored under vacuum in a desiccator overnight. 
Lipid/peptide complexes were formed by thin film hydration, using a solution of E7 
peptide in molecular grade water (Cellgro, Manassas, VA) and subsequent vortexing. 
After 2 h at room temperature, the suspensions were extruded through two 100 nm 
polycarbonate membranes (Fisher Healthcare, Houston, TX) to a size of roughly 120 nm. 
Particle size and zeta potential was measured with a Malvern Zetasizer Nano ZS in water 
(Malvern, Worcestershire United Kingdom). E7 encapsulation was determined by 
Microcon® centrifugal filtrate device (Millipore, Bedford, MA). Unbound peptide was 
measured by Micro BCA™ Protein Assay Kit (Rockford, IL). Amount encapsulated 
calculated as (100 - % unbound peptide). 
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2.2.4 Bone Marrow Derived Dendritic Cells (BMDC) 
Methods to culture bone marrow-derived dendritic cells have been described previously 
32. Briefly, bone marrow from the femurs and tibias of six week old C57BL/6 mice was 
isolated in serum free RPMI 1640 media. Red blood cells were lysed using ACK Lysing 
Buffer (Invitrogen) and cells were plated for 2 h in serum free RPMI 1640 to remove 
suspension cells (lymphocyte precursors). Remaining adherent cells were cultured in 
RPMI 1640 media containing 10 % fetal bovine serum, non-essential amino acids 
(Invitrogen), antibiotic/antimycotic (Sigma-Aldrich, St. Louis, MO) with 1000 U/mL 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1000 U/mL 
interleukin-4 (IL-4) (R&D Systems, Minneapolis, MN) for 6 days changing the media 
every 2 days. BMDCs were used in experiments on day 6. 
 
2.2.5 Interaction of Formulations with BMDC in vitro 
To measure CD86 expression, a sign of activation, BMDC were treated with different 
concentrations of liposomes (free of peptide) for 18 h. Cells were stained with anti-CD86 
(GL1) and anti-CD11c (HL3) antibodies (BD Biosciences, San Jose, CA) and analyzed 
using a FACS Canto II flow cytometer (BD Biosciences). One hundred ng/mL LPS 
served as a control. Isotype controls were used. To measure toxicity, BMDC were treated 
with different concentrations of liposomes (free of peptide) for 18 h and stained with 
propidium iodide (PI) (Sigma-Aldrich) and evaluated using flow cytometry. To measure 
production of chemokine C-C motif ligand 2 (CCL2) in a dose-dependent manner, 
BMDC were treated with varying doses of (R)-DOTAP and (S)-DOTAP liposomes (free 
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of peptide). After 24 h, cell supernatants were collected and analyzed by ELISA (BD 
Biosciences). 
 
2.2.6 Mice and Immunizations 
Six week old female C57BL/6 mice were used in all studies. On day 0, 105 TC-1 cells 
were injected subcutaneously into the hair-trimmed abdomen. On day 6, formulations 
(100 µL) were subcutaneously injected into the contralateral side of the abdomen in a 5 
% dextrose solution. In the initial tumor growth delay experiment, 100 nmol of lipid, and 
20 g of E7 peptide was used. After this initial experiment, an optimal dose was 
determined by delivering lipid in concentrations ranging from 3 to 600 nmol, with a 
constant dose of 20 nmol of peptide. In all future in vivo experiments, lipid formulations 
contained 300 nmol lipid and 20 nmol of E7 peptide. Unencapsulated peptide was not 
removed. Tumors were measured every 2-3 days with calipers, calculating area as 
(length) x (width). Humane sacrifice of mice was performed after tumors reached 20 mm 
in one dimension. All animal protocols were approved by the University of North 
Carolina at Chapel Hill’s Institutional Animal Care and Use Committee. 
 
2.2.7 Interferon gamma (IFN-γ) production by CD8+ T cells 
Mice were injected with 105 TC-1 cells on day 0. On day 6, mice were vaccinated with 
either (R)-DOTAP/E7 or (S)-DOTAP/E7 with lipid and peptide concentration of 300 
nmol and 20 nmol, respectively. On day 14, mice were sacrificed, spleens sterilely 
removed and processed to a single cell suspension by crushing the spleen through a 70 
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µm filter (BD Biosciences). After removal, cells were incubated in RPMI 1640 media 
supplemented with NEAA and antibiotic/antimycotic, 1 µL/mL GolgiStopTM (BD 
Biosciences) and 5 µM E7 or NP peptide for 6 h at 37 °C. Cells were removed, washed 
with staining buffer (BD Pharmingen, San Diego, CA) and stained with anti-CD8 
antibody (53-6.7). Cells were then treated with Cytofix/CytopermTM kit and stained 
intracellularly for IFN-γ (XMG1.2), washed and analyzed by flow cytometry. Percents 
represent IFN-γ+ CD8+ T cells out of the total CD8+ T cell population. 
 
2.2.8 In vivo Cytotoxic T Lymphocyte (CTL) Assay 
The in vivo CTL assay has been described previously and was performed here with slight 
modifications.234 Briefly, mice were injected with 105 TC-1 cells on day 0. On day 6, 
mice were vaccinated with either (R)-DOTAP/E7 or (S)-DOTAP/E7 with lipid and 
peptide concentration of 300 nmol and 20 nmol, respectively. Eight days later, naïve mice 
were sacrificed and splenocytes removed. Splenocytes were pulsed with either 10 µM E7 
or NP peptide for 1-2 h in complete media at 37 °C. Cells were stained with 
carboxyfluorescein succinimidyl ester (CFSE) (Sigma-Aldrich, St. Louis, MO) , with NP 
peptide-pulsed and E7 peptide-pulsed cells stained with 0.4 and 4 µM, respectively in 
serum free media for 15 min. Cells were then washed with complete media and counted. 
Equal numbers of CFSEhigh (E7 pulsed cells) and CFSElow (NP pulsed cells) were mixed 
together and stained with 8 µM PKH-26 (Sigma-Aldrich) according to manufacturer’s 
instructions. Vaccinated mice were injected with 107 labeled cells and in vivo killing of 
the targets was allowed for 16-20 h. After that time, spleens from treated mice were 
removed and made into a single cell suspension, red blood cells lysed, washed and 
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resuspended in phosphate buffered saline (Sigma-Aldrich). The cells were analyzed by 
flow cytometry, first gating for the lymphocyte population, then for the PKH-26 positive 
cells, to determine the amount of specific lysis of the E7 labeled cells. The following 
equation from Byers et al. shows this, with NP and E7 representing the number of cells 
pulsed with E7 or NP peptide present after in vivo killing.234 
 
 
2.2.9 Tumor Infiltrating Lymphocyte Analysis 
TC-1 tumors from mice vaccinated on day 6 were removed on day 14 in a sterile 
environment. Tumors were minced and incubated in RPMI 1640 containing 1 mg/mL 
collagenase type 1 (Worthington, Lakewood, NJ) for 30 min at 37 °C. Tumors were put 
through a 70 µm strainer and formed a single cell suspension. Cells were blocked with Fc 
block (anti CD16/CD32 (2.4G2)) for 15 min, then stained with anti-CD8 (53-6.7) and 
anti-CD4 (RM4-5) and analyzed by flow cytometry. 
Alternately, lymphocytes were isolated from the tumors. Tumors were prepared as 
described above to a single cell suspension. The cells were washed and resuspended in 
complete media. Tumor infiltrating lymphocytes (TIL) were separated from the tumor 
using Ficoll-PaqueTM PLUS (GE Healthcare, Uppsala, Sweden), a density gradient 
method. These tumor infiltrating lymphocytes were plated at a concentration of 2 x 106 
and stimulated with 5 µM E7 or NP peptide for 6 h at 37 °C. The TIL were incubated 
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with Fc Block, antibodies for CD8, stained intracellularly for IFN-γ and analyzed by flow 
cytometry. 
 
2.2.10 Statistical Analysis: 
Statistical analysis was completed by using a two-tailed Student’s t-test. Data was 
statistically significant if the P value was less than 0.05. 
2.3 RESULTS 
2.3.1 Tumor Regression by Therapeutic Vaccination 
One injection of racemic DOTAP/E7 (100 nmol / 20 µg) six days after TC-1 tumor 
inoculation caused regression of preformed tumors (Figure 2.1a), statistically different 
than untreated mice (P<0.0001). (R)-DOTAP/E7 complexes showed the same response, 
indicating that (R)-DOTAP is the active enantiomer in racemic DOTAP (P=0.63). (S)-
DOTAP/E7 showed a partial response, statistically significant from racemic DOTAP/E7 
and (R)-DOTAP/E7 treated mice (P<0.05). The (S)-DOTAP/E7 treated mice also had 
tumor growth that was statistically significant from the untreated control group and the 
control mice treated with E7 alone (P<0.01).  
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Figure 2.1 TC-1 tumor growth inhibition by vaccine delivery in vivo.  
(a) TC-1 tumor growth inhibition in mice by lipid/E7 complexes. Six week old female C57BL/6 mice were 
inoculated with 10,000 TC-1 cells s.c. in the abdomen on day zero. On day 6, treatments were s.c. injected 
into the opposite side of the abdomen. Lipid formulations delivered contained 100 nmol lipid and 20 μg of 
E7 peptide. Sample size and statistics are as follows: n=5-6, *: P<0.05, **: P<0.01, ***: P<0.0001. (b) 
Dose-dependent antitumor activity of racemic DOTAP/E7, (R)-DOTAP/E7 or (S)-DOTAP/E7 complexes. 
Six week old female C57BL/6 mice were injected with 10,000 TC-1 cells s.c. as in previous studies. On 
day 6, treatments were s.c. injected into the opposite side of the abdomen. The dose of lipid was varied 
while the dose of E7 peptide was kept constant at 20 nmol. n=5-6 per dose 
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 (R)-DOTAP/E7 complexes also showed a dose-dependent response comparable to that 
of racemic DOTAP/E7 when evaluating tumor size at day 23 (Figure 2.1b). (S)-
DOTAP/E7 never achieved an optimal dose, even at very high concentrations of lipid 
(600 nmol). The optimal dose assessed from these studies was 300 nmol of lipid, not only 
because it had the greatest response in terms of tumor regression (for (R)-DOTAP /E7 
and racemic DOTAP/E7 treated mice), but it also had the greatest difference between (R) 
and (S)-DOTAP/E7 treated groups. 
 
2.3.2 Formulation Characterization 
As shown in Table 2.1, the average size of (R)-DOTAP/E7 complexes was 126.8 ± 5.1 
nm and (S)-DOTAP/E7 complexes were of comparable size at 125.6 ± 7.8 nm (P=0.69). 
Zeta potentials of the (R) and (S)-DOTAP/E7 complexes also did not vary significantly 
with values of 54.3 ± 4.0 mV and 55.8 ± 1.9 mV, respectively (P=0.37). Encapsulation 
efficiency of E7 peptide with (R)-DOTAP and (S)-DOTAP also did not differ 
significantly, with values of 31.3 ± 16.6 % and 32.1 ± 8.9 % at a dose of 300 nmol lipid, 
and 20 nmol E7 peptide (P=0.87). 
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Table 2.1 Physical properties of the vaccine formulationsa. 
Formulation Particle Size (nm) * Zeta Potential (mV) ** Encapsulation 
Efficiency (%)*** 
R-DOTAP/E7 126.8 ± 5.1 54.3 ± 4.0 31.3 ± 16.6  
S-DOTAP/E7 125.6 ± 7.8 55.8 ± 1.9 32.1 ± 8.9   
a Lipid concentration used in these studies was 6mM, equivalent to 300 nmol of lipid per mouse  
*. P=0.69, n=8-10. 
** P=0.37, n=8-10. 
*** P=0.87, n=13-14.  Encapsulation efficiency includes peptide capture on the surface of the liposomes, 
any trapped within the bilayer, or within an aqueous compartment. 
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2.3.3 Evaluation of (R)-DOTAP and (S)-DOTAP in vitro 
BMDC treated with (R)-DOTAP and (S)-DOTAP for 18 h both showed similar dose-
dependent effects. Activation of BMDC was increased with increasing doses of both (R) 
and (S)-DOTAP (Figure 2.2a). (S)-DOTAP increased CD86 expression more at lower 
doses (45 µM) and the peak of (R)-DOTAP-induced CD86 expression came at higher 
doses (150 µM), however, the difference was not significant. Expression of chemokine 
CCL2 was increased in (R)-DOTAP treated BMDC at doses of 45, 75 and 100 µM 
compared to (S)-DOTAP, however the difference was not significant (Figure 2.2b). 
After an 18 h treatment with either lipid, toxicity to BMDC was similar shown by the 
increased signal from PI (Figure 2.2c). Dose-dependent effects were observed with 
greater toxicity at higher doses, showing an increase in toxicity in 75 µM up through the 
highest dose tested. All toxicity levels were much higher than the LPS treated BMDC. 
We believe the BMDC model is not sufficient to explain the profound difference in (R) 
and (S)-DOTAP activity, thus moved to whole-body experiments to examine the immune 
response in the complete mouse. 
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Figure 2.2 Chiral Lipid Interaction with BMDC. 
BMDC were treated with (R)-DOTAP or (S)-DOTAP liposomes (free of peptide) for 18 h and (a) dose-
dependent activation of CD86 was evaluated (n=3), as well as (b) dose-dependent CCL2 secretion after 24 
h treatment (n=3). (c) BMDCs were also evaluated for toxicity by PI staining of cells after 18 h treatment 
(one representative experiment shown, repeated in triplicate). 
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2.3.4 IFN-γ Production by CD8+ T cells from Vaccinated Mice 
When comparing naïve, tumor-bearing, (R)-DOTAP/E7 treated tumor-bearing mice, and 
(S)-DOTAP/E7 treated tumor-bearing mice for IFN-γ production by CD8+ T cells, (R)-
DOTAP/E7 treated mice showed an antigen specific response (Figure 2.3a). Splenocytes 
isolated from (R)-DOTAP/E7 treated tumor-bearing mice that had been pulsed with E7 
peptide for 6 h produced IFN-γ at a magnitude of 0.8 % of the CD8+ T cells present, 
while the NP peptide pulsed control splenocytes produced 0.0 %. Splenocytes isolated 
from naïve mice, tumor-bearing mice, and (S)-DOTAP/E7 treated mice, whether pulsed 
with NP or E7 peptide, produced 0.0 % CD8+ T cells. The difference between IFN-γ 
secreting CD8+ cells per 104 CD8+ T cells for the two groups was statistically significant 
(P<0.01) (Figure 2.3b). 
As no groups but (R)-DOTAP/E7 treated mice pulsed with E7 produced IFN-γ, 
we incubated the cells with NP or E7 peptide for 12 h to evaluate if a longer incubation 
would show IFN-γ production in any other group (Figure 2.3c). However, while all the 
NP peptide pulsed samples remained at 0.0 %, as expected, (R)-DOTAP/E7 samples 
pulsed with E7 increased to 1.2 % IFN-γ producing cells out of all CD8+ cells. (S)-
DOTAP/E7 treated samples increased from 0.0 % at 6 h to 0.1 % at 12 h. Even with this 
increase, the difference between the (R) and (S)-DOTAP/E7 groups was still significant 
(P<0.02) for the number of IFN-γ secreting CD8+ cells per 104 CD8+ T cells (Figure 
2.3d). 
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Figure 2.3 IFN-γ production from splenocytes of (R)-DOTAP/E7 or (S)-DOTAP/E7 treated mice. 
(a) Splenocytes isolated (on day 14) from tumor-bearing mice treated with (R) or (S)-DOTAP/E7 at 300 nmol 
/ 20 nmol (on day 6). Splenocytes were pulsed with E7 or an irrelevant peptide (NP) for 6 h, washed, and 
stained for CD8 and IFN-γ. The numbers on the contour plots indicate percentage of IFN-γ+ CD8+ T cells out 
of all CD8+ T cells. One representative experiment is shown. (b) IFN-γ secreting CD8+ cells per 104 CD8+ T 
cells after 6 h pulse with peptide. n=6-8. **: P<0.01 (c) IFN-γ production after 12 h pulse with either NP or 
E7 peptide. (d) IFN-γ secreting CD8+ cells per 104 CD8+ T cells after 12 h pulse with peptide. n=6-8. *: 
P<0.02 
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2.3.5 In vivo Cytotoxic T Lymphocyte Assay 
As expected, tumor-bearing mice injected with NP (CFSElow) and E7 (CFSEhigh) pulsed 
cells, showed no specific killing of either population (Figure 2.4a) with the two peaks 
being of equal height, and indeed containing similar numbers of cells.  Shown in Figure 
2.4b, (R)-DOTAP/E7 vaccinated mice either with or without a tumor showed similar 
levels of specific killing of E7 labeled targets that was statistically significant compared 
to tumor-bearing mice (P<0.001). (S)-DOTAP/E7 treated mice, even without a tumor, 
still were statistically different than either (R)-DOTAP/E7 treated group (P<0.05). Tumor 
bearing mice treated with (S)-DOTAP/E7 had specific killing of E7 labeled targets that 
was not different from tumor-bearing mice that had not been vaccinated (P=0.20). These 
results led us to conclude the tumor responds to how the formulation is affecting the 
immune response, thus we examined the tumor. 
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Figure 2.4 In vivo Cytotoxic T Lymphocyte (CTL) Assay. 
(a) Targets pulsed with E7 or an irrelevant peptide (NP) were stained with high (E7) or low (NP) 
concentrations of CFSE, injected into treated mice and in vivo killing was allowed for 16-20 h, then spleens 
removed and analyzed by flow cytometry. (b) Percent specific lysis, P<0.05 between (R)-DOTAP and (S)-
DOTAP groups. No statistical difference exists between the two (R)-DOTAP treated groups, or the (S)-
DOTAP tumor-bearing group and tumor-bearing untreated group. n=15-18 
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2.3.6 Tumor Infiltrating Lymphocytes and Their Actions 
Whole tumors from mice were broken down to determine the concentration of infiltrating 
lymphocytes caused by each treatment (Figure 2.5a). Tumor-bearing mice that had not 
been treated with either formulation, had 0.7 % CD4+ and 0.2 % CD8+ cells out of all 
cells in the solid tumor. (R)-DOTAP/E7 treated mice had much higher levels of CD8+ 
cells in their tumors compared to (S)-DOTAP/E7 treated mice, 0.9 % versus 0.1 %, 
respectively. However, the differences in levels of CD4+ cells in the three groups was less 
dramatic, 0.5 % in (R)-DOTAP/E7 treated mice, compared to 0.2 % in (S)-DOTAP/E7 
treated mice. (R)-DOTAP/E7 treated mice had greater numbers of CD4+ and CD8+ cells 
found in the tumor tissue compared to (S)-DOTAP/E7 treated mice (Figure 2.5b). The 
high levels of CD4+ cells in tumor-bearing mice, similar to (R)-DOTAP/E7 treated mice, 
prompt further study to determine the phenotype of these cells. 
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Figure 2.5 Tumor Infiltrating Lymphocytes. 
Tumor infiltrating lymphocytes assayed from tumors of mice treated with (R) or (S)-DOTAP/E7 (a) CD4+ and 
CD8+ cells (b) CD4+ or CD8+ cells per 10,000 cells in the solid tumor. n=3-4. When comparing (R)-DOTAP 
to (S)-DOTAP or tumor only, P<0.01 for CD8+ cells, however (S)-DOTAP compared to tumor alone P=0.57. 
Looking at the groups with regard to CD4+ cells, all comparisons yield P values greater than 0.3. 
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Lymphocytes isolated from tumors using a density gradient protocol were 
stimulated with NP or E7 peptides for 6 h and assayed for IFN-γ production (Figure 
2.6a). All samples showed some IFN-γ activity in their CD8+ cells in both NP and E7 
pulsed treatments. Background levels of IFN-γ production were determined to be the 
signal from CD8+ NP pulsed cells. These levels in tumor only, (R)-DOTAP/E7 and (S)-
DOTAP/E7 treated mice were 1.2 %, 10.3 % and 3.9 %, respectively. CD8+ T cells from 
(S)-DOTAP/E7 treated mice showed some non-specific activity above control, yet not to 
the level of cells from (R)-DOTAP/E7 treated mice. However, 32.6 % of CD8+ E7 pulsed 
cells produced IFN-γ when isolated from a (R)-DOTAP/E7 treated mouse. This is 
compared to 12.0 % in an (S)-DOTAP/E7 treated mouse, a significant difference in IFN-
γ secreting CD8+ T cells (Figure 2.6b) (P<0.05). With the E7 pulse, the tumor-bearing 
mouse had some activity above background, showing some CD8+ T cells had been 
activated against the tumor by the process of a natural immune response. This experiment 
showed that although (S)-DOTAP/E7 does not have activity as great as (R)-DOTAP/E7, 
the treatment does have some ability to recruit E7 reactive lymphocytes to the tumor. 
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Figure 2.6 IFN-γ production by Tumor Infiltrating Lymphocytes. 
TIL were isolated from tumors of mice vaccinated with (R)-DOTAP/E7 or (S)-DOTAP/E7 and pulsed for 6 h 
with E7 or an irrelevant peptide (NP). (a) Percentages are IFN-γ+CD8+ cells out of all CD8+ cells. One dot plot 
is shown for each group that is representative of three experiments. (b) IFN-γ+ producing cells per 10,000 
CD8+ cells, P<0.05. n=6-7 
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2.4 DISCUSSION 
With the advancements of chiral separation technology, stereospecific drugs are not 
solely for academic investigation. The pharmaceutical industry has developed an interest 
in delivering enantiomerically pure formulations, understanding that the chirality of a 
drug can affect how the molecule acts in the biological milieu. 
By simplifying our formulation to one enantiomer of DOTAP and the E7 peptide, 
we were able to further investigate the immunological action of the DOTAP lipid in 
formulation; both in vitro and in vivo. Our results demonstrate (R)-DOTAP is the active 
component in the DOTAP racemic mixture used by our group in previous vaccine 
studies. This is evident in dose-dependent tumor growth delay studies (Figure 2.1).  
(R)-DOTAP and (S)-DOTAP have similar formulation characteristics of size, 
charge and encapsulation (Table 2.1). E7 peptide has two positively charged amino acids 
(arginine and histidine (only partial)), and a charge-charge association with cationic 
DOTAP is unanticipated. Previously, our group correlated increased antigen 
encapsulation with increased vaccine efficiency when studying an acylated version of E7 
peptide, using racemic DOTAP.235 Thus, even in the presence of (S)-DOTAP (in the 
racemic mixture), a high amount of E7 lipopeptide loading into the liposomes caused 
regression of TC-1 tumors both when delivered on 6 and 10 days after tumor inoculation. 
DOTAP has been hypothesized to facilitate endosomal escape through association with 
anionic lipids (phosphatidylserine) in the interior of the endosome causing destabilization 
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236. Thus, as APC endocytose the vaccine, E7 peptide will be released into the cytosol 
available to be presented by MHC Class I. As the two lipids have similar encapsulation 
efficiencies, shown in Table 2.1, no more antigen could be delivered by the (R)-DOTAP 
than the (S)-DOTAP formulation into the APC.  
DOTAP has previously been shown to induce a tunable amount of ROS which 
was required for anti-tumor efficacy and correlated with activation, CCL2, and toxicity.31 
In our in vitro studies, (R) and (S)-DOTAP produce similar levels of activation and 
toxicity (Figure 2.2a, c) when dosed to BMDC, therefore we do not expect that ROS 
induction is the mechanism with which (R) and (S)-DOTAP differ. While ROS levels 
induced could be the same, the difference in antigen loading does not clearly explain the 
stark differences in cytokine levels produced by the splenocytes and TIL in an (R)-
DOTAP/E7 vaccinated mouse (Figure 2.3. Figure 2.6). 
We hypothesize the presence of the tumor during vaccine administration amplifies 
the difference between (R) and (S)-DOTAP, while the amplification mechanism is not 
known (Figure 2.7). In vitro, the enantiomeric lipids behave similarly to one another in 
regards to BMDC activation, cytokine production and toxicity (Figure 2.2). However, 
the difference between the two molecules in eliciting in vivo CTL response (Figure 2.4) 
is most profound and statistically significant when a tumor is present. Strong differences 
can be seen in splenocyte production of IFN-γ in tumor-bearing vaccinated mice, (Figure 
2.3), and most obviously, in the tumor growth delay data (Figure 2.1). The large numbers 
of TIL that are immunologically active (Figure 2.6) support the tumor growth delay data 
and our hypothesis. The phenotype of the CD4+ cells in the tumors of (R)-DOTAP/E7 
 91
treated mice should be investigated as their function could indicate the exact contribution 
of the tumor. 
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Figure 2.7 Proposed tumor interaction with DOTAP enantiomers.  
In vitro (R) and (S)-DOTAP show little difference in stimulating BMDC, shown by the size of the straight 
arrows. Due to an unknown interaction between the immune system and the tumor, the presence of a tumor in 
the in vivo system amplified the difference between (R) and (S)-DOTAP reflected by the size of the ribbon 
arrows. The distinction between the two formulations is further amplified via talk back from the tumor to the 
immune system. 
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There are three requirements for a peptide vaccine to be effective: an antigen 
specific for the target (tumor), an efficacious adjuvant that can magnify the second 
signals needed for dendritic cells to produce a strong T cell response, and a delivery 
mechanism. (R)-DOTAP/E7 complexes provide all three to cause regression in this 
cervical cancer model. Future studies will expand the application of this adjuvant to other 
tumor models and investigate the mechanism of action that lies behind the enantiospecific 
activity. 
CHAPTER 3 
TRP2 PEPTIDE VACCINE ADJUVANTED WITH (R)-DOTAP INHIBITS 
TUMOR GROWTH IN AN ADVANCED MELANOMA MODEL 
Previously we have shown cationic lipid (R)-DOTAP as the immunologically active 
enantiomer of the DOTAP racemic mixture, initiating complete tumor regression in an 
exogenous antigen model (murine cervical cancer model). Here, we investigate the use of 
(R)-DOTAP as an efficacious adjuvant delivering an endogenous antigen in an 
aggressive murine solid tumor melanoma model. (R)-DOTAP/Trp2 peptide complexes 
showed decreasing size and charge with increasing peptide concentration, taking a rod-
shape at highest concentrations. The particles were stable for at 2 weeks at 4°C. A dose of 
75nmol Trp2 (formulated in (R)-DOTAP) was able to show statistically significant tumor 
growth delay compared to lower doses of 5 and 25nmol which were no different than 
untreated tumors. (R)-DOTAP/Trp2 (75nmol) treated mice also showed increased T cell 
IFN-γ secretion after restimulation with Trp2, as well as CTL activity in vivo. This 
vaccination group also showed the highest population of functionally active tumor-
infiltrating lymphocytes, indicated by IFN-γ secretion after restimulation with Trp2. 
Thus, (R)-DOTAP has shown the ability to break tolerance as an adjuvant. Its activity to 
enhance immunogenicity of other tumor associated antigens should be studied further. 
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Figure 3.1 Abstract summary 
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3.1 INTRODUCTION 
Recent clinical advances for the treatment of melanoma have great potential to 
revolutionalize the field, however not without associated toxicity. The recent FDA 
approval of the anti-CTLA4 antibody ipilimumab for unresectable and metastatic 
melanoma shows a step forward for biological drugs and immunotherapy for melanoma 
However, the approval also came with a boxed warning for immue-related adverse events 
(irAE) which can range from mild to severe.237 Interestingly, the severity of irAE seemed 
to correlate with a positive response to therapy.238  
Intensive research on the genetics of melanoma have led to advances in small 
molecule inhibitors as well.239 Several companies are investigating drugs for melanomas 
with oncogene mutations, most notably, BRAF V600E which occurs in almost 50 % of 
melanoma cases.240 The recent approval of vemurafenib showed up to an 81 % response 
rates in trials.241 Other small molecule BRAF inhibitors are still in the clinical trials and 
include RAF-265, XL281, and GSK2118436. However, even with promising BRAF 
inhibitors selective for patients with the V600E mutation, side effects are seen, such as 
resectable cutaenous carcinoma, and more importantly, induction of resistance.242; 237; 241 
With side effects produced by the new frontier of both biological and small molecule 
drugs for melanoma, there is still space to innovate a treatment that is able to treat 
aggressive tumors with fewer off-target effects.  
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As a treatment option, peptide vaccines offer the safety and specificity of a 
restricted epitope. Specific antigen in the form of peptide sequences (8-10 amino acids 
long) can be delivered to antigen presenting cells (APCs). Restricting the sequence 
choice to bind to major histocompatibility complex (MHC) class I ensures CD8+ T cell 
engagement. Activation of APCs and presentation of the peptide can stimulate a 
corresponding cytotoxic T lymphocyte (CTL) response against the epitope. As an 
antigen, peptides are easy to manufacture and specific, however, they are rarely 
immunostimulatory alone. Dendritic cells pulsed with melanoma tumor-specific peptide 
were unable to stimulate a therapeutic response when injected on the same day as the 
tumor.243 Delivery of a peptide antigen with an adjuvant is required for potent activation 
of APCs, and associated CTL activity. 
In the case of melanoma, sensitizing CTLs against the corresponding endogenous, 
or self-antigen poses yet another challenge. As T cells develop in the thymus, self-
reactive T cells are deleted, and regulatory T cells develop in circulation and particularly 
in the presence of tumors. Some have taken the approach to genetically modify T cell 
receptors to be specific for tumors, instead of efforts to vaccinate and allow a response to 
develop in an aided fashion.244 A strong adjuvant would be required to break through this 
tolerance and stimulate a powerful anti-tumor response.  
While many melanoma peptide antigens are well characterized, tyrosinase-related 
protein 2 (Trp2) is particularly attractive as an antigen. Trp2 peptide (amino acids 180-
188 of the Trp2 protein, sequence: SVYDFFVWL) is MHC class I H-2Kb restricted in 
mouse, allowing for examination of a CD8+ CTL response. The sequence is also HLA-
A2 restricted, thus the potential exists for the same formulation to be tested both in mouse 
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and in humans. Additionally, since melanoma and glioma cells are both neuroectodermal 
in origin, Trp2 is also expressed in this additional cancer line, allowing for a natural 
secondary application of any developed formulation.245; 243 However, as delivery cargo, 
Trp2 peptide is hydrophobic and difficult to formulate in an aqueous solution or delivery 
vehicle. The most successful work with Trp2 peptide as an antigen has been with 
preventative models.246; 247; 248; 249 Few studies examine the treatment of established 
tumors, and none to date have shown any effect in aggressive solid tumor models.250; 251; 
252 
Previously, our group has studied DOTAP lipid as an adjuvant in peptide and 
protein vaccine formulations. A DOTAP/peptide vaccine has shown complete tumor 
regression in an exogenous antigen model.30; 253 Further investigation of the DOTAP 
lipid, showed chiral specificity of the adjuvant activity.253 These studies led us to 
discover (R)-DOTAP as the active immune-stimulating enantiomer. (R)-DOTAP (or even 
the DOTAP racemic mixture) has never been tested as an adjuvant in an endogenous 
tumor model, and indeed the challenges of breaking tolerance are not slight. Particularly, 
treating an established tumor model in melanoma is rarely tested due to the difficulty of 
generating an adequate immune response to cause tumor growth delay due to the 
suppressive effects of an established tumor. In work presented in Section 3, we address 
the formulation challenges of delivering an adequate dose of the innately hydrophobic 
Trp2 peptide and utilize (R)-DOTAP/Trp2 complexes in an advanced melanoma model 
to break tolerance and show statistically significant tumor growth delay. 
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3.2 MATERIALS AND METHODS 
3.2.1 Materials 
(R)-DOTAP, (R)-1,2-dioleoyl-3-trimethylammonium-propane, was obtained from Merck 
KGaA (Darmstadt, Germany). H-2Kb restricted peptides Trp2 (H-SVYDFFVWL-OH, 
amino acids 180-188 from the tyrosinase-related protein 2 over-expressed in human and 
murine melanoma, MW 1175) and Ova (H-SIINFEKL-OH, amino acids 257-264 from 
the ovalbumin, MW 1773) were obtained from Peptide 2.0 (Chantilly, VA), supplied as 
trifluoracetate salts. Molecular biology grade water was obtained from Cellgro 
(Manassas, VA). Sodium methoxide, pure titrant (0.5M in methanol) and HPLC grade 
methanol were obtained from Fisher Scientific (Pittsburgh, PA). Absolute ethanol was 
obtained from Decon Labs, Inc. (King of Prussia, PA). 
 
3.2.2 Trp2 peptide preparation 
Specific weights of Trp2 peptide were dissolved in a 1:1 solution of methanol:ethanol. 
Serial dilution of Trp2 peptide was measured on a Shimadzu UV-Vis spectrophotometer 
(model UV-2501 PC, Columbia, MD), and absorbance recorded. The measurements were 
made in triplicate, and standard curve created utilizing the Beer-Lambert law. The 
extinction coefficient, ε = 5,367.7 (M-1cm-1), was found with the measured absorbance at 
280nm wavelength to estimate Trp2 peptide concentration and encapsulation.  
Trp2 peptide was formulated as a disodium salt for delivery. Peptide arrived as a 
trifluoroacetate salt and was dissolved in HPLC grade methanol in a glass vial and a 
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magnetic stir bar added. The peptide was stirred in an ice bath, as two equivalents of 
sodium methoxide were added drop wise. Titrated peptide was allowed to stir for 10min 
as the solution became clear. Aliquots of the peptide solution were added to water and pH 
measured (pH 9). Methanol was dried off using a rotoevaporator, and peptide was 
resuspended as a 1.5mM working concentration in molecular biology grade water. 
 
3.2.3 Preparation and Evaluation of Vaccine Formulations 
Briefly, 6,000 nmol of (R)-DOTAP dissolved in chloroform was dried in a glass vial 
under a stream of nitrogen and stored under vacuum in a desiccator overnight to ensure 
removal of any remaining chloroform. Lipid/peptide complexes were formed by thin film 
hydration, using a 1mL solution of Trp2 peptide at different concentrations in molecular 
grade water (Cellgro, Manassas, VA) and subsequent vortexing. After 1 h at room 
temperature, the suspensions were extruded ten times through two 100 nm polycarbonate 
membranes (Fisher Healthcare, Houston, TX).  
Particle size and zeta potential were measured with a Malvern Zetasizer Nano ZS 
(Worcestershire, United Kingdom). Samples were prepared for size and charge 
characterization by adding 10 µL 6 mM (R)-DOTAP/(1.5 to 0 mM) Trp2 complexes to 
990 µL of molecular biology grade water. Trp2 peptide encapsulation efficiency was 
measured by adding 50 µL of extruded lipid/peptide complexes to a Microcon 100kDa 
molecular weight cut off centrifugal filtrate device (Millipore, Bedford, MA). The 
column was centrifuged at 10,000 g for 10 min at 25 °C. Flow-through was analyzed 
using 2 µL of sample on a Nanodrop Spectrophotometer, ND-1000 (Thermo Scientific, 
Wilmington, DE), measuring the absorbance at 280 nm wavelength. Concentration of 
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peptide in flow-through (unencapsulated) was calculated using Beer-Lambert law (A280 = 
ε*b*c), with ε = 5,367.7 (M-1cm-1), calculated from a standard curve of Trp2 peptide. 
Final encapsulated concentration was calculated by subtracting the concentration in flow-
through from the known concentration used for hydration. Trp2 peptide loss in the 
column was < 5 %. 
Transmission electron microscope (TEM) images of the (R)-DOTAP/Trp2 
complexes were acquired by the use of a JEOL 100CX II TEM (Tokyo, Japan). Briefly, 4 
µl of nanoparticle solution was dropped on to a 300 mesh carbon coated copper grid (Ted 
Pella, Inc., Redding, CA) for 2 min. Excess fluid was removed with filter paper, and 
copper grid was dried before the observation with TEM. A total of 210 particles from 3 
different fields were measured. Particle dimensions were calculated by measuring the 
longest dimension and the perpendicular diameter. 
 
3.2.4 Tumor cell culture 
B16F10 cells, a murine melanoma model (syngeneic with C57BL/6) were originally 
obtained from American Type Culture Collection (ATCC) (Manassas, VA). Previously, 
in collaboration with Dr. Pilar Blancafort at the University of North Carolina at Chapel 
Hill (UNC), B16F10 was stably transfected with GL3 firefly luciferase gene using a 
retroviral vector to create B16F10-luc.254; 255 B16F10-luc cells were used in all studies 
presented here and maintained in Dulbecco’s Modified Eagle Medium (Gibco 
(Invitrogen), Carlsbad, CA) supplemented with 10 % fetal bovine serum (FBS) 
(Invitrogen, Carlsbad, CA), 100 U/mL penicillin (Invitrogen) and 100 µg/mL 
streptomycin (Invitrogen). 
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3.2.5 Mice and Immunizations 
Six week old female C57BL/6 mice obtained from the National Cancer Institute, were 
used in all studies. On day 0, 3x105 B16F10-luc cells in 50 µL of PBS were injected 
subcutaneously into the hair-trimmed abdomen. On day 6, formulations were 
subcutaneously injected into the contralateral side of the abdomen in 100 µL of 5 % 
dextrose solution. In all experiments, 300nmol (R)-DOTAP per mouse was the 
therapeutic dose of adjuvant used, as shown by our lab previously.253 Tumors were 
measured every 2-3 days with calipers, recording the longest diameter as length and the 
perpendicular dimension as width. Area was calculated as (length) x (width). Humane 
sacrifice of mice was performed after tumors reached 20 mm in one dimension. All 
animal protocols were approved by the University of North Carolina at Chapel Hill’s 
Institutional Animal Care and Use Committee. 
 
3.2.6 Multi-organ interferon gamma (IFN-γ) production by CD8+ T cells 
Mice were inoculated with 3x105 B16F10-luc cells on day 0. On day 6, mice were 
vaccinated with varying doses of (R)-DOTAP/Trp2 (with R-DOTAP at a constant dose of 
300 nmol/mouse). On day 13, mice were sacrificed and spleen, vaccine draining lymph 
node (right inguinal) and tumor draining lymph node (left inguinal) were removed from 
each mouse in a sterile hood. Organs were processed into a single cell suspension by 
crushing through a 70 µm filter (BD Biosciences, San Jose, CA). After removal, cells 
were incubated in Roswell Park Memorial Institute (RPMI) 1640 media supplemented 
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with FBS, non-essential amino acids (NEAA) (Cellgro), antibiotic/antimycotic (Cellgro), 
1 µL/mL GolgiStopTM (BD Biosciences) and 5 µM Trp2 or Ova peptide for 6 h at 37 °C. 
Cells were removed, washed with staining buffer (BD Pharmingen, San Diego, CA) and 
stained with anti-CD8 (clone 53-6.7). Cells were then treated with Cytofix/CytopermTM 
according to kit instructions (BD Pharmingen) and stained intracellularly with anti-IFN-γ 
(clone XMG1.2), washed and analyzed with a FACS Canto flow cytometer (BD 
Biosciences) and analyzed with FACS Diva software (BD Biosciences). 
 
3.2.7 In vivo Cytotoxic T Lymphocyte (CTL) Assay 
The in vivo CTL assay has been described previously and was performed here with slight 
modifications.234; 253 Briefly, mice were inoculated with 3x105 B16F10-luc cells on day 0 
and vaccinated with (R)-DOTAP/Trp2 formulations on day 6. Seven days later, naïve 
mice were sacrificed and splenocytes removed. Splenocytes were pulsed with either 10 
µM Trp2 or Ova peptide for 1-2 h in complete media at 37 °C. Cells were stained with 
carboxyfluorescein succinimidyl ester (CFSE) (Sigma-Aldrich, St. Louis, MO), with Ova 
peptide-pulsed and Trp2 peptide-pulsed cells stained with 0.4 and 4µM, respectively in 
serum free RMPI 1640 media for 15 min. Cells were then washed with complete media 
(RMPI 1640 with FBS, NEAA and antibiotic/antimycotic) and counted. Equal numbers 
of CFSEhigh (Trp2-pulsed cells) and CFSElow (Ova-pulsed cells) were mixed together and 
stained with 8 µM PKH-26 (Sigma-Aldrich) according to manufacturer’s instructions. 
Vaccinated mice were injected with 107 labeled cells and in vivo killing of the targets was 
allowed to take place for 22 h. After that time, spleens from treated mice were removed 
and processed into a single cell suspension and red blood cells lysed with ACK lysing 
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buffer (Invitrogen). Cells were washed in complete media and resuspended in phosphate 
buffered saline (Sigma-Aldrich). The cells were analyzed with a FACS Canto flow 
cytometer (BD Biosciences) and FACS Diva software (BD Biosciences), first gating for 
the lymphocyte population, then for the PKH-26 positive cells, to determine the amount 
of specific lysis of the CFSEhigh Trp2-pulsed cells. The following equation from Byers et 
al., describes Ova and Trp2 representing the number of peptide-pulsed cells present after 
the in vivo killing time allotment.234 
% specific lysis %100
)(
)2( 

xOva
TrpxOva  
where 
Ova
Trpx 2  from naïve mice 
 
3.2.8 Tumor Infiltrating Lymphocyte Analysis 
B16F10-luc tumors from mice vaccinated on day 6 were removed on day 13 in a sterile 
environment. Tumors were minced and processed through a 70 µm strainer to form a 
single cell suspension. Cells were blocked with Fc block (anti CD16/CD32 (clone 
2.4G2)) for 15 min, then stained with anti-CD3 (clone 145-2C11), anti-CD8 (clone 53-
6.7) and anti-CD4 (clone RM4-5) and analyzed by flow cytometry. 
 
3.2.9 Functionality of Tumor Infiltrating Lymphocytes 
Alternately, lymphocytes were isolated from the tumors. Tumors were prepared as a 
single cell suspension (described above). The cells were washed and resuspended in 
complete media. Tumor infiltrating lymphocytes (TIL) were separated from the tumor 
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using Ficoll-PaqueTM PLUS (GE Healthcare, Uppsala, Sweden), a density gradient 
method. Briefly, the single cell suspension of tumor cells were resuspended in 8mL of 
complete media (RPMI 1640 with 10 % FBS, NEAA and antibiotic/antimycotic). This 
volume was layered over 4 mL of Ficoll-PaqueTM PLUS in a 15 mL conical centrifuge 
tube and centrifuged at 2,500 rpm for 30 min at 25 °C. After centrifugation, the cells at 
the density interface were removed, and washed with complete media. To assay for CD8+ 
cell activity, tumor infiltrating lymphocytes were plated at a concentration of 2x106 
cells/mL and stimulated with 5 µM Trp2 or Ova peptide for 6 h at 37 °C. The TIL were 
incubated with Fc Block, anti-CD8, stained intracellularly for IFN-γ and analyzed by 
flow cytometry as described above. 
 
3.2.10 Statistical Analysis 
Statistical analysis was completed by using a two-tailed Student’s t-test. Data was 
qualified as statistically significant if the P value was less than 0.05. 
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3.3 RESULTS 
3.3.1 Formulation Characterization 
Maximum solubility of Trp2 peptide in water was measured at 1.825 mM after 
conversion to a disodium salt, compared to 0.06 mM of the trifluoracetate salt in water, 
an increase of 30.4 fold. 
Our method of preparing (R)-DOTAP/Trp2 complexes by thin film hydration and 
extrusion formed stable nano-sized complexes. We observed decreasing size with 
increasing concentration of Trp2 incorporated, ranging from 120 to 87 nm, for 0 to 1.5 
mM Trp2 used for hydration, respectively (Figure 3.2A). All particles had a 
polydispersity index measurement less than 0.1 (data not shown). Likewise, we observed 
a decrease in zeta potential with increasing Trp2 dose incorporated, as the Trp2 peptide 
formulated as a disodium salt, contains two exposed negative charges (on the aspartic 
acid and C terminus) after conversion from a trifluoroacetate salt (pH 4) to a disodium 
salt (pH 9). Percent entrapment was consistently high over a range of Trp2 doses (Figure 
3.2B). Stability of the complexes was measured over two weeks at 4 °C, showing 
consistent size (no aggregation or flocculation) (Figure 3.2C). TEM images of (R)-
DOTAP/Trp2 (75nmol) show rod-like particles with an average length and width of 78.8 
± 29.8 and 32.9 ± 6.8 nm, respectively (Figure 3.2D). 
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Figure 3.2 R-DOTAP/Trp2 characterization and stability. 
(A) Size, charge and (B) entrapment of Trp2 was evaluated on (R)-DOTAP/Trp2 complexes with varying 
concentrations of Trp2, n=3. (R)-DOTAP/Trp2 nanoparticles were stored at 4°C and (C) size measured 
over a period of two weeks, n=3. Experiment was repeated twice. In (C), the size measured from 0nmol 
Trp2 was the same as that with 5nmol Trp2, overlaying completely at every time point. (D) TEM image of 
(R)-DOTAP/Trp2 (75nmol) complexes. A total of 210 particles from 3 different fields were measured. 
Particle dimensions were calculated by measuring the longest dimension and the perpendicular diameter.\ 
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3.3.2 Tumor Growth Delay by Therapeutic Vaccination 
Mice were inoculated with tumors on day 0, treated with (R)-DOTAP/Trp2 vaccines on 
day 6 with varying concentrations of Trp2 peptide, and tumor growth was followed for 
20 days (Figure 3.3). While (R)-DOTAP/Trp2 nanoparticles delivering 5nmol and 25 
nmol Trp2 had no effect on tumor growth delay, delivery of 75 nmol Trp2 adjuvanted by 
(R)-DOTAP was able to show statistically significant tumor growth delay, with P<0.005 
compared to control mice. Shown in the Figure 3.3 inset, body weight of these tumor-
bearing mice was also monitored, and while no statistical difference exists, there was 
observable weight gain (due to tumor size) in control, (R)-DOTAP/Trp2 (5nmol), and 
(R)-DOTAP/Trp2 (25nmol) groups, that was not seen in the (R)-DOTAP/Trp2 (75nmol) 
group. 
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Figure 3.3 B16F10-luc tumor growth inhibition by (R)-DOTAP/Trp2 complexes in vivo. 
Six week old female C57BL/6 mice were inoculated with 3x105 B16F10-luc cells s.c. in the abdomen on 
day 0. On day 6, treatments were s.c. injected into the opposite side of the abdomen. Lipid formulations 
delivered contained 300nmol (R)-DOTAP and varying doses of Trp2 peptide. Tumors were measured with 
calipers with area calculated as length times width. The inset represents body weight tracked over time. 
Seven mice were used per group. Experiment was repeated twice. *: P<0.005.  
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3.3.3 Multi-Organ IFN-γ Production by CD8+ T cells from Vaccinated Mice 
Seven days after vaccination with various (R)-DOTAP/Trp2 nanoparticles, mice were 
sacrificed and lymph organs of interest extracted and processed to single cell suspensions 
to analyze Trp2 responsiveness in CD8+ populations. Cells from the spleen, tumor-
draining lymph node and vaccine draining lymph node (inguinal for both) were treated 
with Trp2 or a non-specific peptide (Ova), as well as GolgiStopTM to prevent protein 
secretion for 6h and then stained for CD8+ cells as well as intracellular IFN-γ 
accumulation (Figure 3.4). There was no background from Ova-pulsed cells secreting 
IFN-γ for any group in any organ. Naïve mice, tumor-bearing mice, 75 nmol Trp2 
peptide alone, and the lowest dose of (R)-DOTAP/Trp2 (5 nmol) showed no response to 
Trp2 pulse in any lymph organ. 
Of the organs examined, splenocytes showed the highest population of responding 
cells, with mice receiving the (R)-DOTAP/Trp2 (75 nmol) vaccination producing the 
greatest response at 0.3 % of CD8+ cells (Figure 3.4A). (R)-DOTAP/Trp2 (25 nmol) also 
showed some response in CD8+ splenocytes, but at a much lower level (0.1 %). Vaccine-
draining lymph node samples, showed an increased response in 75 and 25 nmol Trp2 
deliverable dose (0.1 %) (Figure 3.4B). Tumor-draining lymph nodes also showed the 
same response for 75 and 25 nmol Trp2 deliverable dose (0.1 %), which possibly 
indicates the contribution of the tumor close to the skin’s surface, dampening the strong 
response of the 75 nmol formulation to the 25 nmol level at those locations (Figure 3.4B, 
C). 
 111
 
Figure 3.4 Multi-organ IFN-γ production from (R)-DOTAP/Trp2 vaccinated mice. 
(A) Splenocytes, (B) vaccine draining lymph nodes, or (C) tumor draining lymph nodes were isolated (on 
day 13) from tumor-bearing mice treated with (R)-DOTAP/Trp2 (300nmol (R)-DOTAP/ varying Trp2 
doses) (on day 6). Resulting cells were pulsed with Trp2 or an irrelevant peptide (Ova) for 6h, washed, and 
stained for CD8 and IFN-γ. The numbers on the contour plots indicate percentage of IFN-γ+CD8+ T cells 
out of all CD8+ T cells. Data from one representative mouse is shown, with five to seven total animals per 
group. Experiment was repeated twice. 
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3.3.4 In vivo Cytotoxic T Lymphocyte Assay 
Seven days after vaccination, tumor-bearing mice were injected with Trp2- and Ova-
pulsed targets labeled with different levels of CFSE for 22 h before sacrificing the mice 
and removing the remaining cells (by processing the spleen). The purpose of this assay is 
to evaluate if a vaccinated mouse can show specific lysis of targets presenting the antigen 
from vaccination (Trp2 peptide). Unvaccinated tumor-bearing mice showed similar 
amounts of specific lysis as 75 nmol Trp2 peptide alone, and (R)-DOTAP/Trp2 (5 nmol) 
and (25 nmol) doses (Figure 3.5). Seventy five nmol of peptide alone (without (R)-
DOTAP), also showed negligible amounts of specific lysis. However, (R)-DOTAP/Trp2 
(75 nmol), showed significant specific lysis after 22 h of in vivo incubation of Trp2- and 
Ova-pulsed targets. This indicates that not only the dose of Trp2, but also the inclusion of 
(R)-DOTAP is crucial to elicit a CTL response. 
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Figure 3.5 In vivo CTL shows specific lysis of Trp2-pulsed targets elicited by (R)-DOTAP/Trp2 
(75nmol) vaccination. 
Targets pulsed with Trp2 or an irrelevant peptide (Ova) were stained with high (Trp2) or low (Ova) 
concentrations of CFSE, injected into (R)-DOTAP/Trp2 vaccinated mice and in vivo killing was allowed 
for 22h, then spleens removed and analyzed by flow cytometry. Percent specific lysis, P<0.05 between (R)-
DOTAP/Trp2 (75nmol) and other groups. Three to five mice were used per group. Experiment was 
repeated twice. 
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3.3.5 Tumor infiltrating lymphocytes 
Seven days after vaccination, tumors were removed, minced and prepared as a single cell 
suspension to detect the infiltrating CD3+CD4+ and CD3+CD8+ lymphocytes (Figure 
3.6). Twenty-five nmol and 75 nmol Trp2 formulated in (R)-DOTAP were able to elicit 
recruitment of both CD4+ and CD8+ T cells into the solid tumor (Figure 3.6). Nearly 1 % 
of the cells in the tumor mass of (R)-DOTAP/Trp2 (75 nmol) vaccinated mice were 
CD3+CD8+ cells; 0.2 % were identified as CD3+CD4+ cells. (R)-DOTAP/Trp2 (25 nmol) 
had a less profound effect, but quantifiable amounts of CD8+ and CD4+ T cells (0.3 % 
and 0.1 %, respectively). Other groups (untreated tumor, 75 nmol Trp2 peptide alone, and 
(R)-DOTAP/Trp2 (5 nmol)), showed lower than 0.1 % CD4+ or CD8+ T cells out of the 
tumor mass. 
 115
 
Figure 3.6 CD3+ Tumor Infiltrating lymphocytes are higher numbers with higher vaccination doses. 
CD4+ and CD8+ tumor infiltrating T cells assayed from tumors of mice treated with varying doses of (R)-
DOTAP/Trp2. Cells were gated on CD3+, and percentages represent CD3+CD4+ or CD3+CD8+ out of total 
numbers of cells in the tumors. Data from one representative animal is shown, three to four mice were used 
per group. Experiment was repeated twice. 
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When lymphocytes were isolated from tumors of vaccinated mice, reactivity to 
Trp2 was examined. After a 6 h pulse with Trp2 or Ova peptide (and GolgiStopTM), cells 
were examined for IFN-γ secretion (Figure 3.7). (R)-DOTAP/Trp2 (75 nmol) showed 
statistically significant response to Trp2 compared to all other groups, nearly 6 % of all 
CD8+ TIL, with P<0.005. There was some background IFN-γ secretion by Ova-pulsed 
cells in tumors of (R)-DOTAP/Trp2 (75 nmol) treated mice. Lower deliverable doses of 
Trp2 (25 nmol and 5 nmol), and unvaccinated mice showed Trp2 reactivity by less than 1 
% of CD8+ TIL. 
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Figure 3.7 Tumor infiltrating lymphocytes respond to Trp2 after a high vaccination dose. 
TIL were isolated from tumors of mice vaccinated with varying doses of (R)-DOTAP/Trp2, pulsed for 6h 
with Trp2 or an irrelevant peptide (Ova) and analyzed for intracellular IFN-γ in CD8+ cells. Percentages are 
IFN-γ+CD8+ cells out of all CD8+ cells., *: P<0.005. Three mice were used per group. Experiment was 
repeated twice. 
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3.4 DISCUSSION 
Even with current advances in melanoma therapy (anti-CTLA4 mAb and small molecule 
BRAF inhibitors), there still exists an opportunity to innovate and further refine 
therapeutic treatment for aggressive melanoma decreasing side effects and honing 
specificity. Data presented here has shown that peptide-based vaccines offer a safe and 
significant advancement against an aggressive murine melanoma solid tumor model. 
 
3.4.1 Overcoming formulation difficulty of the Trp2 peptide 
Others have made efforts to combat the difficulty in formulating Trp2 peptide in an 
aqueous solution, ranging from looking at modifying the epitope to conjugation to larger 
proteins to enhance delivery. 
Tang et. al. investigated increasing Trp2 binding efficacy to HLA-A201 by 
modifying the anchor residues.249 Modifying SVYDFFVWL to SMYDFFVWL (or a 
Trp2 2M modification) was delivered in comparable doses to what we’ve shown in this 
study. When 100 µg (63.8 nmol) was delivered with 50 µg of the PADRE T helper 
epitope (AKFVAAWTLKAAA) in incomplete Freund’s adjuvant (IFA) to a transgenic 
HLA-A2.1/Kb model, higher amounts of IFN-γ was elicited compared to vaccination with 
wild type peptide. Trp2 has also been modified into (SIYDFFVWL), called “deltaV” 
which showed increased T cell responsiveness to Trp2 by intracellular IFN-γ staining. 
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However, when deltaV was delivered with poly(I:C) and anti-CD40 and later boosted 
with these two adjuvants, no increased growth delay was seen with in a prophylactic 
B16F10 model compared to wild type peptide.247 Other inventive ways to deliver Trp2 to 
APCs have been published. Kou et. al. developed a ScFv-peptide conjugate to target Trp2 
to CD11c+ dendritic cells in vitro.248 This conjugate has shown stimulation of T cell 
proliferation, but Trp2 peptide alone showed comparable levels in the study. As a self-
antigen, suppression mechanisms also exist to prevent the expansion of T cells in a tumor 
environment, thus the difficulty of low doses of Trp2 in (R)-DOTAP/Trp2 (5nmol) and 
(25nmol) in eliciting an IFN-γ response (Figure 3.4A). 
 
3.4.2 Common models for murine melanoma rarely include therapeutic treatments 
in advanced solid tumors 
An advanced solid tumor model is rarely investigated in Trp2 peptide-based vaccines; 
more often, a prophylactic model or CTL characterization is tested.246; 247; 248; 249 
However, it is unlikely that a prophylactic melanoma vaccine would ever be 
commercially developed. The potential side effect of vitiligo is not likely to be traded for 
the possibility of protection, particularly as Trp2 peptide reactivity has been tied to this 
autoimmune depigmentation.256 
Trp2 peptide encapsulated in liposomes with p53 peptide, PADRE T helper 
peptide, CpG oligos together to was able to prevent tumor establishment when delivered 
six days after inoculation of 1x104 B16F10 cells.251 However, as a measure of tumor 
challenge, only two-thirds of the control group ever established tumors. Another 
liposomal treatment required CpG to show a therapeutic response, with two doses of 
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liposomal Trp2 and a separate formulation of liposomal CpG delivered in a 1x105 
B16F10 subcutaneous model.250 However it is not clear from the data published from 
either study, that tumors were palpable or even visible when treated. Our choice of an 
advanced tumor model, 3x105 B16F10-luc cells for subcutaneous inoculation, was based 
on all mice having measurable tumors on day 6, compared to inoculation with fewer cells 
(data not shown). Also, while CpG is a well characterized TLR9 agonist, the elegance of 
liposomal (non-viral) delivery is not aptly executed by the above two studies, with 
multiple adjuvants and multiple delivery devices needed. Our adjuvant, (R)-DOTAP also 
acts as the carrier for Trp2 peptide, simplifying the vaccine to active ingredients only, one 
stable and versatile particle that can show response against an established tumor (Figure 
3.2, Figure 3.3). 
Viral delivery of Trp2 peptide or protein has shown non-robust immunity 
compared to the statistically significant tumor growth delay we see with (R)-
DOTAP/Trp2 nanoparticles delivering 75 nmol of antigen (Figure 3.3) in an aggressive 
solid tumor model. Recombinant adeno-associated virus (rAAV) carrying Trp2 cDNA 
delivered 22 days before tumor challenge was unable to induce tumor growth delay.252 
Delivered at a dose of 1010 or 1011 rAAV viral particles were unable to protect against a 
tumor challenge of 3x105 B16F10, even with the addition of other adjuvants, including 
CpG oligonucleotides and imiquimod. Interestingly, like (R)-DOTAP/Trp2 (25nmol), the 
rAAV-Trp2+CpG treatment showed an IFN-γ response from splenocytes, however, was 
not able to break tolerance and show any tumor growth delay. Multiple doses of Trp2 
peptide conjugated to exposed lysines on the tobacco mosaic virus (TMV) was delivered 
with CpG oligonucleotides prior to inoculation with 5x104 B16F1, showing no statistical 
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difference compared to control or TMV with a different melanoma antigen p15e.246 
Additionally, in this challenge model, tumor penetration was 11 out of 12. 
Dendritic cells pulsed with Trp2 peptide have also shown ineffective responses in 
both prophylactic and simultaneous tumor models.243 However, when the HIV TAT 
protein transduction domain was ligated to a 472 amino acid sequence from the Trp2 
protein or to the Trp2 peptide (180-188 amino acids); both showed better tumor 
prevention compared to dendritic cells pulsed with Trp2 peptide only.257; 258 This supports 
the need for an intracellular delivery mechanism like (R)-DOTAP/Trp2 formulations to 
ensure Trp2 peptide is presented on MHC class I. An interesting result of the above 
mentioned study showed in vitro CTL reactivity to B16 cells correlated with tumor size. 
Our in vivo CTL results on day 13, when all groups had statistically indistinguishable 
tumors, is an early indicator of the ability of a formulation to cause statistically 
significant tumor growth delay (Figure 3.5, Figure 3.3). 
Our choice to use an aggressive subcutaneous model versus a lung metastatic 
model was to utilize the existence of a suppressive tumor microenvironment. Many types 
of suppressive immune cell exist in the tumor that tolerize the immune system to the 
tumor’s presence, and combating these cell types with possible therapies should be the 
next frontier of immunotherapy.259 With a larger tumor mass existing in the solid tumor 
model versus the metastatic model, the bar is higher for a vaccine to break this tolerance. 
In a model of transgenic Trp2 peptide specific T cells, the adoptive therapy of T cell 
transfer was able to cause statistically significant decrease in lung nodules (P>0.0001), 
however, had no effect whatsoever on any tumor growth delay in a solid tumor model.260 
The adoptive cell transfer was able to show nearly 98 % specific lysis of Trp2 pulsed 
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targets in an in vivo CTL assay, however, not able to reject the 2x105 B16F10 solid tumor 
inoculation. Even with the addition of a Trp2-pulsed dendritic cell vaccine, no significant 
tumor growth delay was observed in the solid tumor model. While Trp2 specific T cells 
were detected in the solid tumor, they did not affect tumor growth, unlike our detection of 
infiltrating T cells that correlated with tumor growth delay (Figure 3.6, Figure 3.7). 
Future directions in melanoma immunotherapies should tackle established tumors 
with an existing suppressive microenvironment. As shown by the ipilimumab approval 
and increasing numbers of biologic drugs; targeting suppressive mechanisms in and 
around the tumor, shutting down this protective barrier could empower immunotherapy to 
become the standard of care over conventional chemotherapy. Anti-CTLA4 antibodies 
are already being tested in a wide range of tumors, expanding the application beyond 
melanoma.261 The ability and strength of (R)-DOTAP to break tolerance in this model 
after one immunization and the flexibility of the adjuvant to deliver an adequate dose of 
antigen in a stable formulation pushes it forward to be tested in other aggressive tumor 
models and possibly into clinical development. 
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CHAPTER 4 
DELIVERY OF PD-L1 siRNA, MELANOMA PEPTIDE ANTIGEN, AND (R)-
DOTAP AS A THERAPEUTIC VACCINE FOR MELANOMA 
4.1 INTRODUCTION 
The immune system is a complex network of stimulation and suppression, allowing for 
activation against invading pathogens, and prevention of autoimmunity. However, as a 
cell begins to mutate and become cancerous, often, the immune system reacts by trying to 
promote angiogenesis and release growth factors, rather than attack and clear tumor cells. 
There are several cell types and tumor-expressed ligands that may play a role in 
promoting the suppressive tumor microenvironment.262; 263 Cell mediated immunity is 
required for tumor cell rejection, thus pathways that cripple T cells should be disabled to 
restore proper immune function. The FDA approval of ipilumumab, a fully human 
antibody against CTLA4, helps block the receptor on cytotoxic T lymphocytes, 
preventing anergy and inactivation.264; 265 The therapy has shown a 10.9 % response rate 
in melanoma patients and 34 % reduction of risk of death, a significant benefit compared 
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to the previous standard of care in these patients (treatment with the chemotherapy 
darcarbazine).266 
To re-energize T cells, other pathways that limit their function should be 
considered. Dendritic cells upregulate certain receptors to inhibit chronic activation (and 
thus exhaust and anergy) of T cells.267; 268; 269; 270; 271 Tumors employ a similar pathway, 
and often have upregulated levels of surface receptors such as DC-HIL, and PD-L1, 
which prevent recognition by T cells.272; 273 Researchers have delivered siRNA against 
this immune inactivation to tumors, DCs or T cells (the corresponding receptor to PD-L1; 
PD-1), and shown the silencing of these suppressive signals allow for the rebound of T 
cell activity and corresponding tumor growth delay.274; 275; 276; 273 However, as stated 
previously, the immune system is a balance of both activation and suppression. If both 
could be accomplished with a single injection; suppression of inhibition and activation of 
T cell, it may be possible to unleash an even stronger pulse of anti-tumor activity.  
Cancer vaccines have been well established preclinically, and although the FDA-
approved prostate cancer vaccine Sipuleucel-T has not gained mainstream use as quickly 
as expected, the approval is a solid proof-of-concept. In the case of Sipuleucel-T, a fusion 
protein of prostate cancer tumor associated antigen (TAA) prostatic acid phosphatase 
(PAP) and GM-CSF are delivered to APCs ex vivo, and the reinjected into the patient, 
showed a 22 % reduction in the risk of death in its pivotal trial.277 Other peptide vaccines 
have been developed, particularly in melanoma, to invigorate a specific CTL population, 
break tolerance and cause tumor growth delay of even prevention (if dosed in a 
prophylactic manner).278; 279; 280; 281; 282 Cases of spontaneous regression have been 
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observed in melanoma, often in tandem with vitiligo, thus the development of 
immunotherapies is an exciting opportunity for enhanced immune activation.283; 284; 285; 286 
Our laboratory has developed a Trp2 peptide/(R)-DOTAP therapeutic vaccine 
which statistically improves tumor growth delay in a B16F10 melanoma model after 
subcutaneous delivery.287 Trp2 (Tyrosinase-related protein 2) is a protein overexpressed 
in many melanomas and also in glioma cells based on the shared neuroectodermal origins 
of these tumors.245 Additionally, the Trp2 peptide used (SVYDFFVWL) is H-2Kb 
restricted, to ensure CD8+ T cell engagement.288 The antigen/adjuvant combination 
creates rod-shaped particles, rather than traditional liposomes that are formed most often 
in peptide/lipid combinations.289; 290; 291 In contrast to our work with Trp2 peptide, 
traditionally, only very soluble antigen peptides are even considered for investigation. 
The unique rod shaped particles led us to hypothesize a specific interaction between the 
hydrophobic residues of the peptide and the fatty acid chains of the (R)-DOTAP. 
Admittedly, this unique formulation has limited application, only towards tumors in 
which Trp2 peptide is expressed, however, it widens the opportunity for investigation of 
poorly soluble peptides with the lipid adjuvant, (R)-DOTAP, whose enantiomeric 
adjuvant specificity was discovered by our group.33 
Uniting the opportunity to deliver both peptide and nucleic acids is a look to the 
past for the Huang group, as our peptide antigen delivery with lipid adjuvant grew from a 
non-viral nanoparticle primarily developed for gene delivery. Soluble peptides were 
easily incorporated into a DNA core and lipid coated particle. Gao and Huang developed 
LPD, a carrier that delivered lipid, polycation and DNA, which has subsequently been 
investigated further as a gene delivery system.292; 293; 294; 295; 296 When a water soluble 
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antigen (E7 peptide, RAHYNIVTF), was incorporated, the nanoparticle was found to 
have efficacy against a tumor expressing E7 protein (TC-1, a murine model of HPV16-
induced cervical cancer). This formulation was thoroughly tested in our laboratory, 
delivering even proteins (vs. peptides) and correspondingly evaluated as a vaccine 
formulation.35; 36; 37; 42 
Studies by Vangasseri et al and Chen et al increased our understanding and 
discovered that DOTAP was the efficacious adjuvant.39; 30 The CpG motifs on the 
plasmid DNA were attributed to an increased TNF-α response and had no effect on the 
tumor regression data. As an adjuvant, (R)-DOTAP has shown efficacy in two tumor 
models; one with exogenous tumor antigens (HPV16 E7 protein in the TC-1 model),33 
and endogenous tumor antigens (Trp2 protein in the B16F10 model),287 showing a safe 
and efficacious response. 
Our studies with (R)-DOTAP/Trp2 as well as observance of the need to quench 
the suppressive immune response in tumor therapy, led us to develop a tri-modal delivery 
vehicle. Our (R)-DOTAP acts as adjuvant, Trp2 peptide as antigen and simultaneously, 
PD-L1 siRNA to release the breaks APCs use to temper or slow cytotoxic T lymphocytes 
from being active against Trp2-presenting B16F10 established tumors in a C57BL/6 
model. By delivering all three signals subcutaneously, we target the particles to APCs in 
the subcutaneous space and draining lymph nodes (as shown by Chen et al).30 We 
hypothesize this tri-modal particle, which we term RTP for the three components, will 
show enhanced tumor growth delay, compared to control siRNA containing formulations, 
termed RTC. 
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4.2 MATERIALS AND METHODS 
4.2.1 Materials 
(R)-DOTAP, (R)-1,2-dioleoyl-3-trimethylammonium-propane] was obtained from Merck 
KGaA (Darmstadt, Germany). NBD-DOPC, 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) was 
obtained by Avanti Polar Lipids (Alabaster, AL). H-2Kb restricted peptides Trp2 (H-
SVYDFFVWL-OH, amino acids 180-188 from the Tyrosinase-related protein 2 over-
expressed in human and murine melanoma, MW 1175) and Ova (H-SIINFEKL-OH, 
amino acids 257-264 from the ovalbumin, MW 1773) were obtained from Peptide 2.0 
(Chantilly, VA), supplied as trifluoracetate salts. Molecular biology grade water was 
obtained from Cellgro (Manassas, VA). Sodium methoxide, pure titrant (0.5M in 
methanol) and HPLC grade methanol were obtained from Fisher Scientific (Pittsburgh, 
PA). Absolute ethanol was obtained from Decon Labs, Inc. (King of Prussia, PA). PD-L1 
siRNA (5’ – CCC ACA UAA AAA ACA GUU G dTdT – 3’)297 and control siRNA (5′-
AAT TCT CCG AAC GTG TCA CGT-3′)298 were obtained from Dharmacon 
ThermoScientific (Lafayette, CO). TexasRed labeled oligonucleotides (5’-75TexasRed-
XN/CAA GGG ACT AGG CTG-3’) were obtained from Integrated DNA Technologies 
(Coralville, IA). 
Trp2 peptide was formulated as a disodium salt for delivery as described 
previously.287 
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4.2.2 Preparation and Evaluation of RTP Formulations 
(R)-DOTAP was obtained as a powder and dissolved in chloroform. Twenty µmol of 
lipid was dried in a glass vial under a stream of nitrogen and stored under vacuum in a 
desiccator overnight to ensure removal of any remaining chloroform. The thin film of 
lipid was hydrated with 1 mL molecular biology grade water and subsequently vortexed. 
After 1 h at room temperature, the suspensions were extruded 10x through two 100 nm 
polycarbonate membranes, then 10x through two 50 nm membranes (Fisher Healthcare, 
Houston, TX). Extruded liposomes were stored at 4 °C. 
The core of the particle was made by mixing 5 µL of molecular biology grade 
water with 12 µL of 2 mg/mL siRNA (PD-L1, control or TexasRed-labeled 
oligonucleotides), then 18 µL of 2 mg/mL protamine sulfate salt sourced from Salmon, 
Grade X (Sigma-Aldrich) in molecular biology grade water and allowed to sit at room 
temperature for 5 min. Then, 50 µL of 1.5 mM Trp2 disodium salt (in molecular biology 
grade water), was added to the core by gentle mixing and allowed to sit for an additional 
5 min at room temperature. Subsequently, 15 µL of 20 mM of (R)-DOTAP liposomes 
was added to the core-peptide aggregates and allowed to incubate at room temperature 
for 20 min. RTP is used throughout the manuscript to denote (R)-DOTAP/Trp2 
peptide/PD-L1 siRNA; RTC is used to denote (R)-DOTAP/Trp2 peptide/control siRNA; 
and RT(TxRed) is used to denote (R)-DOTAP/Trp2 peptide/TexasRed oligonucleotides. 
Particle size and zeta potential were measured with a Malvern Zetasizer Nano ZS 
(Worcestershire, United Kingdom). Trp2 peptide encapsulation efficiency was measured 
using a Microcon 100 kDa MWCO centrifugal filtrate device (Millipore, Bedford, MA). 
Flow-through was analyzed using 2 µL of sample on a Nanodrop Spectrophotometer, 
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ND-1000 (Thermo Scientific, Wilmington, DE), measuring the absorbance at 280 nm 
wavelength. Concentration of peptide in flow-through (unencapsulated) was calculated 
using Beer-Lambert law (A280 = ε*b*c), with ε = 5367.7 (M-1cm-1), calculated from a 
standard curve of Trp2 peptide.287 Final encapsulated concentration was calculated by 
subtracting the concentration in flow-through from the known concentration used for 
hydration. Trp2 peptide loss in the column was < 5 %. 
Transmission electron microscope (TEM) images of the RTP complexes were 
acquired by the use of a JEOL 100CX II TEM (Tokyo, Japan). Briefly, 4 µl of 
nanoparticle solution was dropped on to a 300 mesh carbon coated copper grid (Ted 
Pella, Inc., Redding, CA) for 2 min. Excess fluid was removed with filter paper, and 
copper grid was dried before the observation with TEM. Particles from several different 
fields were measured. Particle dimensions were calculated by measuring the diameter in 
case of spherical particles, or in the case of rod-shaped or oval particles, the largest 
dimension and the corresponding diameter perpendicular to the first measurement. One 
hundred particles were examined per field and particles from three fields were compiled. 
 
4.2.3 Bone Marrow Derived Dendritic Cells (BMDC) 
Methods to culture bone marrow-derived dendritic cells have been described 
previously.32 Briefly, bone marrow from the femurs and tibias of six week old C57BL/6 
mice was isolated in serum free RPMI1640 media. Red blood cells were lysed using 
ACK Lysing Buffer (Invitrogen) and cells were plated for 2 h in serum free RPMI 1640 
to remove suspension cells (lymphocyte precursors). Remaining adherent cells were 
cultured in RPMI 1640 media containing 10 % fetal bovine serum (FBS), non-essential 
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amino acids (NEAA) (Invitrogen), antibiotic/antimycotic (Sigma-Aldrich, St. Louis, MO 
with 1000 U/mL granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1000 
U/mL interleukin-4 (IL-4) (R&D Systems, Minneapolis, MN) for 6 days changing the 
media every 2 days. BMDCs were used in experiments on day 6. 
 
4.2.4 In vitro Uptake and in vivo Biodistribution 
To analyze particle uptake, the 20 mM (R)-DOTAP was formulated to include 1 mol % 
NBD-DOPC. BMDCs at a concentration of 1x106 cells/mL were seeded into 5 mL BD 
Falcon Flow Tubes (BD Biosciences). RTC was added to each tube in a dose of 50µM 
(R)-DOTAP, 12.5 µM Trp2 peptide, and 250 nM siRNA, based on the known toxicity of 
(R)-DOTAP in doses higher than 75 µM, and keeping the same ratios of Trp2 and siRNA 
as in the in vivo formulation.33 Uptake was analyzed at 0, 5, 15, 30, 60 and 240 min of 
incubation at 37°C with 95 % humidity and 5 % CO2. Tubes were removed and placed on 
ice in the dark before they were analyzed via on a FACS Canto flow cytometer and 
FACSDiva software (both from BD Bioscience, San Jose, CA). Samples were acquired 
on flow, then diluted 1:1 with 0.4 % Trypan Blue (Sigma) and evaluated with flow 
cytometry. Trypan Blue quenches the fluorescence on the surface of the cell, allowing for 
detection of internalized particles. 
To analyze in vivo uptake, C57BL/6 mice were s.c. injected 1 cm above the right 
inguinal lymph node with RT(Texas Red Oligos). Mice were imaged at 0, 20 min, 1 h, 2 
h, and 4 h after injection using a Kodak in vivo imaging System Fx Pro (Carestream 
Health Products, Rochester, NY), and analyzed using Carestream Molecular Imaging 
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Software (Rochester, NY). Inguinal lymph nodes and spleens were removed and imaged 
using the Kodak camera and Carestream imaging software. 
 
4.2.5 Interaction of Formulations with BMDC in vitro 
To measure CD86, PD-L1 or H-2Kb expression, BMDC were seeded at 1x106 cells/mL 
into BD Falcon tubes and treated with different formulation. RTP and RTC particles were 
treated at concentrations of 50 µM R-DOTAP, 12.5 µM Trp2 and 250 nM PD-L1 siRNA. 
Likewise, RTC particles had the same amounts of R-DOTAP, Trp2 and siRNA. Controls 
consisted of 25 µM (R)-DOTAP, 12.5 µM Trp2 peptide, or 250 nM PD-L1 siRNA. After 
48 h, cells were stained with anti-CD86-FITC (GL1), anti-CD11c-PE (HL3) anti-H-2Kb-
FITC (AF6-88.5), or anti-PD-L1-PE (MIH5) antibodies (BD Biosciences, San Jose, CA) 
and analyzed by using flow cytometry. Control isotype antibodies were used to assess 
non-specific staining. 
To measure toxicity, BMDC were treated with different concentrations of RTP, 
RTC or appropriate controls (mentioned above) for 24 h and stained with propidium 
iodide (PI) (Sigma-Aldrich) and evaluated using flow cytometry. 
 
4.2.6 BMDC-splenocyte Co-culture Experiments to Evaluate T cell Reaction in 
vitro 
BMDCs were incubated at a concentration of 2x106 cells in 2 mL of BMDC media in 6 
well plates. Cells were treated with RTP particles containing 50 µM of R-DOTAP, 12.5 
µM Trp2 peptide and 250 nM of PD-L1 siRNA, or 250 nM control siRNA (in the case of 
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RTC particles), or associated controls of lipid alone, peptide alone, PD-L1 siRNA alone 
(in concentrations equal to those in RTP particles). 
To measure T cell proliferation, carboxyfluorescein succinimidyl ester (CFSE)-
pulsed splenocytes from naïve mice were added to treated BMDC and evaluated 36 h 
later. In brief, spleens were removed from C57BL/6 mice, crushed through a 70 um filter 
and red blood cells lysed. Afterwards, cells were washed, and incubated in serum-free 
RPMI with 4 µM CFSE for 15 min at 37 °C. Cell were then washed in complete RPMI 
media made of RPMI1640 media supplemented with 10 % FBS, NEAA and 
antibiotic/antimycotic (Cellgro), Splenocytes were incubated with treated BMDCs in a 
100:1 ratio, and 20 U IL-2/mL was added to the media to sustain T cell growth. Thirty-
six h later, wells were imaged with a Vista Vision light microscope, cells were removed 
and wells washed with PBS. Samples were analyzed with flow cytometry to evaluate the 
dye-dilution due to cell division. 
To measure specificity of response, splenocytes were removed, made into a 
single-cell suspension (as above), and incubated in a 100:1 ratio with 24 h treated 
BMDCs, plus 20 U/mL IL-2. Thirty-six h later, suspension cells were removed, and 
resuspended at 2x106 cells in complete RPMI media, plus 1 µL/mL GolgiStopTM (BD 
Biosciences) and 5 µM Trp2 or Ova peptide for 6 h at 37 °C. Cells were removed, 
washed with staining buffer (BD Pharmingen, San Diego, CA) and stained with anti-
CD8-APC (53-6.7). Cells were then treated with Cytofix/CytopermTM according to kit 
instructions (BD Pharmingen) and stained intracellularly with anti-IFN-γ-FITC 
(XMG1.2), washed and analyzed by using flow cytometry. 
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4.2.7 Tumor Cell Culture 
B16F10 cells, a murine melanoma model (syngenaic with C57BL/6) were originally 
obtained from American Type Culture Collection (ATCC) (Manassas, VA). Previously, 
in collaboration with Dr. Pilar Blancafort at the University of North Carolina at Chapel 
Hill, B16F10 was stably transfected with GL3 firefly luciferase gene using a retroviral 
vector to create B16F10-luc.254; 255 B16F10-luc cells were used in all studies presented 
here and maintained in Dulbecco’s Modified Eagle Medium (Gibco (Invitrogen), 
Carlsbad, CA) supplemented with 10 % fetal bovine serum (Invitrogen, Carlsbad, CA), 
100 U/mL penicillin (Invitrogen) and 100 µg/mL streptomycin (Invitrogen). 
 
4.2.8 Interferon Gamma (IFN-γ) Production by CD8+ T cells 
Mice were vaccinated with RTP, RTC formulations or associated controls in a dose of 
300 nmol (R)-DOTAP lipid, 75 nmol Trp2 peptide or 24 µg siRNA. Seven days later, 
mice were sacrificed and spleens sterilely removed from each mouse. Spleens were 
processed into a single cell suspension by crushing through a 70 µm filter (BD 
Biosciences, San Jose, CA). After removal, cells were incubated in complete RPMI 
media, 1 µL/mL GolgiStopTM and Trp2 or Ova peptide, stained for CD8 and IFN-γ and 
analyzed via flow cytometry as described above. 
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4.2.9 Mice and Immunizations 
Six week old female C57BL/6 mice obtained from the National Cancer Institute, were 
used in all studies. On day 0, 3x105 B16F10-luc cells in 50 µL of PBS were injected 
subcutaneously into the hair-trimmed abdomen. On day 6, RTP or RTC were 
subcutaneously injected into the contralateral side of the abdomen in 100 µL of 5 % 
dextrose solution. In all experiments, 300 nmol (R)-DOTAP per mouse was the 
therapeutic dose of adjuvant used, as shown previously.253 Tumors were measured every 
2-3 days with calipers, recording the longest diameter as length and the perpendicular 
dimension as width. Area was calculated as (length) x (width). Humane sacrifice of mice 
was performed after tumors reached 20 mm in one dimension. All animal protocols were 
approved by the University of North Carolina at Chapel Hill’s Institutional Animal Care 
and Use Committee. 
 
4.2.10 Statistical Analysis: 
Statistical analysis was completed by using a two-tailed Student’s t-test unless otherwise 
specified. Tumor growth delay data was analyzed using repeated measures ANOVA. 
Data was qualified as statistically significant if the P value was less than 0.05. 
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4.3 RESULTS 
4.3.1 Formulation of RTP particles by optimal combination of PD-L1 siRNA with 
Trp2 peptide and (R)-DOTAP 
Protamine was mixed with siRNA to create a solid core. Afterwards, Trp2 peptide as a 
disodium salt was added at different Trp2:siRNA weight ratios (Figure 1A). Greater than 
1, the ratios created particles above 3,000 nm, indicating the possible hydrophobic 
interactions with increasing amounts of Trp2. Eventually, the size stabilized to slightly 
larger than 4,000 nm, and 3.125 was the ratio chosen for further experiments. The 
“core+Trp2” was then incubated with different mol/mol ratios of (R)-DOTAP to Trp2 
peptide and size was measured over time (Figure 1B). This showed a time-dependent 
decrease in size for most ratios, and further investigation showed after 20 min of 
incubation, equilibrium had been reached. With this new optimized timeline, of 5 min for 
core mixing, 5 min for “core+Trp2” incubation and 20 min incubation after lipid 
addition; size and zeta potential of the RTP particles was measured over a range of (R)-
DOTAP/Trp2 mol/mol ratios (Figure 1C). The particles were stable over a range of 
ratios, with size around 60-80 nm and charge increasing from 40 to 60 mV as the 
positively charged lipid was added (Figure 1D).  
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Figure 4.1 RTP Particle Optimization. 
siRNA and protamine was mixed together in a weight ratio of 3:2. A) The protamine/siRNA mixture was 
then added to Trp2 peptide and allowed to incubate at room temperature for 5 minutes and then particle 
size was measured (n=3). The highest Trp2/siRNA ratio was used moving forward. B) (R)-DOTAP was 
added to the protamine/siRNA/Trp2 aggregates in different molar ratios and particle size measured at 
different time points (n=3). C) To optimize the shortest amount of time for size, particle size was measured 
over time after addition of different (R)-DOTAP ratios (n=3). D) After 5 min mixing of protamine/siRNA, 
addition of Trp2 peptide and 5 minutes incubation, then 30 sec mixing with different ratios of (R)DOTAP 
and 20 min incubation at RT, size and zeta potential of the different formulations were measured. 
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After optimization and stabilization of the protocol, the final times of 5 min 
incubation after core components of protamine and siRNA were mixed, 5 min incubation 
of Trp2 peptide and core particles and 20 min incubation of core+Trp2 peptide with (R)-
DOTAP lipid (Figure 2). TEM images were taken at each step in the process to help 
visualize the particles being created. After mixing of the siRNA and core, we could see 
small (23 ± 3 nm) particles aggregated by excess protamine (Figure 2A). When lowered 
amounts of protamine were used, particles aggregated and flocculated after the addition 
of lipid, in contrast to aggregating and flocculating after the addition of Trp2, indicating 
that the protamine stabilizes the lipid in the core (data not shown). As mentioned above, 
we observed aggregates much larger in size (102 ± 25 nm) from the addition of Trp2 
peptide to the core particles, indicting an anchoring of the negatively charged Trp2 to the 
positively charged core (Figure 2B). To better understand the (R)-DOTAP/“core+Trp2” 
interaction and structure, lipid was added in 3 different (R)-DOTAP/Trp2 mol/mol ratios: 
2, 4 and 6 (Figure 2C, 2D, 2E). With a low ratio, aggregates were observed (length 204 
± 86 nm, width 120 ± 45 nm), due to incomplete fusion of liposomes to “core+Trp2” 
particles. With a ratio of 4:1, small round particles (diameter 33 ± 14 nm) were mainly 
observed with some rod shaped particles (7 % of total particles via TEM, (length 216 ± 
64 nm, width 44 ± 8 nm). The rod shaped particles are similar to particles we have 
observed previously with (R)-DOTAP/Trp2 lipid/peptide complexes without siRNA.287 
Finally, at a mol/mol ratio of 6, mostly small round particles were observed (diameter 31 
± 9 nm) and 7 % aggregated particles (length: 307 ± 122 nm, width: 117 ± 25 nm). This 
6:1 ratio was consistent with particle sizing and some aggregates, which resemble the 
blobs in the 2 ratio image, possibly indicating excess liposomes added. As (R)-DOTAP 
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(as well as many cationic lipids), is known to be toxic to BMDCs in high doses, we chose 
the RTP with a ratio of 4 to be used in subsequent experiments to eliminate any unneeded 
lipid. The RTP ratio of 4 was utilized also to take advantage of the consistently sized 
particles (Figure 2D). 
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Figure 4.2 TEM images of RTP particle characterization at each step. 
TEM images were taken at each step of the formulation. A) 18 μL of 2 mg/mL protamine was mixed for 10 
sec with 12 μL of siRNA (and 5μL of molecular biology grade water) and allowed to incubate at room 
temperature for 5 min. Core particle size from TEM image was 22 ± 3 nm. B) 50μL of 1.5mM Trp2 peptide 
was added to the protamine/siRNA mixture, mixed for 10 sec, incubated at room temperature for 5 min. 
Core+Trp2 particle size from TEM image was 102 ± 26 nm. C) (R)-DOTAP was added in a 2:1 molar ratio 
with Trp2 (7.5 μL added), mixed for 30 sec, allowed to incubate for 20 min at RT. TEM images showed 
oval shaped aggregates with the longest dimension 204 ± 86 nm and shorter dimension 120 ± 45 nm. D) 
(R)-DOTAP was added in a 4:1 molar ratio with Trp2 (15 μL added), mixed for 30 sec, allowed to incubate 
for 20 min at RT. 4:1TEM images showed small spherical particles (diameter 33 ± 14 nm) indicated by a 
white arrowhead and 7 % rod-shaped particles (length 216 ± 64 nm, width 44 ± 8 nm) indicated by a white 
arrow. E) (R)-DOTAP was added in a 6:1 molar ratio with Trp2 (22.5 μL added), mixed for 30 sec, allowed 
to incubate for 20 min at RT. 6:1TEM images showed small spherical particles (diameter: 30 ± 9 nm) and 7 
% aggregated particles (length: 308 ± 122 nm, width: 117 ± 25 nm). 
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4.3.2 Uptake and Biodistribution of RTP particles 
RTC particles were used to detect uptake in BMDCs (Figure 3A). (R)-DOTAP(99 mol 
%)+NBD-DOPC(1 mol %) were used as the label for uptake. Endocytosis occurred very 
quickly with nearly 40 % cells NBD positive after 5 min, and stable both on the surface 
of the cell and endocytosed after 4 h.  
C57BL/6 mice with trimmed abdomens were subcutaneously injected 
approximately 1 cm above the right inguinal lymph node with RT(TxR) particles at 
different time points (Figure 3B). Mice were sacrificed and placed on their abdomens 
and imaged to analyze particle migration based on the TexasRed signal. After 20 min, the 
injection site is clearly visible. In the subsequent animal samples, one can observe the 
migration of the injection site towards the inguinal lymph node. After whole body 
imaging, the secondary lymph organs of interest were removed; spleen, left inguinal 
lymph node and right inguinal lymph node (Figure 3C). The right inguinal lymph node 
at 4 h showed a strong positive signal, while no other time points showed any 
fluorescence over background. Inguinal lymph nodes showed higher relative background 
compared to the spleens. Spleens never showed any fluorescence above background at 
any time points measured (up to 4 h). Excised spleens are shown in the left most column 
of Figure 3C. 
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Figure 4.3 Delivery of RTP particles in vitro and in vivo. 
A) 1e6 BMDCs cells were incubated with RTP or associated controls. BMDCs were treated with 25 µM 
RTP particles containing 1 mol % DOPC-NBD in the lipid bilayer to monitor uptake via flow cytometry. 
Internalized particles were estimated by running the same sample after the addition of 0.5 % Trypan blue in 
a 1:1 dilution. B) Six-week-old C57BL/6 mice were injected at different time points to evaluate RT 
(TexasRed oligos) drainage to lymph nodes. Twenty four µg TexasRed oligos were dosed per mouse. Mice 
were imaged using the Kodak In Vivo Imaging System. C) Spleen and both inguinal lymph nodes were 
removed to detect particles (TexasRed oligos), and imaged with the Kodak In Vivo Imaging System. 
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4.3.3 Surface molecule expression and toxicity of RTP in BMDCs 
BMDCs were used to analyze the in vitro response of APCs to RTP particles (and 
associated controls) (Figure 4). BMDCs were analyzed for four different signals; CD86 
to indicate activation of APCs, PD-L1 protein surface expression to analyze the effect of 
the siRNA delivery, H-2Kb surface expression to ensure the delivery vehicle would not 
cripple the APC ability to present Trp2 peptide, and finally, propidium iodide, to analyze 
the toxicity. Forty-eight h after stimulation with RTP (50 µM (R)-DOTAP, 12.5 µM 
Trp2, 250 nM PD-L1 siRNA), BMDCs showed the highest level of CD86-positive and 
H-2Kb-positive cells among all treated groups (Figure 4A, 4C). While RTP-treated cells 
also showed a 30 % decrease in PD-L1-positive cells, while RTC had a much more minor 
response (less than 10 % decrease) (Figure 4B). Toxicity of treatments was lower than 
20 % of all treated groups, measured by PI positive cells. The treatments with the highest 
levels of toxicity were (R)-DOTAP as well as RTP particles, however, the difference was 
not statistically significant (Figure 4D). 
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Figure 4.4 In vitro RTP characterization with BMDCs. 
1x106 BMDCs were incubated for 48 h with 25 µM RTP and associated controls. After 48 h BMDCs were 
stained with corresponding antibodies (or propidium iodide) and monitored via flow cytometry for A) 
CD86 activation, B) PD-L1 surface expression, C) H-2Kb surface expression, or D) toxicity (via PI positive 
cells, indicating cell permeability). 
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4.3.4 In vitro co-culture to determine RTP-treated BMDCs affect on splenocytes 
Co-culture experiments were used to analyze the interactions between BMDCs and 
splenocytes to determine the efficiency of activating T cells after 36 h of co-incubation. 
CFSE-dye dilution showed that RTP and RTC both elicited dye-dilution, indicating cell 
expansion, with RTP at slightly higher levels (Figure 5). All the control groups in the 
dye-dilution study showed background levels of expansion, except for (R)-DOTAP 
which showed a slight increase over background. Light microscopy of these co-cultures 
showed obvious differences between RTP, RTC and the controls. While only RTP and 
RTC show clonal clusters of cells, RTP had larger clusters on average, compared to RTC. 
When the plates were gently washed to remove the clusters and collect the suspension 
cells, the resulting cells were analyzed for ability to identify Trp2 peptide by IFN-γ 
production. Cells were pulsed for 6 h with either OVA peptide or Trp2 peptide (both H-
2Kb restricted). Both RTC and RTP showed increased IFN-γ secretion after Trp2 peptide 
pulse, however OVA-peptide pulse also showed a similar amount of IFN-γ in RTP 
treated samples. Untreated as well as (R)-DOTAP, Trp2 peptide and PD-L1 siRNA-
treated samples all showed low levels of stimulation, relatively equal in both peptide-
pulsed groups.  
 
 145
 
Figure 4.5 T cell activation and proliferation. 
2x106 BMDCs were activated by incubating with RTP and associated controls for 24 h. Activated BMDCs 
were further incubated in 1:100 ratio with CSFE-stained splenocytes (unstained in C) for 36 h to evaluate 
the T-cell proliferation and IFN-γ secretion. A) Flow cytometry analysis of CFSE dye dilution. B) Light 
microscope images for T cell proliferation in cultures. One representative experiment is shown of three. 
(Inset picture represents an activated dendritic cell with T cells surrounding). C) Activated BMDCs were co 
cultured with unstained splenocytes (1:100 ratio) for 36 h. Splenocytes (suspension cells) were isolated and 
stimulated with target peptide (Trp2, filled bars) or untargeted peptide (OVA, open bars), IL-2 and Golgi 
stop for 12 h. The cells were stained with CD8+ and IFN- γ antibodies and analyzed by flow cytometry. 
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4.3.5 RTP affects the IFN-γ production and PD-L1 surface expression in vivo 
Mice were subcutaneously injected with RTP, RTC or associated controls and tested for 
an antigen-specific CD8+ T cell response. Seven days after injection, mice were 
humanely sacrificed, and splenocytes were incubated with GolgiStop and pulsed with 
either OVA or Trp2 peptide for 6 h. Cells were then stained for surface expression of 
CD8 and intracellular IFN-γ. RTP and RTC treated-mice showed IFN-γ production 
greater than controls in Trp2 pulsed splenocytes, however RTC showed slightly higher 
levels, although not statistically different than RTP (Figure 6A). Tissue samples were 
taken from draining lymph nodes as well as spleen and analyzed for PD-L1 knockdown 
in vivo in both CD11b+ (macrophages) and CD11c+ (dendritic) cells. DLNs of mice 
treated with RTP showed lower levels of PD-L1 in both dendritic and macrophage cell 
compartments compared to RTC or control (Figure 6B, 6C). CD11b+ splenocytes from 
mice treated with RTP had lower levels of PD-L1 compared to the other groups, 
however, CD11c+ splenocytes had levels not different from RTC.  
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Figure 4.6 In vivo activity of RTP particles. 
Six-week-old C57BL/6 mice were injected s.c. with RTC or RTP formulations. Eight days later, 
splenocytes were isolated and red blood cells lysed. A) Splenocytes were incubated with GolgiStop and 
pulsed with Ova or Trp2 for 6 h. Cells were then stained with anti-CD8 and anti-IFN-γ and examined via 
flow cytometry. B) Splenocytes were stained with anti-CD45, anti-CD11b, anti-CD11c, anti-PD-L1. Cells 
were gated on CD45 and CD11b or CD11b to select macrophage (CD11b+) or dendritic cell (CD11c+) 
populations, then examined for PD-L1 levels. 
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4.3.6 RTP delivery induces tumor growth delay 
Mice were s.c. injected with B16F10 on day 0 on the left side of the abdomen, and tumor 
size and body weight was monitored for 20 days at which point all the mice in the study 
were sacrificed. On day 8, mice were injected with RTC, RTP or left untreated. Mice 
treated with RTP showed improved tumor growth delay compared to RTC or control 
mice (Figure 7). RTC did show some effect, but was not statistically significant from the 
untreated control. It was, however, statistically significantly different from tumor growth 
delay of RTP. The average body weight of the mice treated with RTP stayed fairly 
constant over time, while the body weight of RTC and control mice increased at the same 
relative rate, with no statistical differences between any groups. 
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Figure 4.7 In vivo tumor growth delay after RTP administration. 
Six-week-old C57BL/6 mice were inoculated with 3x105 B16F10 cells s.c. in the right side of the 
abdomen. Eight days later, mice were injected s.c. contra-laterally with RTC or RTP formulations, and 
tumor areas were measured for 20 days (n=5). Area was calculated by length x width ((mm) x (mm)). Inset 
is a chart of body weight. Weight was monitored after vaccination at every tumor measurement. ***: 
P=0.038 via repeated measures ANOVA 
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4.4 DISCUSSION 
Subcutaneous delivery has long been used as a vaccination route studied in laboratories. 
However, it should be noted that most vaccines approved for use in humans are 
intramuscular, a simpler injection technique that promotes a stronger depot effect 
compared to subcutaneous that more easily facilitates lymph drainage. Subcutaneous 
drainage to lymph nodes is facilitated by two mechanisms. First, injection volume exerts 
a certain amount of interstitial pressure. Second, local inflammation by the injection or 
activation of APCs that are stationed in the skin or circulating nearby will sample their 
environment and if activated, drain to the lymph nodes. Macrophages have been shown to 
drive this process, even though dendritic cells are more effective as APCs.299 We 
observed increased downregulation of PD-L1 in macrophages compared to dendritic cells 
and the difference in the type of cells facilitating uptake may be responsible. The 
downregulation in draining lymph nodes is not consistent across samples with no 
significant different which could be attributed to sporatic uptake from the injection site 
after dosing (Figure 6B, 6C). 
Our data show that the downregulation of PD-L1 in dendritic cells does not to 
affect the clonal expansion of T cells in vitro (Figure 5A). The PD-1/PD-L1 (or PD-
1/PD-L2) interaction stops the proliferation of T cells through the PI3K pathway, after 
silencing of PD-L1, we would expect to see an increase in proliferation.300 However we 
did not observe a clonal expansion in the PD-L1 silenced population compared to RTC 
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treatment (Figure 5A), as has been similarly observed by other investigators 
downregulating PD-L1 in vitro.276 There may be engagement of PD-L2, or clonal 
expansion may only be observable in vivo, as the cell culture dish can not recreate the 
complex environment of the lymph node. With the knockdown of PD-L1 in DCs and 
subsequent removal of the PD-1/PD-L1 checkpoint, we hypothesize that the non-specific 
response seen in Figure 5C is due to natural killer T cells. In a PD-L1-/- knockout model, 
dendritic cells from the knockout were pulsed with melanoma antigen (and an adjuvant) 
and subsequently re-injecting into a donor mouse, which was inoculated with B16 
melanoma cells the following day.301 The mice that were treated with dendritic cells from 
the knockout had greater tumor growth delay compared to the mice treated with WT DCs 
pulsed similarly. This effect was attributed to the increased population of invariant 
natural killer T cells (iNKT). However, our experiments published here, are the first time 
this knockdown has be achieved in vivo, and with a therapeutic, rather than prophylactic 
model. The tumor microenvironment is much more challenging in therapeutic model, as 
mentioned previously. 
The RTC platform takes advantage of molecular interactions to deliver nucleic 
acids, antigen and adjuvant. As dendritic cells drive the T cell priming process, more 
specifically controlling their signals could facilitate a bespoke response. The possibilities 
for the nucleic acid cargo are endless. Some other options to control the DC/T cell 
interaction would be to deliver siRNA against PD-L2 or IDO to prevent 
immunesuppression.  Alternatively, the platform allows an opportunity to deliver genes 
to amplify the immune response, such as IL-2, GM-CSF, CD80/86, MHC I, or an 
additional antigen. 
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Trp2 peptide has very low solublity, and the interactions between the two 
negative charges with the positive core of protamine and siRNA anchors the peptide into 
the formulation, exposing the more hydrophobic residues to the aqueous solution, 
inducing aggregation. We see evidence of this, with the addition of (R)-DOTAP and 
hypothesize the aggregates are dispersed by the hydrophobic interactions of (R)-DOTAP 
interacting with the Trp2 hydrophobic resides. 
Future advances in this formulation should address a new target, to see if more 
controlled growth reduction can be initiated due to the non-specific in vivo activation of T 
cells we observed (Figure 5C). Also, while the structural organization of the particles 
ensures the protection of the siRNA from the external solution by the layer of Trp2 and 
(R)-DOTAP, aggregates have shown more drainage into the lymph nodes. Therefore, 
certain techniques that could maintain the structural organization (and protection of the 
siRNA), potentially allowing the particles to associate in a network which would help 
delivery, faster drainage and immune response. 
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CHAPTER 5 
DISCUSSION 
5.1 DISCUSSION OF RESEARCH RESULTS AND FUTURE PLANS 
The DOTAP enantiomers were investigated as adjuvants in an E7 peptide/lipid complex 
as a therapeutic vaccine in an established murine cervical cancer model. Delivery in vivo 
yielded tumor regression with (R)-DOTAP/E7 complexes similar to that with a racemic 
DOTAP with E7 peptide, in a dose-dependant fashion. These data are supported by IFN-γ 
production by CD8+ splenocytes, in vivo cytotoxic T-lymphocytes (CTL) response, 
CD8+ tumor-infiltrating lymphocytes (TIL), and IFN-γ production by CD8+ TIL in (R)-
DOTAP/E7-vaccinated mice. With (S)-DOTAP/E7 is delivered, tumor progression is 
delayed. While IFN-γ production is absent from CD8+ splenocytes in mice vaccinated 
with (S)-DOTAP/E7, IFN-γ production by CD8+ TIL is present, supporting our 
hypothesis that (S)-DOTAP has limited activity. Activation of bone marrow-derived 
dendritic cells by the enantiomeric formulations has also been evaluated, as well as 
cytokine production and toxicity with no considerable differences between the groups. 
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The results show the DOTAP enantiomers act differently as adjuvants in vivo, with (R)-
DOTAP being more effective at stimulating a CD8+ anti-tumor response. Investigation of 
the specific mechanism of (R)-DOTAP should be further explored. If there potentially 
exists a DOTAP-specific receptor, differences in affinity binding could explain the 
pharmacodynamic disparities between (R) and (S). However, and perhaps more 
interesting is if (S)-DOTAP stimulates an inhibitory immune response. This action would 
greatly expand the use of (S)-DOTAP into an adjuvant for autoimmune disease. 
However, the differences in vivo between (R)- and (S)-DOTAP do not clearly 
explain why one enantiomer works and the other is less effective. We consider the role of 
(S)-DOTAP as less immunostimulatory, rather than wholly ineffective. This is supported 
by the statistically significant tumor growth delay of the (S)-DOTAP/E7 treated mouse 
compared to control (Figure 2.1). Also from the tumor growth delay data, we must 
consider that the racemic mixture of DOTAP/E7, contains 50% (S)-DOTAP. If the (S) 
enantiomer had immunosuppressive effects, we would expect to see less growth delay 
from the racemic mixture than from pure (R)-DOTAP.  
It is plausible that a receptor or reaction exists that is stereospecific for DOTAP. 
This could occur in one of two ways; increased stability of the (R)-DOTAP lipid in vivo 
causing preferential cleavage of (S)-DOTAP or an immunostimulatory receptor for which 
(R)-DOTAP has higher affinity. Stereospecific activity of lipases has been established in 
the literature, and is the most likely cause of decreased (S)-DOTAP acitivty.302; 303; 304; 305; 
306 Under this hypothesis, enough (S)-DOTAP would be cleaved as to prevent specific 
interaction with APCs. Additionally, racemic DOTAP complexes would be able to retain 
enough (R)-DOTAP for eventual delivery an signally. It is unlikely that there is a specific 
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DOTAP receptor, but rather, DOTAP signals through an established pathway that is 
TNF-α independent (unpublished work by Wei-Yun Sheng, Huang Lab). DOTAP is most 
commonly used in immunology as a delivery vehicle for nucleic acids (particularly CpG), 
a specific DOTAP receptor has not been investigated.  More could be understood on the 
location of DOTAP signaling (either intracellular, or extracellular) by the creation of 
particles with asymmetric bilayers, delivery in vitro and assessment of CD86 
upregulation. Additionally, by parcing out the location of APC activation, the 
stereospecific lipase activity could be investigated in further depth, comparing lipase 
activity intracellularly, in cell culture media, in subcutaneous space, or after intravenous 
delivery.  (R)- and (S)-DOTAP have not been compared via different methods of delivery 
and any new data from different delivery mechanisms may help explain the differences in 
activity. 
Use of (R)-DOTAP was expanded to deliver self-antigen in an aggressive murine 
solid tumor melanoma model. (R)-DOTAP/Trp2 peptide complexes showed decreasing 
size and charge with increasing peptide concentration, taking a rod-shape at highest 
concentrations. The particles were stable for at 2 weeks at 4°C. A dose of 75nmol Trp2 
(formulated in (R)-DOTAP) was able to show statistically significant tumor growth delay 
compared to lower doses of 5 and 25nmol which were no different than untreated tumors. 
(R)-DOTAP/Trp2 (75nmol) treated mice also showed increased T cell IFN-γ secretion 
after restimulation with Trp2, as well as CTL activity in vivo. This vaccination group also 
showed the highest population of functionally active tumor-infiltrating lymphocytes, 
indicated by IFN-γ secretion after restimulation with Trp2. We showed (R)-DOTAP able 
to break tolerance in an aggressive self-antigen tumor model. 
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The formulation of Trp2 peptide antigen posed interesting challenges in this work.  
Increasing the peptide solubility allowed for an increased deliverable dose. We 
hypothesize a specific interaction between the hydrophobic amino acids in the peptide 
and the hydrophobic tails of (R)-DOTAP due to the shape of the particles seen in Figure 
3.2D. Previous examination of DOTAP and E7 peptide formulations had shown rounded 
complexes (data not shown). E7 peptide is highly soluble in aqueous solution but only 30 
% of peptide is entrapped in DOTAP complexes, compared to nearly 100 % of Trp2 
(Table 2.1, Figure 3.2B). The role of hydrophobic interactions can increase peptide 
loading in lipid carriers, as we have seen with lipidated E7.235 Understanding more about 
the characteristics of peptides that increase loading may facilitate identification of 
candidate antigens that would benefit most from lipid delivery. Trp2 peptide could be 
used as a model antigen to expanding the application of (R)-DOTAP/amplipathic peptide 
formulation. Selective modification of individual residues (either to glycine or 
phenylalanine) and a rapid screening process (such as the experiments presented in 
Figure 3.2), may lead to further understanding of ideal antigen candidates. By 
characterizing the structure-function relationship, only the most suitable peptides can be 
pursued. While we don’t claim that lipid-based delivery is the best delivery option for 
every antigen in every situation; understanding how to maximize the potential of (R)-
DOTAP could lead to many interesting projects in the future. 
The (R)-DOTAP/Trp2 vaccine may be efficacious in models other than murine 
melanoma. The vaccine should be tested in additional murine tumor models that express 
Trp2, such as glioblastoma, to verify the robustness of the treatment. The Trp2 peptide 
epitope used, SVYDFFVWL, is also HLA-A2 restricted. Investigation with human 
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leukocytes ex vivo may increase understanding of the potential for expansion into clinical 
testing. 
Expanding the versatility of (R)-DOTAP/Trp2, we developed a vaccine 
formulation to silencing the PD-L1 pathway in DCs, to amplify the immune response. 
The tri-modal vaccine, RTP, combined delivery of (R)-DOTAP, Trp2 peptide and PD-L1 
siRNA to DCs. The spherical particles were stabilized by a layered approach, first 
charge-charge interactions to capture the siRNA, followed by hydrophobic interactions to 
complex the amphipathic peptide antigen, which interacted both with the positively 
charged core as well as the hydrophobic chains of the lipid adjuvant. The successful 
incorporation of siRNA into the particles yielded a versatile vehicle that could potentially 
deliver alternative siRNA sequences targeting other genes, or even deliver DNA to 
upregulate certain genes in DCs. (R)-DOTAP/Trp2/PD-L1 siRNA particles, termed RTP, 
were found to induce IFN-γ secretion in vitro and in vivo. Interestingly, the IFN-γ 
response was the same for target peptide (Trp2)-pulsed and off-target (Ova)-pulsed 
peptides, indicating the stimulation of a non-specific cell population, we hypothesize to 
be NKT cells. However, the in vivo result of tumor growth delay is puzzling as the IFN-γ 
production does not correlate. For further investigation, alternative genetic cargo may be 
of greater effect. Delivering plasmids of GM-CSF or IL-2 in the RT(DNA) particles 
could increase maturation of the APCs. Alternatively, a peptide and DNA vaccine could 
be directly compared, measuring the response to each antigen. The difficulty of the RTC 
formulation is the dependency of the particle on the structure of Trp2 peptide. As 
mentioned above, further investigation of the crucial number of hydrophobic resides 
would enable us to understand the anchorage of the peptide to (R)-DOTAP. For RTC 
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formulation, we hypothesize that the negative charge on the carboxylic acid at the distal 
end of the peptide assists in complexing the peptide to the protamine-DNA core. 
Delivery is another opportunity to improve this formulation. After subcutaneous 
delivery, particles were found in draining lymph nodes. Macrophages and DCs showed 
down regulation of PD-L1 surface expression after in vivo dosing. However, consistent 
down regulation was not observed. This indicates a potential for improvement of the 
vaccine. While targeted or larger particles often yield higher uptake by APCs, protection 
of the siRNA cargo is paramount. Therefore, it would be valuable to investigate a way to 
network the small (80nm) spherical particles together to create larger aggregates, more 
attractive to APC uptake. By incorporating a biotinylated lipid into the (R)-DOTAP 
bilayer during particle coating, and subsequent incubation with avadin, we believe it 
possibility to produce large spiderweb-like networks of particles, with the siRNA 
protected in the particle core. In investigations of building liposomes-within-liposomes, a 
similar utilization of biotin-avidin was employed, creating web-like structures.307; 308 
Alternatively, targeting to macrophages using mannose or mannin has been widely 
investigated and could enhance in this formulation by surface coating of mannin, or 
incorporation of mannose-labeled lipids into the bilayer. 
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5.2 ENDING REMARKS 
In closing, this work established the stereospecific adjuvanticity of (R)-DOTAP in 
several models. Investigation of (R)-DOTAP with different peptide antigens lead to 
diverse formulation characteristics. Further, incorporation of siRNA into the melanoma 
optimized particle created an increased tumor growth delay, and versatility of siRNA 
delivery cargo. Cancer immunotherapy is a field with growing clinical demand, and the 
next generation of treatments will evolve from novel investigations such as this. 
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